



This is a repository copy of *Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation*.

White Rose Research Online URL for this paper:

<http://eprints.whiterose.ac.uk/1769/>

---

### Monograph:

Ward, S., Kaltenthaler, E., Cowan, J. et al. (1 more author) (2003) Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Technical Report. Gray Publishing , Tunbridge Wells.

ISSN 1366-5278

---

### Reuse

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.


### Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.

# **Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation**

S Ward  
E Kaltenthaler  
J Cowan  
  

**Health Technology Assessment  
NHS R&D HTA Programme**





### **How to obtain copies of this and other HTA Programme reports.**

An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (<http://www.ncchta.org>). A fully searchable CD-ROM is also available (see below).

Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public **and** private sector purchasers from our Despatch Agents, York Publishing Services.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.

You can order HTA monographs from our Despatch Agents, York Publishing Services by:

- fax (with **credit card or official purchase order**)
- post (with **credit card or official purchase order or cheque**)
- phone during office hours (**credit card only**).

Additionally the HTA website allows you **either** to pay securely by credit card **or** to print out your order and then post or fax it.

#### **Contact details are as follows:**

York Publishing Services  
PO Box 642  
YORK YO31 7WX  
UK

Email: [ncchta@yps-publishing.co.uk](mailto:ncchta@yps-publishing.co.uk)  
Tel: 0870 1616662  
Fax: 0870 1616663  
Fax from outside the UK: +44 1904 430868

NHS and public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30–40 titles). The commercial subscription rate is £300 per volume. Please contact York Publishing Services at the address above. Subscriptions can only be purchased for the current or forthcoming volume.

#### **Payment methods**

##### *Paying by cheque*

If you pay by cheque, the cheque must be in **pounds sterling**, made payable to *York Publishing Distribution* and drawn on a bank with a UK address.

##### *Paying by credit card*

The following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.

##### *Paying by official purchase order*

You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK.

#### **How do I get a copy of HTA on CD?**

Please use the form on the HTA website ([www.ncchta.org/htacd.htm](http://www.ncchta.org/htacd.htm)). Or contact York Publishing Services (see contact details above) by email, post, fax or phone. *HTA on CD* is currently free of charge worldwide.

---

The website also provides information about the HTA Programme and lists the membership of the various committees.

# **Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation**

S Ward\*  
E Kaltenhaler  
J Cowan  
N Brewer

School of Health and Related Research, University of Sheffield, UK

\* Corresponding author

**Declared competing interests of authors:** none of the authors have any financial interest in the companies producing or marketing capecitabine or Uftoral.

Published November 2003

---

This report should be referenced as follows:

Ward S, Kaltenhaler E, Cowan J, Brewer N. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. *Health Technol Assess* 2003;7(32).

*Health Technology Assessment* is indexed in *Index Medicus/MEDLINE* and *Excerpta Medica/EMBASE*.

# NHS R&D HTA Programme

The NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.

The research reported in this monograph was commissioned by the HTA Programme on behalf of the National Institute for Clinical Excellence (NICE). Technology assessment reports are completed in a limited time to inform the appraisal and guidance development processes managed by NICE. The review brings together evidence on key aspects of the use of the technology concerned. However, appraisal and guidance produced by NICE are informed by a wide range of sources.

The research reported in this monograph was funded as project number 01/56/01.

The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme, NICE or the Department of Health. The editors wish to emphasise that funding and publication of this research by the NHS should not be taken as implicit support for any recommendations made by the authors.

## Criteria for inclusion in the HTA monograph series

Reports are published in the HTA monograph series if (1) they have resulted from work commissioned for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA Programme Director:

Professor Kent Woods

Series Editors:

Professor Andrew Stevens, Dr Ken Stein, Professor John Gabbay,  
Dr Ruairidh Milne, Dr Chris Hyde and Dr Rob Riemsma

Managing Editors:

Sally Bailey and Sarah Llewellyn Lloyd

The editors and publisher have tried to ensure the accuracy of this report but do not accept liability for damages or losses arising from material published in this report.

ISSN 1366-5278

© Queen's Printer and Controller of HMSO 2003

This monograph may be freely reproduced for the purposes of private research and study and may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising.

Applications for commercial reproduction should be addressed to HMSO, The Copyright Unit, St Clements House, 2–16 Colegate, Norwich, NR3 1BQ.

Published by Gray Publishing, Tunbridge Wells, Kent, on behalf of NCCHTA.

Printed on acid-free paper in the UK by St Edmundsbury Press Ltd, Bury St Edmunds, Suffolk.

T

## Abstract

### Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation

S Ward,\* E Kalenthaler, J Cowan and N Brewer

School of Health and Related Research, University of Sheffield, UK

\* Corresponding author

**Objectives:** To evaluate the clinical and cost-effectiveness of capecitabine and tegafur with uracil (UFT/LV) as first-line treatments for patients with metastatic colorectal cancer, as compared with 5-fluorouracil/folinic acid (5-FU/FA) regimens.

**Data sources:** Electronic databases, reference lists of relevant articles and sponsor submissions were also consulted.

**Review methods:** Systematic searches, selection against criteria and quality assessment were performed to obtain data from relevant studies. Costs were estimated through resource-use data taken from the published trials and the unpublished sponsor submissions. Unit costs were taken from published sources, where available. An economic evaluation was undertaken to compare the cost-effectiveness of capecitabine and UFT/LV with three intravenous 5-FU/LV regimens widely used in the UK: the Mayo, the modified de Gramont regimen and the inpatient de Gramont regimens.

**Results:** The evidence suggests that treatment with capecitabine improves overall response rates and has an improved adverse effect profile in comparison with 5-FU/LV treatment with the Mayo regimen, with the exception of hand–foot syndrome. Time to disease progression or death after treatment with UFT/LV in one study appears to be shorter than after treatment with 5-FU/LV with the Mayo regimen, although it also had an improved adverse effect profile. Neither capecitabine nor UFT/LV appeared to improve health-related quality of life. Little information on patient preference was available for UFT/LV, but there was indicated a strong preference for this over 5-FU/LV. The total cost of capecitabine and UFT/LV treatments were estimated at £2111 and £3375, respectively, compared with the total treatment cost for the Mayo regimen of £3579. Cost estimates were also presented

for the modified de Gramont and inpatient de Gramont regimens. These were £3684 and £6155, respectively. No survival advantage was shown in the RCTs of the oral drugs against the Mayo regimen. Cost savings of capecitabine and UFT/LV over the Mayo regimen were estimated to be £1461 and £209, respectively. Drug acquisition costs were higher for the oral therapies than for the Mayo regimen, but were offset by lower administration costs. Adverse event treatment costs were similar across the three regimens. It was inferred that there was no survival difference between the oral drugs and the de Gramont regimens. Cost savings of capecitabine and UFT/LV over the modified de Gramont regimen were estimated to be £1353 and £101, respectively, and over the inpatient de Gramont regimen were estimated to be £4123 and £2870, respectively.

**Conclusions:** The results show that there are cost savings associated with the use of oral therapies. No survival difference has been proven between the oral drugs and the Mayo regimen. In addition, no evidence of a survival difference between the Mayo regimen and the de Gramont regimens has been identified. However, improved progression-free survival and an improved adverse event profile have been shown for the de Gramont regimen over the Mayo regimen. Further research is recommended into the following areas: quality of life data should be included in trials of colorectal cancer treatments; the place of effective oral treatments in the treatment of colorectal cancer, the safety mechanisms needed to ensure compliance and the monitoring of adverse effects; the optimum duration of treatment; the measurement of patient preference; and a phase III comparative trial of capecitabine and UFT/LV versus modified de Gramont treatment to determine whether there was any survival advantage and to collate the necessary economic data.



# Contents

<b>Glossary and list of abbreviations .....</b>	vii	Cost and benefit assumptions .....	55
<b>Executive summary .....</b>	ix	Need for further research .....	56
<b>1 Aim of the review .....</b>	1	<b>8 Conclusions .....</b>	57
<b>2 Background .....</b>	3	<b>Acknowledgements .....</b>	59
Description of underlying health problem .....	3	<b>References .....</b>	61
Current service provision .....	4	<b>Appendix 1 WHO criteria for evaluation of response .....</b>	65
Description of new intervention .....	6	<b>Appendix 2 5-FU-based treatment regimens .....</b>	67
<b>3 Effectiveness .....</b>	9	<b>Appendix 3 Continuous infusion versus bolus 5-FU regimens – meta-analysis .....</b>	69
Methods for reviewing effectiveness .....	9	<b>Appendix 4 Continuous infusion versus bolus 5-FU regimens – RCTs .....</b>	75
Results .....	10	<b>Appendix 5 Summary of de Gramont study results .....</b>	81
<b>4 Economic analysis .....</b>	29	<b>Appendix 6 Performance status scales .....</b>	83
Overview .....	29	<b>Appendix 7 Search strategies .....</b>	85
Identification of studies .....	29	<b>Appendix 8 National Cancer Institute common toxicity criteria .....</b>	91
Methods for economic evaluation .....	36	<b>Appendix 9 Unit costs used in economic evaluation .....</b>	93
Cost analysis .....	42	<b>Health Technology and Assessment reports published to date .....</b>	95
Impact on the NHS .....	47	<b>Health Technology and Assessment Programme .....</b>	103
<b>5 Implication for other parties .....</b>	49		
Work days lost .....	49		
Support of families and friends .....	49		
Transportation .....	49		
<b>6 Factors relevant to the NHS .....</b>	51		
Outreach clinics .....	51		
Cost incentives within the NHS .....	51		
Pharmacy and nursing time .....	51		
Training for doctors and nurses .....	51		
Concordance .....	51		
Place of oral chemotherapy in combination therapy .....	52		
<b>7 Discussion .....</b>	53		
Main results .....	53		
Assumptions, limitations and uncertainties .....	55		



# Glossary and list of abbreviations

## Glossary

**Adjuvant chemotherapy** Chemotherapy given after apparently curative surgery to increase the chance of cure.

**Advanced disease** Cancer which has spread either locally or to distant sites such that a curative complete resection cannot be performed.

**Cost-effectiveness** Measures the net cost of providing a service and the outcomes obtained.

**Cost minimisation** If health effects are known to be equal, only costs are analysed and the least costly alternative is chosen.

**Duration of response** Period from first day of treatment until the date progressive disease was first noted.

**Failure-free survival** The length of time from the start of treatment to either the first evidence of disease progression, unacceptable toxicity or death.

**First-line treatment** Treatment of patients for advanced disease who have not previously received chemotherapy for advanced disease (but may have received previous adjuvant therapy).

**Friction-cost method** A valuation of work time lost based on the assumption that in short periods of illnesses (a friction period) the productivity losses associated with the loss of a single worker are less than the productivity of that worker had she/he been able to work.

**Progression-free survival** The length of time from the start of treatment to either the first evidence of disease progression or death.

**Response rate** See Appendix 1.

**Second-line treatment** Treatment of patients who have previously received chemotherapy for advanced disease.

**Time to progression** From date of randomisation to the first recorded observation of progressive disease or the occurrence of death from any cause.

**Time to treatment failure** As for time to disease progression but additionally including toxicity-related premature withdrawals, failure to return and treatment refusals as events.

## List of abbreviations

5-FU	5-fluorouracil
AIO	Arbeitsgemeinschaft Internische Onkologie
AUC	area under the curve
BMS	Bristol-Myers Squibb

BNF	British National Formulary
CI	confidence interval
CR	complete response

*continued*

### List of abbreviations continued

DPD	dihydropyrimidine dehydrogenase	MdG	modified de Gramont
ECOG	Eastern Cooperative Oncology Group	MRC	Medical Research Council
EORTC QLQ-C30	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire	NCCTG	National Colorectal Cancer Treatment Group
FA	folinic acid (leucovorin, calcium folinate)	NCIC	National Cancer Institute of Canada
FDA	Food and Drug Administration	NICE	National Institute for Clinical Excellence
FLIC	Functional Living Index – Cancer	NS	not significant
IRC	Independent Review Committee	PD	progressive disease
ITT	intention to treat	PR	partial response
i.v.	intravenous	PSSRU	Personal and Social Services Research Unit
LV	leucovorin (folinic acid, calcium folinate)	PVI	protracted venous infusion
LYG	life-year gained	RCT	randomised controlled trial
MAOP	Mid-Atlantic Oncology Program	SWOG	Southwest Oncology Group
		QoL	quality of life
		UFT	tegafur with uracil (Uftoral®)
		VAT	value added tax

All abbreviations that have been used in this report are listed here unless the abbreviation is well known (e.g. NHS), or it has been used only once, or it is a non-standard abbreviation used only in figures/tables/appendices in which case the abbreviation is defined in the figure legend or at the end of the table.

## Executive summary

### Description of proposed service

The service evaluated in this review is the use of capecitabine and tegafur with uracil (UFT/LV) as first-line treatments for patient with metastatic colorectal cancer.

### Epidemiology

Colorectal cancer (cancers of the colon and rectum combined) accounts for 13% of all cancers in England and Wales and is the second most common cancer in the UK, after lung cancer. In 1997, 28,900 cases of colorectal cancer were diagnosed in England and Wales, of which about two-thirds were in the colon and one-third in the rectum. Incidence increases with age. The median age of patients at diagnosis is just under 70 years.

Approximately 80% of patients with colorectal cancer undergo surgery and, of these, 40% will remain disease-free in the long term.

Approximately 20% of patients with colorectal cancer present with advanced disease and, of these, approximately 50% will have liver metastases. Median survival after diagnosis of metastatic disease is approximately 6–9 months. Patients may have a variety of symptoms, both physical and psychological, which detract from their quality of life and often require hospital admission.

Colorectal cancer is a significant cause of premature mortality, with 48% of deaths occurring in the under-75 age group. It is also a significant cause of morbidity. The main aims of treatment for patients with metastatic colorectal cancer are to relieve symptoms, increase survival and improve quality of life.

### Number and quality of studies and direction of evidence

Two published randomised controlled trials (RCTs) of capecitabine, along with one separate report pooling data from the same two studies, met the inclusion criteria. These studies compared treatment with capecitabine to treatment with the

Mayo clinic 5-fluorouracil/leucovorin (5-FU/LV) regimen. Duration of response, time to disease progression or death, time to treatment failure and overall survival were found not to be significantly different between the two treatments. Overall response rates, assessed by the investigator, were significantly greater in both trials in the capecitabine group, whereas overall response rates, as assessed by an independent review committee, were found to be significantly greater for the capecitabine group in one of the trials and pooled data. With regard to toxicity, patients in the capecitabine group reported less diarrhoea, stomatitis, nausea and alopecia of all grades than those in the 5-FU/LV groups. Those in the capecitabine group also had significantly less grade 3–4 neutropenia and less frequent hospitalisation for adverse events. Hand–foot syndrome and grade 3 hyperbilirubinaemia was significantly greater in the capecitabine group. Despite this improved toxicity profile, the reported health-related quality of life did not differ significantly between the capecitabine and 5-FU/LV groups in either trial.

Two RCTs of treatment with Uftoral®/leucovorin (UFT/LV) met the inclusion criteria. One trial compared UFT/LV with the standard Mayo 5-FU/LV regimen and the other compared UFT/LV with a modification of the Mayo regimen. There were no significant differences with regard to overall response rates, duration of response or survival between UFT/LV and 5-FU/LV in either trial. Time to disease progression was significantly inferior for the UFT/LV group than the 5-FU/LV group in one study, although there was no difference in time to disease progression between UFT/LV and 5-FU/LV in the second study. Treatment with UFT/LV was associated with significantly less diarrhoea, nausea/vomiting, mucositis, neutropenia and thrombocytopenia of all grades compared with 5-FU/LV in one study and fewer episodes of stomatitis/mucositis, neutropenia, thrombocytopenia and anaemia of any grade in the other study. With regard to grade 3–4 toxicity, mucositis, neutropenia, thrombocytopenia and anaemia were much less frequent in the UFT/LV group in one study and grade 3–4 stomatitis/mucositis and neutropenia were much less common in the second study.

Significantly increased bilirubin was more common among UFT/LV patients than in those treated with 5-FU/LV in the first study. As with the capecitabine studies, despite this improved toxicity profile, reported health-related quality of life did not differ significantly between the UFT/LV and 5-FU/LV groups in either trial.

Economic evidence reviewed in this analysis includes a pharmaco-economic study of UFT costs in South America and two resource-use studies, one relating to evidence from the Hoff capecitabine trial and the other to results from the UFT/LV trial by Carmichael. None of the evidence identified was directly applicable to the situation of England and Wales. Two sponsor submissions received by the National Institute for Clinical Excellence (NICE) from Roche and Bristol-Myers Squibb were also reviewed.

## **Summary of benefits**

There is good evidence to suggest that treatment with capecitabine improves overall response rates and has an improved adverse effect profile in comparison with 5-FU/LV treatment with the Mayo regimen, with the exception of hand-foot syndrome. There is no evidence comparing capecitabine with infusional 5-FU schedules such as the de Gramont or modified de Gramont regimens, both commonly used as standard treatment in the UK.

Time to disease progression or death after treatment with UFT/LV in one study appears to be shorter than after treatment with 5-FU/LV with the Mayo regimen. There is no evidence comparing UFT/LV with treatment with the de Gramont or modified de Gramont regimen. Treatment with UFT/LV had an improved adverse effect profile compared with 5-FU/LV treatment with the Mayo regimen.

Neither capecitabine nor UFT/LV appeared to improve health-related quality of life. Information on patient preference was available for UFT/LV only from a small crossover trial. Patients appeared strongly to prefer treatment with UFT/LV over 5-FU/LV.

## **Costs**

Costs were estimated through resource-use data taken from the published trials and the unpublished sponsor submissions. Unit costs were

taken from published sources, where available. The total cost of capecitabine and UFT/LV treatments were estimated at £2111 and £3375 respectively, compared with the total treatment cost for the Mayo regimen of £3579. Cost estimates were also presented for the modified de Gramont and inpatient de Gramont regimens. These were £3684 and £6155, respectively.

## **Cost-effectiveness**

An economic evaluation was undertaken to compare the cost-effectiveness of capecitabine and UFT/LV with three intravenous 5-FU/LV regimens widely used in the UK: the Mayo, the modified de Gramont regimen and the inpatient de Gramont regimens.

No survival advantage was shown in the RCTs of the oral drugs against the Mayo regimen. Cost minimisation analyses were therefore undertaken for both oral therapies against the Mayo regimen. Cost savings of capecitabine and UFT/LV over the Mayo regimen were estimated to be £1461 and £209, respectively. Drug acquisition costs were higher for the oral therapies than for the Mayo regimen, but were offset by lower administration costs. Adverse event treatment costs were similar across the three regimens.

No direct evidence comparing either capecitabine or UFT/LV treatment with de Gramont regimens was identified and therefore an indirect comparison was undertaken for the purposes of economic evaluation. On the basis that no proven survival difference between the Mayo and the de Gramont regimens was identified, it was inferred that there was no survival difference between the oral drugs and the de Gramont regimens. Cost minimisation analyses of the oral therapies against the de Gramont regimens were performed. Cost savings of capecitabine and UFT/LV over the modified de Gramont regimen were estimated to be £1353 and £101, respectively. Cost savings of capecitabine and UFT/LV over the inpatient de Gramont regimen were estimated to be £4123 and £2870, respectively.

Cost-effectiveness analyses were also undertaken, for illustrative purposes, to explore the impact of adopting an assumption of survival benefit of de Gramont regimens over the oral regimens. Infusional regimens have been shown to be more effective than bolus regimens in terms of progression-free survival, tumour response and toxicity. The impact of a potential difference in

progression-free survival between the oral drugs and the infusional regimens was explored in terms of the impact on the cost per progression-free life year gained. The results are illustrative only. Further direct evidence on the survival benefits and costs of oral therapies relative to infusional regimens is required before any robust conclusions can be drawn from this type of analysis.

## Conclusion

The results show that there are cost savings associated with the use of oral therapies. No survival difference has been proven between the oral drugs and the Mayo regimen. In addition, no evidence of a survival difference between the Mayo regimen and the de Gramont regimens has been identified. However, improved progression-free survival and an improved adverse event profile have been shown for the de Gramont regimen over the Mayo regimen and these need to be taken into consideration. These issues can only be indirectly addressed in the absence of direct randomised comparisons between the oral drugs and optimum infusional 5-FU regimens.

## Need for further research

The following points have been identified as areas requiring further research:

- Quality of life data should be included in trials of colorectal cancer treatments. Well-validated instruments should be used and this research should be conducted by independent researchers. It may be necessary to use more

than one instrument in order to identify differences in quality of life and then the components of quality of life that vary with different treatments.

- More research is needed to determine the place of effective oral treatments in the treatment of colorectal cancer. This should focus on when such treatments should be given alone and when they should be given in combination with other chemotherapeutic agents. Research is needed on the combination of oral agents with other chemotherapy agents (notably irinotecan and oxaliplatin) and novel agents.
- Some types of patients may benefit more from oral treatment than others. Research is needed to determine what safety mechanisms are needed in order to ensure compliance and the monitoring of adverse effects.
- The optimum duration of treatment needs to be determined with respect to, for example, disease progression, response, unacceptable toxicity or death. Intermittent treatment with a pause after 12 weeks for those with stable or responding disease also needs to be considered.
- The issue of patient preference must be given careful consideration in future trials and all trials should incorporate the measurement of patient preference.
- In order to make a precise estimate of the cost-effectiveness of capecitabine and UFT/LV versus modified de Gramont treatment, a phase III comparative trial would be necessary to determine whether there was any survival advantage and to collate the necessary economic data. This would also give clinicians clear information on survival to present to patients who can then make an informed choice with regard to treatment.



# Chapter I

## Aim of the review

The overall aim of this review is to evaluate the clinical and cost-effectiveness of capecitabine and tegafur with uracil as first-line treatments for patients with metastatic colorectal cancer, as compared with 5-fluorouracil/folinic acid (5-FU/FA) regimens. It reviews these drugs in relation to their licensed indications. Capecitabine is indicated for first-line monotherapy for metastatic colorectal cancer. Tegafur with uracil is indicated for first-line treatment of metastatic colorectal cancer in combination with calcium folinate. This review does not consider the use of chemotherapy in an adjuvant setting or the use of these drugs in combination with other chemotherapy agents or as second-line treatment.

The review does not focus solely on differences between treatment in overall survival and disease progression rates as there is also a need to consider changes in quality of life (QoL) associated with new drug treatment. The review therefore includes any significant impacts that such treatments may have on health-related QoL.

Progression-free survival is considered to be a particularly important outcome measure in relation to the treatment of metastatic colorectal cancer because disease progression may impair both physical and emotional health. However, progression may only become a problem when symptoms develop. Tumour response (see Appendix 1) does not necessarily correspond to

subjective benefit in terms of quality of survival, and subjective improvement (a clinical response) is possible without an objective response. If survival advantage is only modest compared with that provided by alternative regimens, disease-related symptoms and QoL obviously become particularly relevant outcome measures.

The following objectives are therefore contained within the overall aim of the review:

1. to evaluate the clinical effectiveness of the two drugs in terms of disease progression rates, tumour response and time to treatment failure
2. to estimate their effects on overall survival, progression-free survival and QoL adjusted survival
3. to evaluate their adverse-effect profiles and toxicities
4. to estimate the incremental cost-effectiveness of the drugs in comparison to conventional therapy
5. to estimate the possible overall cost of these drugs in England and Wales

In undertaking to achieve the above aims, the review also considers factors such as patient preference and compliance to treatment. Issues associated with routinely used intravenous agents will be considered, such as complications from catheter use.



# Chapter 2

## Background

### Description of underlying health problem

#### Epidemiology of colorectal cancer

Colorectal cancer (cancers of the colon and rectum combined) accounts for 13% of all cancers in England and Wales.<sup>1</sup> It is the second most common cancer in the UK after lung cancer. In 1997, 28,900 cases of colorectal cancer were diagnosed in England and Wales, of which about two-thirds were in the colon and one-third were in the rectum.<sup>1</sup> Males are more frequently affected than females, with an age-standardised male:female ratio of 1.5:1,<sup>1</sup> although some studies suggest that incidence rates for males and females may be similar.<sup>2</sup> The incidence rate per 100,000 (all ages) is 53.5 for men and 36.7 for women.<sup>3</sup> Incidence increases continuously with age in both sexes for both colon and rectal cancers.<sup>1</sup> The median age of patients at diagnosis is just under 70 years.<sup>4</sup>

Risk factors for colorectal cancer are thought to include diets high in fats and animal proteins and low in fruit and vegetables and fibre. Other risk factors associated with developing colon cancer are lack of physical activity and family history of the disease. There is some evidence that colon cancer in women may be related to sex hormones or reproductive history. The risk of developing colorectal cancer is also raised for patients with one or more adenomatous polyps as occurs in familial adenomatous polyposis and other hereditary conditions. The incidence of colorectal cancer is three to four times greater in developed countries than in developing countries.<sup>1</sup> At present there are no established screening services for the general population.<sup>4</sup>

**TABLE 1** Death rates for colorectal cancer in England and Wales in 1998<sup>5</sup>

	Age (years)					Total
	0-44	45-64	65-74	75+		
Deaths	203	2783	4132	7866	14,984	
Rate per 100,000 population	0.6	23.0	93.9	202.3	28.6	

Death rates for England and Wales for 1998 are illustrated in *Table 1*.

Large differences in survival exist according to the stage of disease.<sup>2</sup> The overall 5-year survival rate in England is 35%; however, within Britain, there is evidence of wide variations in treatment and outcomes.<sup>3</sup> *Table 2* shows the modified Dukes' staging of colorectal cancer with 5-year survival.

On average, patients survive for 3 years after diagnosis.<sup>4</sup> Median survival after diagnosis of metastatic disease is approximately 6–9 months. The 5-year survival rate for advanced colorectal cancer is lower than 5%.<sup>6</sup> Patients may develop a variety of symptoms during this time, both physical and psychological.<sup>7</sup> In about 20% of cases of colorectal cancer, patients present with advanced disease and, of these, approximately 50% will have liver metastasis.<sup>6</sup>

#### Significance in terms of ill-health

Colorectal cancer is a significant cause of premature death, with 48% of deaths occurring in the under-75 age group. It is also a significant

**TABLE 2** Modified Dukes' staging of colorectal cancer, with 5-year survival<sup>a3</sup>

Dukes' stage (modified)	Definition	Approximate frequency at diagnosis (%)	5-year survival (%)
A	Cancer localised within bowel wall	11	83
B	Cancer which penetrates the bowel wall	35	64
C	Cancer spread to the lymph nodes	26	38
D	Cancer with distant metastases (most often in the liver)	29	3

<sup>a</sup> Data from St. Vincent's Hospital, Dublin. These figures are illustrative only, since stage frequency and survival statistics vary between published series from different centres.

cause of morbidity. When treating patients with metastatic colorectal cancer, the main aims of treatment are to relieve symptoms, increase survival and improve QoL. Individual patient preferences for treatment are also important to consider.

There is some evidence that extended survival is not always associated with an overall improvement in QoL. The treatments assessed in this report provide palliative care and offer no real chance of long-term survival. For this reason, information regarding health-related QoL, particularly that associated with treatment-related toxicity, will be given careful consideration. Since chemotherapy can cause disabling adverse effects, assessing QoL outcomes is essential.

## **Current service provision**

### **Overview of current service**

The NHS Executive document 'Improving Outcomes in Colorectal Cancer' outlines current service provision for the diagnosis, treatment and follow-up of patients with colorectal cancer.<sup>4</sup> Approximately 80% of patients with colorectal cancer undergo surgery<sup>3</sup> and chemotherapy is used as an adjuvant treatment after surgery to improve survival.<sup>3</sup> About 50% of patients treated with curative surgery will go on to develop advanced disease and of those with advanced disease, 50% will present with liver metastasis.<sup>6</sup>

Once metastatic disease develops, curative treatment is rarely possible. Resection of liver metastases produces occasional cures in cases where there is no evidence of extra-hepatic disease and the position and size of the metastases is favourable; similarly, resection of isolated lung metastases may be worthwhile. However, for the large majority of patients, treatment is aimed at modest extension of survival with palliation of symptoms. In this situation, chemotherapy is the principle active treatment, although palliative radiotherapy and surgery have a role for some patients with localised symptoms.

There is clear evidence that chemotherapy improves survival and prolongs time to disease progression in patients with advanced colorectal cancer.<sup>8-10</sup> Chemotherapy delays the occurrence or progression of symptoms by about 6 months and improves symptoms, weight gain and functional performance in about 40% of patients.<sup>6</sup> However, patients must be sufficiently fit to receive chemotherapy. Referral patterns and treatment

policies for patients with advanced colorectal cancer vary widely in the UK.<sup>6</sup>

5-Fluorouracil (5-FU) has been the main treatment for advanced colorectal cancer for over 40 years, usually in combination with calcium folinate [calcium leucovorin, leucovorin (LV), folinic acid]. Fluorouracil is a prodrug which is converted intracellularly into metabolites that inhibit the enzyme thymidylate synthase. This prevents DNA synthesis and inhibits RNA and protein synthesis.<sup>11</sup> 5-FU is usually given as a bolus intravenous injection or via infusion as it has erratic oral bioavailability.<sup>11</sup> The addition of calcium folinate enhances response rates.<sup>12</sup>

Trials comparing chemotherapy given immediately on diagnosis of advanced or recurrent disease with chemotherapy for the palliation of symptoms have shown that early chemotherapy increases median survival and that symptom-free survival increases from a median of 2 months to 10 months ( $p < 0.001$ ).<sup>3</sup>

### **5-FU regimens**

A variety of 5-FU-based regimens are currently in use in the UK. Details of these 5-FU regimens are listed in Appendix 2, involving mainly bolus injection or continuous infusion. Bolus regimens typically require frequent hospital visits. Continuous infusion regimens require placement of a venous access device, the use of a portable infusion pump and intravenous infusion supplies.<sup>13</sup> The use of infusional regimens is frequently associated with complications such as infections and thromboses,<sup>14</sup> while bleeding and pneumothorax occur rarely.

Internationally, the most commonly used bolus regimen is the so-called Mayo Clinic or National Colorectal Cancer Treatment Group (NCCTG) schedule and this is also the most frequently used comparator in clinical trials. It is not used as often in the UK as in the past and its use as a comparator in clinical trials is a reflection of current practice in the USA rather than in the UK.

A meta-analysis comparing continuous infusion of 5-FU with bolus administration found that continuous infusion administration was superior in terms of tumour response and resulted in a slight increase in overall survival.<sup>15,16</sup> The results of the meta-analysis are presented in detail in Appendix 3.

The three infusional regimens currently in use in the UK are the Lokich, the de Gramont and the

modified de Gramont, with the de Gramont and modified de Gramont being more frequently used. A randomised trial comparing the de Gramont regimen with the Mayo bolus regimen found the de Gramont regimen to have significantly better response rates and progression-free survival than the Mayo regimen and equivalent median survival times.<sup>17</sup> Grade 3–4 toxicities also occurred in more patients in the Mayo regimen than in the de Gramont. The results of this trial are presented in detail in Appendix 4.

The de Gramont regimen has been demonstrated to be equivalent to the Lokich infusional regimen in terms of survival, QoL and response rates, although the Lokich regimen was associated with more central line complications and hand–foot syndrome<sup>18</sup> (palmar–plantar erythrodysesthesia), which causes unpleasant and painful reddening of the soles of the feet and palms of the hands.

Response rates, progression-free survival and median overall survival for the de Gramont regimen have been reported in comparisons of this regimen with other treatment regimens.<sup>19,20</sup> The range of reported response rates, progression-free survival and overall median survival for the de Gramont regimen from four studies are reported in Appendix 5. It is difficult to compare the results of different studies for several reasons, apart from the fact that they use different comparators. Some studies report intention to treat (ITT) analyses whereas others use per protocol analyses. In one study, de Gramont and colleagues<sup>17</sup> only included patients with measurable lesions in the response rate analyses in both arms of the trial. Some values have been assessed by the investigators themselves whereas others have used independent assessors. Finally, the studies were designed to use different primary outcome measures and are therefore not directly comparable. However, the figures reported in Appendix 5 give an overall picture of the range of values reported in these studies.

The de Gramont regimen is repeated every 14 days. It can be administered on an inpatient or outpatient basis. A modified de Gramont regimen has been developed whereby LV and bolus 5-FU are given only on the first day of treatment, followed by a higher dose 5-FU infusion over 46 hours. This requires the insertion of a central line as a day-case procedure, thus enabling most patients to be treated as outpatients, spending half a day in the day unit and receiving a home visit from a district nurse for each course of treatment. A dose-escalation study was used to confirm the

activity of this regimen and to establish the optimum dose.<sup>21</sup> A pilot study has indicated that this modified de Gramont regimen is associated with higher compliance, fewer treatment delays and significantly higher QoL than the inpatient de Gramont regimen.<sup>22</sup> However, for any regimen which uses indwelling venous lines, the line itself may present significant problems. For example, a report from the Royal Marsden Hospital has indicated that 11% of Hickman lines used for protracted venous infusion 5-FU have to be removed unplanned, most commonly because of superficial infection, pain, line slippage, septicaemia or thrombosis.<sup>23</sup>

Approximately 60% of patients who receive first-line 5-FU/LV therapy have a response or a period of stable disease. This is temporary, however, and drug resistance develops. About 40% of patients have disease that does not respond to 5-FU. Second-line treatments may then be used. Recently, the National Institute for Clinical Excellence (NICE) recommended that irinotecan monotherapy may be used as second-line treatment for patients who have failed an established 5-FU-containing treatment regimen.<sup>24</sup>

## Combination therapies

Recently interest has centred on the possibility of combining drugs with different mechanisms to treat colorectal cancer. Several randomised controlled trials (RCTs) have demonstrated that combination chemotherapy with 5-FU/LV and either oxaliplatin or irinotecan produces a higher response rate, longer time to progression and in some cases better overall survival than 5-FU/LV alone.<sup>21,20</sup> A current Medical Research Council (MRC) trial (CR08; FOCUS) is further examining these combinations, comparing their effect on overall survival and QoL when used as routine first-line therapy for all patients, or as planned second-line therapy after an initial trial of 5-FU/LV alone. This trial is expected to report in 2004; meanwhile, NICE has recommended that oxaliplatin/5-FU/LV should be considered for patients with metastases that are confined to the liver and may become resectable following treatment.<sup>24</sup>

## Variation in services

Patterns for referral vary widely throughout the country. Performance status will have a bearing on whether or not a patient is eligible for chemotherapy. Those with a poor performance status (3 or 4 on the WHO Performance Scale) are not able to benefit from chemotherapy. Therefore, many patients, particularly elderly patients, are managed in the primary care setting.

There is no clear evidence as to which 5-FU regimen is most frequently used in the UK. As the de Gramont regimen was recently found to be superior<sup>17</sup> to the Mayo regimen, more clinicians are now using this or the modified de Gramont regimen. Treatment regimen may also vary depending on where patients would like to be treated. As the de Gramont regimen is relatively expensive, some centres may not use it.<sup>7</sup>

### **Current service cost**

The care and treatment of patients with colorectal cancer in the UK have been estimated to account for approximately 2% of all bed days and for between 10 and 20% of all palliative care provision.<sup>25</sup>

## **Description of new intervention**

Two new drugs, capecitabine and tegafur with uracil, have been proposed for first-line treatment of patients with metastatic colorectal cancer. They will be discussed separately below. Both drugs are administered orally.

### **Summary of product characteristics**

#### **Capecitabine (Roche)**

Capecitabine (*N*-[1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl]-*m*-pentyl carbamate; Ro 09-197) is a cytotoxic fluoropyrimidine carbamate. It is an oral 5-FU pro-drug with no anti-tumour activity itself.<sup>26</sup> It is metabolised in the body via three sequential enzyme steps to produce 5-FU within tumours. Capecitabine is preferentially activated in tumour tissue.<sup>13</sup>

The UK licence for capecitabine is held by Roche and it is marketed as Xeloda®. Xeloda is available as blisters of film-coated tablets in two sizes: 60 × 150 mg (six blisters of 10 tablets) and 120 × 500 mg (12 blisters of 10 tablets).

Xeloda is indicated for first-line monotherapy of metastatic colorectal cancer. It is also used in the treatment of advanced or metastatic breast cancer.

The recommended dose is 1250 mg/m<sup>2</sup> administered twice daily (morning and evening; equivalent to 2500 mg/m<sup>2</sup> total daily dose) for 14 days followed by a 7-day rest period.<sup>27</sup>

Xeloda is contraindicated in patients with

- a history of severe and unexpected reactions to fluoropyrimidine therapy

- known hypersensitivity to capecitabine, 5-FU or any of the excipients
- known dihydropyrimidine dehydrogenase (DPD) deficiency
- pregnancy and lactation
- severe leucopenia, neutropenia or thrombocytopenia
- severe hepatic impairment
- severe renal impairment (creatinine clearance below 30 ml/min)
- treatment with sorivudine or its chemically related analogues, such as brivudine.

#### **Tegafur with uracil (UFT) (Bristol-Myers Squibb Company)**

Tegafur [FT; ftorafur; 1-(tetrahydro-2-furanyl)-5-fluorouracil] is a furanyl nucleoside analogue of FudR.<sup>28</sup> Tegafur is a prodrug of fluorouracil and the addition of uracil inhibits the degradation of 5-FU. Early clinical trials of UFT were conducted in Japan,<sup>29</sup> where it has been licensed for use since 1983 and has been used to treat a variety of solid tumours.<sup>30</sup> The addition of LV (calcium folinate) acts as a modulator and leads to an improvement in response rates,<sup>28</sup> although this has also been shown to increase toxicity.<sup>31</sup> UFT/LV has been approved for use in the European Union.<sup>32</sup>

The UK licence for UFT is held by Bristol-Myers Squibb and it is marketed as Uftoral®. Uftoral is available as hard, white, opaque capsules imprinted with the code TC434. Each capsule contains tegafur (100 mg) plus uracil (224 mg). Uftoral is indicated as first-line treatment of metastatic colorectal cancer, in combination with calcium folinate in adults.

The recommended dose of Uftoral is tegafur 300 mg/m<sup>2</sup> (with uracil 672 mg/m<sup>2</sup>) daily, combined with 90 mg/day oral calcium folinate, given in three divided doses (preferably every 8 hours) for 28 days with subsequent courses repeated after 7-day intervals giving a treatment cycle of 35 days.<sup>27</sup>

Uftoral is contraindicated in patients who

- have a known hypersensitivity to 5-FU, tegafur, uracil or any of the excipients
- are pregnant or attempting to become pregnant
- are breastfeeding
- are adolescents, children or infants
- have severe hepatic impairment
- present with evidence of bone marrow suppression from previous radiotherapy or antineoplastic agents
- have a known deficiency of hepatic CYP2A6.

### **Identification of patients**

These treatments would only be suitable for patients able to self-medicate or who live with someone able to undertake a supervisory role.

### **Criteria for treatment**

These interventions, capecitabine and UFT/LV, would be used mainly by people with a WHO performance status of 2 or less (see Appendix 6).

These treatments would most likely be supplied in dedicated oncology centres with consultant oncologist supervision. Support for home use of

these drugs would be needed via a call centre or visits from trained nurses.

### **Degree of diffusion**

Both capecitabine and UFT/LV are already in use as first-line treatment for metastatic colorectal cancer, but the full extent of use is not known. The use of these drugs is frequently within the context of clinical trials. There is significant usage of these agents in private practice and some usage in NHS practice whenever a reason for avoidance of a central line can be substantiated.



# Chapter 3

## Effectiveness

### **Methods for reviewing effectiveness**

#### **Identification of studies**

The search strategy aimed to identify all literature relating to the clinical and cost-effectiveness of capecitabine and UFT for the treatment of metastatic colorectal cancer. The main searches were conducted in April and May 2002.

Fifteen electronic bibliographic databases were searched, covering biomedical, science, social science, health economic and grey literature. A list of databases is provided in Appendix 7.

In addition, the reference lists of relevant articles and sponsor submissions were hand-searched and various health services research-related resources were consulted via the Internet. These included health economics and health technology assessment organisations, guideline-producing agencies, generic research and trials registers and specialist sites. A list of these additional sources is given in Appendix 7. Citation searches were conducted on key papers and authors using the Science and Social Science Citation Index facilities.

A combination of free-text and thesaurus terms were used. 'Population' search terms (e.g. colorectal, colon, rectum, neoplasm, carcinoma, adenocarcinoma) were combined with 'intervention' terms (e.g. capecitabine, xeloda, fluoropyrimidine, tegafur, uftoral). Three searches were performed in MEDLINE: the first was the main MEDLINE search, the second was for the epidemiology of colorectal cancer and the third was performed to identify further references specifically on the two 5-FU regimens (de Gramont and Mayo Clinic). Copies of the search strategies used in the major databases are included in Appendix 7.

No language or date restrictions were applied to the searches. The search performed in MEDLINE for the epidemiology of colorectal cancer was limited to 1990–present to ensure that only recent data were reviewed. No language or study/publication-type restrictions were applied to the main searches. An economic evaluations filter was used in the main searches performed in MEDLINE and EMBASE to assist with the

identification of articles for the cost-effectiveness aspect of the review (see Appendix 7).

#### **Inclusion and exclusion criteria**

The titles and abstracts of the papers identified through the search process outlined above were assessed for relevance to the study question using the following criteria.

##### **Inclusion criteria**

Subjects: adults with metastatic colorectal cancer.

Intervention: capecitabine or UFT/LV used alone as first-line treatment.

Comparators: 5-FU/LV regimens for metastatic colorectal cancer.

Outcome measures to include the following:

- survival rates
- progression-free survival
- tumour response
- time to treatment failure
- health-related QoL
- adverse events
- patient preference
- compliance
- cost.

Methodology, to include at least one of the following:


- systematic reviews or meta-analyses
- RCTs
- non-randomised studies (for outcomes where no data from RCTs are available)
- economic evaluations.

Full copies were obtained of all those papers which appeared to be relevant or which could not be assessed on the basis of the abstract alone.

##### **Exclusion criteria**

Papers describing the use of chemotherapy in an adjuvant setting were excluded. Papers describing randomised phase II trials were excluded where phase III evidence was available.

*Figure 1* shows a summary of study selection and exclusion.



**FIGURE 1** Summary of flow of study selection and exclusion: clinical effectiveness. <sup>a</sup>These studies refer to papers of trials of capecitabine and UFT/LV. Other papers are included in this report dealing with background information, patient preference, QoL and toxicity. Studies used in the cost-effectiveness analysis are listed in Chapter 4.

## Quality assessment strategy

The RCTs were assessed for quality using the Jadad criteria.<sup>33</sup> Other criteria were used to assess the quality of the meta-analyses<sup>34</sup> and non-randomised studies.<sup>35</sup>

## Data extraction strategy

Data were extracted by one researcher and checked by a second using customised data extraction forms. Any disagreements were resolved by discussion.

The data extracted from the relevant studies will be presented separately for the two interventions. Where available, the following data will be reviewed in relation to each intervention:

- duration of treatment
- progression-free survival
- overall survival
- tumour response rates
- time to progression or death
- duration of response
- treatment-related deaths
- grade 1–4 toxicities
- QoL
- patient preference.

No meta-analyses of the capecitabine trials were identified, although a study of pooled data was identified.<sup>36</sup> No meta-analyses of the UFT/LV

trials were identified or undertaken. The two trials used different 5-FU regimens and also different dosages of calcium folinate (LV). Meta-analysis was therefore felt to be inappropriate.

## Choice of outcomes

As described above, a variety of end-points form part of the data extracted from the relevant trials in this review. Relevant end-points in evaluating treatments for colorectal cancer include tumour response rates, progression-free survival and overall survival. However, it is not clear how these outcomes relate to each other and which, if any, are most important. In a meta-analysis of 25 randomised trials of first-line treatment comparing standard bolus 5-FU treatment with a variety of experimental fluoropyrimidines, the authors concluded that an increase in tumour response rates translated into an increase in overall survival. However, it was emphasised that knowledge that a treatment improves tumour response rates does not necessarily accurately predict benefit with regard to overall survival.<sup>37</sup>

In another study, Louvet and colleagues<sup>38</sup> suggested that progression-free survival, rather than overall survival, is the most appropriate primary end-point for interpreting effectiveness in studies of metastatic colorectal cancer treatments. They analysed data from 29 phase III trials and found significant correlations between progression-free survival and response rates, between response rates and overall survival and between progression-free survival and overall survival. The strongest correlation was between response rates and progression-free survival.

Progression-free survival reflects the effectiveness of the first-line treatment whereas overall survival reflects the effectiveness of first-line treatment and any second-line treatment used. When comparing treatments where overall survival is equivalent, the use of other end-points is even more important than treatments resulting in different survival times. These end-points include response rates, time to disease progression, tolerability and patients' convenience.<sup>39</sup> Because of the uncertainties surrounding choice of outcome measure, all outcomes reported in the trials are included in this review.

## Results

Two large phase III RCTs<sup>40,41</sup> and one study of pooled data of capecitabine<sup>36</sup> were identified. The evidence from these trials is summarised below in

the next section. No phase III RCTs of capecitabine were excluded from the review.

Two large phase III RCTs of UFT/LV were identified.<sup>42,43</sup> The results of these trials, together with supplementary information, are summarised in the section 'Quality of research available: UFT/LV' (p. 20). No phase III RCTs of UFT/LV were excluded from the review.

Information on QoL and patient preference is presented separately within the relevant sections.

### **Quantity and quality of research available: capecitabine**

Capecitabine is licensed for use as first-line treatment as monotherapy for patients with metastatic colorectal cancer. It is also licensed for use in the treatment of advanced or metastatic breast cancer. This review will deal only with its use in the treatment of metastatic colorectal cancer.

Three studies have been identified which deal with the use of capecitabine as first-line treatment for metastatic colorectal cancer, two RCTs<sup>40,41</sup> and a study of pooled data from these two RCTs.<sup>36</sup> The capecitabine studies included in this review are listed in *Table 3*.

**TABLE 3** Capecitabine studies included in the review

Study	Study site	Comparators, dosage and procedure	Type of study	Numbers randomised	Funding
Hoff <i>et al.</i> , 2001 <sup>40</sup>	61 centres in USA, Canada, Brazil and Mexico	Capecitabine 1250 mg/m <sup>2</sup> twice daily in 3-week cycles (2 weeks of treatment followed by a 1-week rest period)	Open label, phase III RCT	Capecitabine n = 302  5-FU/LV n = 303	Hoffman-LaRoche
Van Cutsem <i>et al.</i> , 2001 <sup>41</sup>	59 centres in Europe, Australia, New Zealand, Taiwan and Israel	Capecitabine 1250 mg/m <sup>2</sup> twice daily in 3-week cycles (2 weeks of treatment followed by a 1-week rest period)  5-FU/LV in Mayo clinic regimen: rapid intravenous (i.v.) injection of 20 mg/m <sup>2</sup> LV followed by an i.v. bolus injection of 425 mg/m <sup>2</sup> 5-FU daily, days 1–5 every 4 weeks	Open label, phase III RCT	Capecitabine n = 301  5-FU/LV n = 301	Hoffman-LaRoche
Twelves 2002 <sup>36</sup>	120 centres (pooled results of above two trials)	As above	Pooled data from the above two phase III trials	Capecitabine n = 603  5-FU/LV n = 604	Not reported

These studies relate to comparisons between treatment with capecitabine and an intravenous 5-FU regimen (Mayo). The two RCTs<sup>40,41</sup> were designed with identical protocols to facilitate pooling of the data. The third study<sup>36</sup> shows the pooled data from these two trials.

### **Study characteristics of included capecitabine studies**

*Tables 4* and *5* illustrate the study design and patient details, respectively. As stated previously, the RCTs were designed with identical protocols. Therefore, the inclusion/exclusion criteria outlined in *Table 4* were identical. Both RCTs were adequately powered to demonstrate at least equivalence in overall response rates. Apart from alkaline phosphatase levels in the Hoff study,<sup>40</sup> there was baseline comparability between the two groups in both RCTs. Baseline levels of serum alkaline phosphatase were significantly elevated in the capecitabine group compared with the 5-FU/LV group, indicating that the 5-FU/LV patients were of an inherently better prognosis.

*Table 5* describes the patient details of the capecitabine studies. For information on the

**TABLE 4** Study design: capecitabine

<b>Study</b>	<b>Length of study</b>	<b>Inclusion criteria</b>	<b>Exclusion criteria</b>	<b>Power calculation</b>	<b>Baseline comparability</b>
Hoff <i>et al.</i> , 2001 <sup>40</sup>	Assessments performed up to 30 weeks for most patients and 48 weeks for those receiving prolonged therapy	Patients with advanced or metastatic disease and no previous chemotherapy for metastatic disease. Adjuvant chemotherapy completed at least 6 months before trial enrolment; histological or cytological confirmation of colorectal adenocarcinoma was required and also at least one bidimensionally measurable indicator lesion that had not been irradiated; at least 18 years of age; Karnofsky performance status ≥70%; life expectancy of at least 3 months	Pregnancy or lactation, hypersensitivity to 5-FU or had previous severe reaction to fluoropyrimidines, history of other cancer within previous 5 years (except for cured basal cell carcinoma of the skin or <i>in situ</i> cervical carcinoma), experimental drugs or radiotherapy within 4 weeks before enrolment or not fully recovered from recent major surgery; patients with organ allografts; CNS involvement of their disease, neurological or psychiatric disorders to interfere with treatment compliance, significant cardiac disease or MI in last 12 months; serious uncontrolled infections; malabsorption syndrome, lack of physical integrity of the upper gastrointestinal tract; abnormalities in neutrophils, platelets, serum creatinine or serum bilirubin, alanine transferase (ALT), aspartate transferase (AST) or alkaline phosphatase (five times upper normal limit for ALT, AST and alkaline phosphatase allowed for those with liver metastases and 10 times alkaline phosphatase for patients with bone metastases)	Sample size was sufficient to achieve 80% power to demonstrate at least equivalence in overall response rates	Yes, apart from serum alkaline phosphatase concentrations at baseline (significantly higher in capecitabine group than 5-FU/LV group, $p < 0.0025$ )
Van Cutsem <i>et al.</i> , 2001 <sup>41</sup>	As above	As above	As above	As above	Yes
Twelves, 2002 <sup>36</sup>	As above	As above	As above	As above	Yes

Karnofsky performance score, see Appendix 6. The primary tumour site was the colon in the majority of patients treated with either capecitabine or 5-FU/LV and the most common site of metastasis was the liver.

#### **Study quality of included capecitabine studies**

Table 6 shows the study quality of the two capecitabine RCTs. The Jadad criteria were used to assess the quality of the RCTs.<sup>33</sup> The Jadad criteria consist of three categories: randomisation

**TABLE 5** Patient details: capecitabine

<b>Study</b>	<b>Sex (M/F)</b>	<b>Age (years)</b>	<b>Performance score</b>	<b>Primary site</b>	<b>Sites of metastasis</b>	
Hoff et al., 2001 <sup>40</sup>	Capecitabine: 181/121 5-FU/LV: 197/106	Median (range): Capecitabine 64.0 (23–86) 5-FU/LV 63.0 (24–87)	Karnofsky performance score: Capecitabine 88.3 5-FU/LV 88.5 Mean 10.0 SD 9.8 Median 90 Range 70–100	Site of primary tumour (%): Colon 222 (73.5) Rectal 79 (26.2) Capecitabine 70 (23.1) 5-FU/LV	Metastatic sites at baseline: Liver 232 Lymph nodes 116 Lung 107 Peritoneum 41 Soft tissue 30 Other 94	
Van Cutsem et al., 2001 <sup>41</sup>	Capecitabine 57/43% 5-FU/LV 57/43%	Median (range): Capecitabine 64.0 (29–84) 5-FU/LV 63.5 (36–86)	Karnofsky performance score: Capecitabine 89.7 5-FU/LV 89.6 Mean 9.7 SD 9.7 Median 90 Range 70–100	Site of primary tumour (%): Colon 66.1 Rectal 33.6 Capecitabine 65.1 5-FU/LV 34.9	Metastatic sites at baseline: Liver 230 Lymph nodes 82 Lung 89 Peritoneum 37 Soft tissue 27 Other 40	
Twelves, 2002 <sup>36</sup>	Capecitabine 60/40% 5-FU/LV 61/39%	Median (range): Capecitabine 64 (23–86) 5FU/LV 63 (24–87)	Karnofsky performance status (%), mean (range): Capecitabine 89 (70–100) 5-FU/LV 89 (70–100)	Site of primary tumour (%), colon/rectal cancer (%): Capecitabine 70/30 5-FU/LV 71/29	Predominant metastatic sites at baseline (%): Liver (%) 77 Lung (%) 12	

SD, standard deviation.

**TABLE 6** Trial quality assessment: capecitabine

Study	Randomised/method	Blinding/appropriate method	Description of withdrawals and dropouts	Jadad score
Hoff et al., 2001 <sup>40</sup>	Yes, computer-generated randomisation code	Open-label trial, so patients were not blinded to treatment. An IRC was blinded to clinical condition of the patient and investigator's assessment and assessed tumour responses solely on the basis of X-ray or scan imaging	Withdrawals and dropouts well described	3/5
Van Cutsem et al., 2001 <sup>41</sup>	Yes, computer-assisted randomisation centre	As above	Withdrawals and dropouts well described	3/5

(including method to generate the sequence of randomisation and whether or not the method was appropriate), double blinding and description of withdrawals and dropouts. The maximum number of possible points is five. The Jadad score of both RCTs was 3, indicating that the studies were of moderate quality. Neither study was double blinded, which resulted in loss of points according to these criteria. However, blinding would be virtually impossible when comparing an oral drug with a bolus 5-FU regimen, as the mode of delivery is different for the two treatments. The problem of blinding was partly overcome in these studies by the use of an Independent Review Committee (IRC) to assess response rates.

The pooled data report<sup>36</sup> included the two RCTs. As they were designed using identical protocols, pooling was an appropriate method of synthesis. The trials were of identical size, giving them equal weight. Meta-analysis techniques were not used in the synthesis so it is not appropriate to assess the quality of the study as if it were a meta-analysis but rather as a large RCT. In this case, the pooled data would receive a score of 3 according to the Jadad criteria, again indicating moderate quality.

#### Assessment of effectiveness of capecitabine

Outcomes for the capecitabine trials are listed in *Table 7* and results are given in *Table 8*. Primary outcomes in both trials were tumour response rates and secondary outcomes included time to response, duration of response, time to disease progression and overall survival. Analyses of efficacy were based on all patients randomised, indicating an ITT analysis.

#### Tumour response rates

Information on the definition of response rates can be found in Appendix 1. Both the Hoff<sup>40</sup> and Van Cutsem<sup>41</sup> studies had tumour response rates as a

primary outcome. Both studies reported response rates as measured by the study investigator and by an IRC, a panel of radiologists who were blinded to study treatment, clinical condition of the patient and investigator's assessment.

In the Hoff study,<sup>40</sup> overall response rates for the capecitabine group were significantly greater than for the 5-FU/LV group when assessed by investigator or by the IRC. Overall response rates were 24.8% [95% confidence interval (CI): 20.1 to 30.1%] for capecitabine and 15.5% (95% CI: 11.6 to 20.1%) for 5-FU/LV ( $p = 0.005$ ) when assessed by investigator. When assessed by the IRC, overall response rates were 25.8% (95% CI: 21.0 to 31.2%) for capecitabine and 11.6% (95% CI: 8.2 to 15.7%) for 5-FU/LV ( $p = 0.0001$ ).

In the Van Cutsem study,<sup>41</sup> investigator-assessed overall response rates were significant for capecitabine at 26.6% (95% CI: 21.7 to 32.0%) compared with 5-FU/LV at 17.9% (95% CI: 13.8 to 22.8%) ( $p = 0.013$ ). However, in the IRC-assessed group, response rates were 18.9% (95% CI: 14.7 to 23.8%) for capecitabine compared with 15.0% (95% CI: 11.1 to 19.5%) for the 5-FU/LV group (not significant) (NS).

In the Twelves study,<sup>36</sup> data from the above two studies were pooled. Investigator-assessed overall response rates were significantly better for the capecitabine arm (25.7% compared with the 5-FU/LV arm (16.7%) ( $p < 0.0002$ ). Overall response rates assessed by the IRC were also significantly better for the capecitabine arm (22.4%) compared with 13.2% for the 5-FU/LV group (13.2%) ( $p < 0.0001$ ). Confidence intervals were not reported.

#### Duration of response

Both the Hoff<sup>40</sup> and the Van Cutsem<sup>41</sup> studies reported no significant difference in mean

**TABLE 7** Outcomes: capecitabine

<b>Study</b>	<b>ITT analysis</b>	<b>Primary end-points</b>	<b>Secondary end-points</b>	<b>Duration of treatment</b>
Hoff et al., 2001 <sup>40</sup>	Yes, analyses of efficacy were based on all randomised patients	Tumour response rate	Time to response, duration of response, time to disease progression, time to treatment failure, overall survival and QoL (results presented separately)	Capecitabine: mean daily dose corresponded to 80% of the scheduled dose and mean duration of treatment was 4.3 months  5-FU/LV: mean daily dose corresponded to 86% of the scheduled dose and mean duration of treatment was 4.6 months
Van Cutsem et al., 2001 <sup>41</sup>	Yes, analyses of efficacy were based on all randomised patients	Tumour response rate	Time to response, duration of response, time to disease progression, time to treatment failure, overall survival and QoL (results presented separately)	Capecitabine: median dose per cycle was 82–100% of that planned; median duration of treatment was 147 days  5-FU/LV: median dose per cycle was between 95–100% of that planned and median duration of treatment was 140 days
Twelves, 2002 <sup>36</sup>	Yes	Tumour response rate	Time to response, time to disease progression, overall survival and time to treatment failure	Not reported

duration of response between the capecitabine and 5-FU/LV groups. In the Hoff study,<sup>40</sup> the median duration of response [complete response (CR) and partial response (PR)] was 9.1 months in the capecitabine group (54 events) and 9.5 months in the 5-FU/LV group (30 events) ( $p = 0.37$ ). In the Van Cutsem study,<sup>41</sup> the median duration of response in responding patients (PR or CR) was 7.2 months in the capecitabine group and 9.4 months in the 5-FU/LV group ( $p = 0.17$ ). Duration of response was not reported by Twelves.<sup>36</sup>

#### Time to disease progression or death

All three studies<sup>36,40,41</sup> report no significant differences in time to disease progression or death between the capecitabine and 5-FU/LV groups. For the Hoff study,<sup>40</sup> median time to disease progression or death was 4.3 (95% CI: 4.1 to 5.1) months for the capecitabine group and 4.7 (95% CI: 4.3 to 5.5) months for the 5-FU/LV group. The Van Cutsem study<sup>41</sup> reported median time to disease progression or death for the capecitabine group as 5.2 months and for the 5-FU/LV group as 4.7 months.

Time to treatment failure in the three studies was also not significantly different between the capecitabine and 5-FU/LV groups. In the Hoff study,<sup>40</sup> the capecitabine group had a time to treatment failure of 4.1 months and the 5-FU/LV group 3.1 months. The Van Cutsem study<sup>41</sup> had a time to treatment failure of 4.2 months for the capecitabine group and 4.0 months for the 5-FU/LV group.

#### Survival

Median overall survival was equivalent for the capecitabine and 5-FU/LV groups in all three studies.<sup>36,40,41</sup> Values were 12.5 and 13.3 months, respectively, for the Hoff study,<sup>40</sup> 13.2 and 12.1 months, respectively, for the Van Cutsem study<sup>41</sup> and 12.9 and 12.8 months, respectively, for the Twelves pooled data report.<sup>36</sup>

#### Secondary chemotherapy

No information was given for either trial or the pooled data regarding crossover to other treatments or information concerning the addition of other chemotherapeutic agents.

**TABLE 8** Results: capecitabine

Study	Response rate	Duration of response	Median time to disease progression or death	Survival
Hoff et al., 2001 <sup>40</sup>	Response rates (%)			
		Capecitabine (n = 302) 5-FU/LV (n = 303)	Median duration of response (CR and PR) was 9.1 months in the capecitabine group (54 events) and 9.5 months in the 5-FU/LV group (30 events) ( $p = 0.37$ )	Median time to disease progression or death
	Investigator			Capecitabine 4.3 (95% CI: 4.1 to 5.1) months (269 events) 5-FU/LV 4.7 (95% CI: 4.3 to 5.5) months (271 events)
	Overall response, CR or PR	75 (24.8) 3 (1.0)	47 (15.5) <sup>a</sup> 3 (1.0)	( $p = 0.72$ , log-rank test)
	CR	72 (23.8)	44 (14.5)	Hazard ratio 1.03 (95% CI: 0.87 to 1.22)
	PR	146 (48.3)	158 (52.1)	
	Stable disease	57 (18.9)	59 (19.5)	
	PD	22 (7.3)	38 (12.5)	
	Missing post-baseline			
	IRC			
	Overall response, CR or PR	78 (25.8)	35 (11.6) <sup>b</sup>	Time to treatment failure Capecitabine: 4.1 months (227 events) 5-FU/LV: 3.1 months (280 events)
	CR	1 (0.3)	1 (0.3)	( $p = 0.19$ , log-rank test)
	PR	77 (25.5)	34 (11.2)	Hazard ratio 0.90 (95% CI: 0.76 to 1.06)
	Stable disease	148 (49.0)	181 (59.7)	
	progressive disease (PD)	43 (14.2)	36 (11.9)	
	Missing post-baseline	30 (9.9)	49 (16.2)	

*continued*

**TABLE 8** Results: capecitabine (cont'd)

<b>Study</b>	<b>Response rate</b>		<b>Duration of response</b>		<b>Median time to disease progression or death</b>	<b>Survival</b>
Van Cutsem et al., 2001 <sup>41</sup>	<i>Response rates (%)</i>		Capecitabine (n = 301) 5-FU/LV (n = 301)		Median duration of response in responding patients (PR or CR) was 7.2 months in the capecitabine group and 9.4 months in the 5-FU/LV group (p = 0.17)	
	<i>Investigator Overall response, CR or PR</i>		26.6	17.9 <sup>c</sup>	Median time to disease progression or death Capecitabine 5.2 months 5-FU/LV 4.7 months (log-rank p = 0.65) Hazard ratio: 0.96 (95% CI: 0.81 to 1.14)	
	<i>IRC</i>		Overall response, CR or PR CR PR Stable disease PD Missing post-baseline		Time to treatment failure Capecitabine 4.2 months 5-FU/LV 4.0 months (log-rank p = 0.89)	
Twelves, 2002 <sup>36</sup>	<i>Response rates (%)</i>		Capecitabine (n = 603) 5-FU/LV (n = 604)		Not reported	
	<i>Investigator</i>		PR + CR (%) (p < 0.0002)		Median time to disease progression or death Capecitabine 4.6 months (95% CI: 4.3 to 5.3) 5-FU/LV 4.7 months (95% CI: 4.3 to 5.4)	
	Stable disease (%)		47.8 52.2		Median time to treatment failure Capecitabine 4.2 months 5-FU/LV 3.6 months	
	<i>IRC</i>		PR + CR (%) (p < 0.0001)		Median time to response 1.7 months for capecitabine and 2.4 months for 5-FU/LV	
	Stable disease (%)		52.9 57.6			
	Both overall response rates were significantly higher in favour of capecitabine using two-sided $\chi^2$ test with Schouten correction					

<sup>a</sup> p = 0.005.<sup>b</sup>  $\chi^2$  test showed the response rate for capecitabine to be significantly greater than that achieved with 5-FU/LV (p = 0.0001).<sup>c</sup> p = 0.013.<sup>d</sup> Confidence intervals and log-rank p values from Hoff et al.<sup>44</sup>

**TABLE 9** Toxicity: capecitabine

Study	Types of side-effects				Treatment-related deaths
Hoff et al., 2001 <sup>40</sup>	<i>Patients with grade 3 and 4 adverse reactions related to treatment; number (%)<sup>a</sup></i>				
		Capecitabine (n = 299)		5-FU/LV (n = 294)	
	All reactions	Grade 3 121 (40.5)	Grade 4 8 (2.7)	Grade 3 105 (35.7)	Grade 4 14 (4.8)
	Total no. of events	199	10	190	19
	Diarrhoea	41 (13.7)	5 (1.7)	33 (11.2)	8 (2.7)
	Hand-foot syndrome	54 (18.1)	NA	2 (0.7)	NA
	Stomatitis	9 (3.0)	0	45 (15.3)	2 (0.7)
	Vomiting	10 (3.3)	1 (0.3)	13 (4.4)	1 (0.3)
	Dehydration	6 (2.0)	1 (0.3)	10 (3.4)	1 (0.3)
	Sepsis	0	0	1 (0.3)	1 (0.3)
	Myocardial infarction	0	0	0	1 (0.3)
	Sudden death	0	1 (0.3)	0	0
	Pneumonia	0	1 (0.3)	0	1 (0.3)
	Septicemia	0	1 (0.3)	0	0
	Viral infection	0	0	0	1 (0.3)
	Renal failure	0	0	0	1 (0.3)
	Respiratory distress	0	0	0	1 (0.3)
	Drug toxicity NOS	0	0	0	1 (0.3)
	<i>Adverse reactions requiring hospitalisation; number (%)</i>				
		Capecitabine (n = 299)		5-FU/LV (n = 294)	
	Total patients hospitalised <sup>b</sup>	34 (11.4)		60 (20.4)	
	Dehydration	8 (2.7)		9 (3.1)	
	Diarrhoea	12 (4.0)		8 (2.7)	
	Infection	1 (0.3)		2 (0.7)	
	Nausea	0		1 (0.3)	
	Neutropenia	0		4 (1.4)	
	Neutropenic fever	0		10 (3.4)	
	Sepsis	0		1 (0.3)	
	Stomatitis	0		10 (3.4)	
	Vomiting	3 (1.0)		5 (1.7)	
	Other	12 (4.0)		12 (4.1)	
	Lower overall incidence and later onset of grade 3 or 4 adverse reactions with capecitabine throughout the entire treatment period ( $p = 0.0037$ , log-rank test) with the difference particularly pronounced during the first 4–5 months. Fewer patients in the capecitabine group required hospitalisation for adverse reactions than in the 5-FU/LV group ( $p = 0.003$ ).				
Van Cutsem et al., 2001 <sup>41</sup>	<i>Patients with grade 3 and 4 adverse reactions related to treatment; number (%)</i>				Capecitabine: 3 patients died from treatment-related adverse reactions (one each from gastrointestinal necrosis, pulmonary embolism and myocardial infarction)
		Capecitabine (n = 297)		5-FU/LV (n = 299)	
		Grade 3	Grade 4	Grade 3	Grade 4
	Diarrhoea	28 (9.4)	4 (1.3)	28 (9.4)	3 (1.0)
	Hand-foot syndrome	48 (16.2)	NA	1 (0.3)	NA
	Stomatitis	3 (1.0)	1 (0.3)	39 (13.0)	1 (0.3)
	Sepsis	0	1 (0.3)	5 (1.7)	2 (0.7)
	Deep venous thrombosis	4 (1.3)	1 (0.3)	0	0
	Neutropenic fever	0	0	2 (0.7)	1 (0.3)
	NA = not applicable, an adverse reaction is listed if reported at grade 3 in >5% of patients in at least one of the treatment groups and all adverse grade 3 or 4 reactions reported in ≥1% of the patients with at least one grade 4 adverse event				
	5-FU/LV: four patients died from treatment-related adverse reactions (cardiac failure, renal tubular necrosis, sepsis and enterocolitis)				

continued

**TABLE 9** Toxicity: capecitabine (cont'd)

Study	Types of side-effects	Treatment-related deaths	
Adverse reactions requiring hospitalisation; number (%)			
		Capecitabine (n = 297)	5-FU/LV (n = 299)
All adverse reactions	35 (11.8)	47 (15.7)	
Dehydration	5 (1.7)	0	
Diarrhoea	13 (4.4)	14 (4.7)	
Hand-foot syndrome	2 (0.7)	0	
Infection	0	4 (1.3)	
Neutropenia	1 (0.3)	2 (0.7)	
Sepsis	1 (0.3)	6 (2.0)	
Stomatitis	1 (0.3)	11 (3.7)	
Vomiting	1 (0.3)	1 (0.3)	
Other	14 (4.7)	11 (3.7)	
Twelves, et al., 2002 <sup>36</sup>	Significantly lower ( $p < 0.001$ ) incidence of diarrhoea (48 vs 58%), stomatitis (24 vs 62%), nausea (38 vs 47%) and alopecia (6 vs 21%) for capecitabine compared with 5-FU/LV. Incidence of vomiting and fatigue was similar in both treatment groups. Hand-foot syndrome (all grades) was the only adverse event to occur more frequently with capecitabine than 5-FU/LV. Hand-foot syndrome led to hospitalisation (0.3%) or withdrawal from treatment (1.7%) infrequently. Grade 3–4 stomatitis occurred in 2% of capecitabine patients but 15% of 5-FU/LV patients ( $p < 0.0001$ )	Treatment-related mortality was 1% in each group.	
	Grade 3 or 4 neutropenia was significantly more common in the 5-FU/LV group than the capecitabine group (21.1 vs 2.2%). Hyperbilirubinaemia was higher in the capecitabine group with a higher percentage in the capecitabine group developing total bilirubin levels $> 1.5$ and $\leq 3$ times the upper limit of normal (grade 3: 18.3% for capecitabine vs 3.3% for 5-FU/LV, $p < 0.0001$ ). Grade 4 hyperbilirubinaemia showed similar rates in both groups (4.5 vs 2.5%, $p = 0.07$ ).		
	Hospitalisation for treatment-related adverse events was significantly less frequent in the capecitabine group than the 5-FU/LV group (11.6 vs 18.0%, $p = 0.0002$ )		
<sup>a</sup> NOS = not otherwise specified; NA= not applicable; an adverse reaction is listed if it was reported at grade 3 in $\geq 5\%$ of patients or grade 4 in any patient.			
<sup>b</sup> Patients could be hospitalised more than once for different adverse events.			

## Toxicity

Toxicity in the form of grade 3 and 4 adverse reactions are listed in *Table 9*. For information on toxicity grading, see Appendix 8.

The Hoff<sup>40</sup> study reports that patients in the capecitabine group had a significantly lower incidence of any grade of diarrhoea, stomatitis, nausea and alopecia compared with the 5-FU/LV group ( $p < 0.0002$ ). The patients in the capecitabine group had a significantly higher incidence of hand-foot syndrome than the 5-FU/LV group. With regard to grade 3 toxicities, stomatitis (15.3 versus 3%) and neutropenia (values not reported) were significantly more frequent in the 5-FU/LV group ( $p < 0.0001$ ). Grade 3 hand-foot syndrome (18.1 versus 0.7%) ( $p < 0.00001$ ) and grade 3–4 hyperbilirubinaemia were more frequently reported in the capecitabine

group than in the 5-FU/LV group. Fewer patients in the capecitabine group required hospitalisation for treatment-related toxicity than those in the 5-FU/LV group (11.4 versus 20.4%) ( $p = 0.003$ ).

The Van Cutsem<sup>41</sup> study also reported significantly less stomatitis and alopecia of any grade in the capecitabine group compared with the 5-FU/LV group ( $p < 0.00001$ ). Hand-foot syndrome was again more frequent in the capecitabine group ( $p < 0.00001$ ). The capecitabine group had a lower incidence of grade 3–4 stomatitis (1 versus 13%) and neutropenia (values not reported) ( $p < 0.00001$ ) but greater incidence of grade 3 hand-foot syndrome (16.2 versus 0.3%) ( $p < 0.00001$ ) and uncomplicated grade 3–4 hyperbilirubinaemia ( $p < 0.0001$ ). Patients in the capecitabine group had fewer hospitalisations due to adverse effects than the 5-FU/LV group (11.8 versus 15.7%) ( $p$  value not reported).

The Twelves study,<sup>36</sup> which pooled data from the above two trials, reported a significantly lower incidence of diarrhoea, stomatitis, nausea and alopecia in the capecitabine group compared with the 5-FU/LV group. Grade 3–4 neutropenia also occurred more frequently in the 5-FU/LV group. Hand–foot syndrome and grade 3 hyperbilirubinaemia occurred more frequently in the capecitabine group. Hospitalisation for adverse events was significantly less frequent in the capecitabine group than the 5-FU/LV group (11.6 versus 18%) ( $p = 0.002$ ). Treatment-related mortality was 1% for each group.

#### **Health-related quality of life**

QoL was assessed in both RCTs of capecitabine although the data have not been published. QoL data were reported in the Roche sponsor submission to NICE.<sup>45</sup> No published health-related QoL studies for capecitabine were identified in the literature searches. Both of the RCTs<sup>40,41</sup> measured QoL using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). The results showed that there was no significant difference in global QoL between the capecitabine and 5-FU/LV groups in either trial. The QoL data are presented in more detail in the section ‘Quality of life evidence’ (p. 35).

#### **Patient preference**

None of the three studies<sup>36,40,41</sup> reported information on patient preference.

#### **Conclusions on effectiveness of capecitabine**

Two trials were identified<sup>40,41</sup> that compared capecitabine with 5-FU/LV administered via the Mayo regimen. An additional study was identified<sup>36</sup> that pooled the data from these two trials. No studies were identified that compared capecitabine treatment with the de Gramont or modified de Gramont 5-FU/LV regimens, both commonly used regimens in the UK.

One study<sup>41</sup> reported only investigator-assessed overall response rates to be significantly greater in the capecitabine group than the 5-FU/LV group. The other trial<sup>40</sup> and the pooled data both found that investigator-assessed and IRC-assessed overall response rates were significantly greater in the capecitabine group than the 5-FU/LV group.

Duration of response, time to disease progression or death, time to treatment failure and overall survival were found not to be significantly different between the capecitabine groups and the 5-FU/LV groups in the two trials and in the pooled data.

With regard to toxicity, patients in the capecitabine groups reported less diarrhoea, stomatitis, nausea and alopecia of all grades than those in the 5-FU/LV groups. Those in the capecitabine group also had significantly less grade 3–4 neutropenia and less frequent hospitalisation for adverse events. Hand–foot syndrome and grade 3 hyperbilirubinaemia was significantly greater in the capecitabine group.

#### **Quantity and quality of research available: UFT/LV**

Tegafur plus uracil administered with folinic acid (UFT/LV) is licensed for use in the UK as first-line treatment of metastatic colorectal cancer. Two phase III RCTs of UFT/LV were identified (011 and 012). Information on these studies was obtained from a variety of sources.

Both studies relate to comparison of UFT/LV with bolus 5-FU. The first, study 011<sup>46</sup> ( $n = 816$ ), compared UFT/LV with the Mayo regimen. The second, study 012<sup>47</sup> ( $n = 380$ ), compared UFT/LV with a modification of the Mayo regimen, where treatment was repeated every 35 days as opposed to the standard 28 days in the Mayo regimen. This non-standard variation of the Mayo regimen is a less dose-intensive regimen and has not been tested for efficacy.

The two trials also differ in that study 011<sup>46</sup> used different dosages of LV for patients in the USA and non-US patients. Patients in the USA received 75 mg/day and those in other countries received 90 mg/day. In study 012,<sup>47</sup> all patients received 90 mg/day of LV.

The UFT/LV studies included in this review are listed in *Table 10*.

#### **Study characteristics of included UFT/LV studies**

*Tables 11* and *12* show the study characteristics of the two included UFT/LV trials.

Inclusion and exclusion criteria were similar although there were some differences, notably that study 012<sup>47</sup> had an upper age limit of 75 years.

The Douillard study (study 011)<sup>46</sup> was adequately powered to demonstrate equivalence as non-inferiority of survival while the Carmichael study (study 012)<sup>47</sup> was adequately powered to determine time to progression.

Baseline comparability was reported and no significant differences between the UFT/LV and 5-FU/LV groups were reported in either of the

**TABLE 10** UFT/LV studies included in the review

Study	Study site	Comparators, dosage and procedure	Type of study	Numbers randomised	Funding
Douillard et al., 2002 <sup>46</sup> Study 011	85 sites in the USA, Canada, Europe and Israel	UFT (300 mg/m <sup>2</sup> /day) with LV (75 or 90 mg/day) given orally for 28 days every 35 days (patients in the USA received 75 mg/day and those in other countries received 90 mg/day)  5-FU (425 mg/m <sup>2</sup> /day) and LV (20 mg/m <sup>2</sup> /day) given i.v. for 5 days every 28 days (Mayo Clinic regimen) for the first two cycles and repeated at intervals of 4–5 weeks	Open-label, phase III RCT	UFT/LV: 409 5-FU/LV: 407	Bristol-Myers Squibb
Carmichael et al., 2002 <sup>47</sup> Study 012	47 sites in Canada, Europe, Israel, Australia and New Zealand	Oral UFT 300 mg/m <sup>2</sup> /day and LV (90 mg/day) both administered for 28 days every 35 days  5-FU (425 mg/m <sup>2</sup> /day) and LV (20 mg/m <sup>2</sup> /day both given i.v. for 5 days every 35 days (not standard Mayo regimen)	Open-label, phase III RCT	380 patients randomised to study (190 for each treatment)	Bristol-Myers Squibb

studies, apart from differences in baseline QoL in the Carmichael study.<sup>47</sup>

No information on the primary tumour site was presented for either study. The most common site of metastases was the liver in both studies.

#### **Study quality of included UFT/LV studies**

The Jadad criteria were used to assess the quality of the RCTs.<sup>33</sup> The Jadad criteria consist of three categories: randomisation (including method to generate the sequence of randomisation and whether or not the method was appropriate), double blinding and description of withdrawals and dropouts. The maximum number of possible points is 5. The Jadad score of both RCTs was 3, indicating moderate quality. Neither study was double blinded, which resulted in loss of points according to these criteria. However, blinding would be virtually impossible when comparing an oral drug with a bolus 5-FU regimen, as the mode of delivery is different for the two treatments. There was no independent assessment of response rates in either study. *Table 13* describes the quality of the two UFT/LV studies.

#### **Assessment of effectiveness of UFT/LV**

*Table 14* describes the outcomes used in the

UFT/LV studies and *Table 15* shows the results. The Douillard study<sup>46</sup> (study 011) used overall survival as the primary end-point whereas the Carmichael study<sup>47</sup> (study 012) used time to disease progression as the primary end-point.

#### **Tumour response rates**

In both studies there was no significant difference between the UFT/LV group and the 5-FU/LV group with regard to overall tumour response rates. Response rates were assessed by the sponsor's physician and an internal review was conducted. In the Douillard study,<sup>46</sup> overall response rates were 11.7% for the UFT/LV group and 14.5% for the 5-FU/LV group, whereas in the Carmichael study,<sup>47</sup> overall response rates were 10.5% for the UFT/LV group and 9.0% for the 5-FU/LV group.

#### **Duration of response**

Both studies reported no significant differences with regard to duration or response, although actual values were not reported for either study.<sup>48</sup>

#### **Time to disease progression or death**

In the Douillard study,<sup>46</sup> time to disease progression was significantly greater in the 5-FU/LV group than the UFT/LV group (3.8 versus

**TABLE II** Study design: UFT/LV

<b>Study</b>	<b>Length of study</b>	<b>Inclusion criteria</b>	<b>Exclusion criteria</b>	<b>Power calculation</b>	<b>Baseline comparability</b>
Douillard et al., 2002 <sup>46</sup> Study 011	Recruitment between June 1995 and August 1997	Previously untreated metastatic colorectal cancer with evaluable or measurable disease; adequate bone marrow (absolute granulocyte count $\geq 2000/\text{mm}^3$ , platelets $\geq 100,000/\text{mm}^3$ ); liver (bilirubin normal) and renal function (creatinine normal); age $\geq 18$ years; unsuitable for definitive surgical resection, prior adjuvant chemotherapy completed more than 6 months prior to enrolment; Eastern Cooperative Oncology Group (ECOG) 0–2	Unstable medical conditions; concurrent serious infections, an oncological emergency on presentation; history of malignant neoplasms other than skin cancer or <i>in situ</i> carcinoma of the cervix	Study designed with 80% power to show equivalence of UFT/LV with 5-FU/LV as non-inferiority of survival	No significant differences reported in baseline characteristics between treatment groups
Carmichael et al., 2002 <sup>47</sup> Study 012	Recruitment between May 1996 and July 1997	Histologically confirmed metastatic colorectal adenocarcinoma with bidimensionally measurable disease or evaluable disease located outside previously irradiated fields (all measurements $\geq 1.5$ cm); between 18 and 75 years; completed any prior colorectal adjuvant treatment at least 6 months prior to enrolment; granulocyte count $\geq 2000/\text{mm}^3$ ; platelet count $100,000/\text{mm}^3$ ; total bilirubin $\leq 1.5 \times$ upper limit of normal; ECOG 0–2	Concurrent uncontrolled medical disorders or prior malignancies other than skin cancer or <i>in situ</i> carcinoma of the cervix; oncology emergency on presentation	Sample size gave study 80% power to detect a hazard ratio of 1.40 between the two treatments with regard to time to progression	No significant differences reported in baseline characteristics between treatment groups apart from differences in baseline QoL

3.5 months,  $p = 0.01$ ). The actual difference was therefore 0.3 month (10 days) and the confidence intervals overlap. Also, the timing of tumour assessments for patients receiving UFT/LV differed from that of patients on 5-FU/LV, making it difficult to compare progression between the arms of the study. There was no significant difference in

time to disease progression in the Carmichael study<sup>47</sup> between the UFT/LV and the 5-FU/LV groups (3.4 and 3.3 months, respectively).

### Survival

There were no significant differences in median survival time between the UFT/LV group and the

**TABLE 12** Patient details: UFT/LV

<b>Study</b>	<b>Sex (M/F)</b>	<b>Age (years)</b>	<b>Performance score</b>		<b>Primary site</b>	<b>Sites of metastasis</b>	
Douillard et al., 2002 <sup>46</sup> Study 011	UFT/LV: 249/160 5-FU/LV: 245/162	Median (range) UFT/LV: 64 (29–88) 5-FU/LV: 64 (22–90)	ECOG (%) performance status	Not reported	Extent of disease (%)	UFT/LV	5-FU/LV
			UFT/LV	5-FU/LV	Liver	325 (79)	237 (80)
			0	45	Lymph node/soft tissue in primary area	120 (29)	124 (30)
			1	48	Lymph node/soft tissue outside primary area	23 (6)	18 (4)
			2	7	Lung	113 (28)	115 (28)
					Visceral, other	29 (7)	30 (7)
					Intestine	15 (4)	35 (9)
					Ascites	5 (1)	9 (2)
					Bone	7 (2)	1 (<1)
					Pleural effusion	2 (<1)	4 (1)
					Not reported	0 (0)	1 (<1)
Carmichael et al., 2002 <sup>47</sup> Study 012	UFT/LV: 128/62 5-FU/LV: 122/68	Median (range) UFT/LV: 61 (30–77) 5-FU/LV: 62 (29–81)	ECOG (%) performance status	Not reported	Extent of disease (%)	UFT/LV	5-FU/LV
			UFT/LV	5-FU/LV	Liver	149 (78)	146 (77)
			0	39	Lymph node/soft tissue in primary area	64 (34)	65 (34)
			1	47	Lymph node/soft tissue outside primary area	17 (9)	14 (7)
			2	14	Lung	58 (31)	55 (29)
					Visceral, other	12 (6)	8 (4)
					Intestine	28 (15)	21 (11)
					Ascites	4 (2)	8 (4)
					Bone	2 (1)	9 (5)
					Pleural effusion	6 (3)	4 (2)
					Not reported	2 (1)	2 (1)

**TABLE 13** Trial quality assessment: UFT/LV

<b>Study</b>	<b>Randomised/method</b>	<b>Blinding/appropriate method</b>	<b>Description of withdrawals and dropouts</b>	<b>Jadad score</b>
Douillard et al., 2002 <sup>46</sup> Study 011	RCT, secure remote centralised randomisation procedure	Open-label trial, no blinding reported	Withdrawals and dropouts clearly described	3/5
Carmichael et al., 2002 <sup>47</sup> Study 012	RCT, secure remote centralised randomisation procedure	Open-label study, no blinding reported	Withdrawals and dropouts clearly described	3/5

**TABLE 14** Outcomes: UFT/LV trials

<b>Study</b>	<b>ITT analysis</b>	<b>Primary end-points</b>	<b>Secondary end-points</b>	<b>Duration of treatment</b>
Douillard et al., 2002 <sup>46</sup> Study 011	Analyses of efficacy are based on data from all randomised patients	Survival	Response rate; time to disease progression	Median duration of treatment in weeks (range) UFT/LV: 16.6 (0.7–120) 5-FU/LV: 16.7 (0.7–69.4)
Carmichael et al., 2002 <sup>47</sup> Study 012	Analyses of efficacy are based on data from all randomised patients	Time to disease progression	Response rates, median survival	Mean percentage of planned dose UFT/LV: 92.6 5-FU/LV: 85.1

5-FU/LV group for either study.<sup>46,47</sup> Median survival in the Douillard study (study 011)<sup>46</sup> was 12.4 months in the UFT/LV group and 13.4 months in the 5-FU/LV group, whereas in the Carmichael study (study 012),<sup>47</sup> median survival was 12.2 months in the UFT/LV group and 10.3 months in the 5-FU/LV group.

Additional analysis of survival was reported by Benner,<sup>49</sup> showing survival for study 011 to be worse in US study sites.<sup>49</sup> As stated previously, the US sites in study 011 used a different dosage of LV compared with the non-US sites, which could potentially be responsible for the difference in survival. No US sites were included in study 012, in which all UFT/LV patients received the same dosage of LV.

#### Secondary chemotherapy

In the Douillard study,<sup>46</sup> secondary chemotherapy was administered to 52% of patients in the

UFT/LV group and 50% in the 5-FU/LV group, although data on type of drugs were not collected. In the Carmichael study,<sup>47</sup> 41% of patients in the UFT/LV group and 39% in the 5-FU/LV group received secondary chemotherapy, including fluoropyrimidines, irinotecan and oxaliplatin.

#### Toxicity

Table 16 shows the toxicity results for the UFT/LV trials (see Appendix 8 for toxicity criteria). In the Douillard study,<sup>46</sup> UFT/LV was associated with significantly less diarrhoea, nausea/vomiting, mucositis, neutropenia and thrombocytopenia than 5-FU/LV for all grades. Grade 3–4 toxicity was also found less commonly with UFT/LV than with 5-FU/LV for mucositis (1 versus 20%), neutropenia (1 versus 56%), thrombocytopenia (0 versus 2%) and anaemia (3 versus 7%). Increased bilirubin, without other liver function abnormalities, was significantly more common in

**TABLE 15** Results: UFT/LV trials

<b>Study</b>	<b>Response rate</b>		<b>Duration of response</b>	<b>Median time to disease progression or death</b>	<b>Survival</b>
Douillard et al., 2002 <sup>46</sup> Study 011	Response rates				
		UFT/LV (n = 409)	5-FU/LV (n = 407)	No significant differences between treatment arms with regard to duration of response; values not reported	3.5 months (95% CI: 3.0 to 4.4 months) for UFT/LV and 3.8 months (95% CI: 3.6 to 5.0) for 5-FU/LV ( $p = 0.01$ , stratified log-rank)
	Total tumour response, n (%)	48 (11.7)	59 (14.5)		Median survival 12.4 months (95% CI: 11.2 to 13.6 months) for UFT/LV group and 13.4 months (95% CI: 11.6 to 15.4 months) for 5-FU/LV group (NS)
	CR	8 (2)	8 (2)		
	PR	40 (10)	51 (13)		
	Stable disease	148 (36)	168 (41)		
	PD	167 (41)	130 (32)		
	Unevaluable	46 (11)	50 (12)		
	Toxicity/early death	21	21		
	Not assessed	19	15		
	Never treated	4	10		
	Other	2	4		
Carmichael et al., 2002 <sup>47</sup> Study 012	Response rates				
		UFT/LV (n = 190)	5-FU/LV (n = 190)	No significant differences between treatment arms with regard to duration of response; values not reported	3.4 months (95% CI: 2.6 to 3.8 months) for UFT/LV and 3.3 months (95% CI: 2.5 to 3.7 months) for 5-FU/LV ( $p = 0.591$ )
	Total tumour response, n (%)	20 (10.5)	17 (9)		Median survival 12.2 months (95% CI: 10.4 to 13.8) for UFT/LV and 10.3 months (95% CI: 8.2 to 13.0) for 5-FU/LV ( $p = 0.682$ )
	CR	2 (1)	2 (1)		
	PR	18 (9)	15 (8)		
	Stable disease	65 (34)	71 (37)		
	PD	81 (43)	83 (44)		
	Unevaluable	24 (13)	19 (10)		
	Toxicity/early death	11	4		
	Not assessed	2	4		
	Never treated	3	4		
	Other	8	7		

**TABLE 16** Toxicity for UFT/LV trials

Study		Types of side-effects						Treatment-related deaths	
		Any (CTC grades 1–4)		Severe (CTC grades 3 and 4)					
		UFT/LV, N (%)	5-FU/LV, N (%)	UFT/LV, N (%)	5-FU/LV, N (%)	p-Value			
Douillard et al., 2002 <sup>46</sup> Study 011	Diarrhoea	271 (67)	299 (76)	86 (21)	63 (16)	NS	A total of 65 patients died within 30 days of last administration of treatment drug, 10% in UFT/LV group and 6% in 5-FU/LV group. In the UFT/LV group, 7% died due to the disease alone and 3% due to other causes, including cardiac arrest, pulmonary embolism, aspiration pneumonitis, lactic acidosis and disease/toxicity.		
	Nausea/vomiting	273 (67)	296 (75)	53 (13)	39 (10)	NS			
	Mucositis	97 (24)	297 (75)	6 (1)	76 (20)	<0.00			
	Neutropenia	52 (13)	302 (77)	3 (1)	219 (56)	<0.00			
	Thrombocytopenia	84 (21)	123 (31)	0 (0)	8 (2)	0.003			
	Anaemia	333 (83)	343 (87)	13 (3)	26 (7)	0.032			
Carmichael et al., 2002 <sup>47</sup> Study 012	Diarrhoea	102 (54)	111 (60)	NS	33 (18)	21 (11)	NS	In the 5-FU/LV group, 3% died due to disease alone, 1 died due to 5-FU/LV toxicity and the rest due to other causes including cardiac and/or respiratory arrest, pulmonary embolism and myocardial infarction	
	Nausea/vomiting	106 (56)	108 (58)	NS	17 (9)	17 (9)	NS		
	Stomatitis/mucositis	34 (18)	102 (55)	<0.001	3 (2)	29 (16)	<0.001		
	Neutropenia	21 (11)	120 (67)	<0.001	5 (3)	55 (31)	<0.001		
	Thrombocytopenia	33 (18)	50 (28)	0.025	1 (1)	4 (2)	NS		
	Anaemia	143 (76)	160 (89)	0.002	9 (5)	7 (4)	NS		
UFT/LV treatment resulted in fewer episodes of febrile neutropenia ( $p < 0.001$ ) and documented infection ( $p = 0.40$ )									

UFT/LV patients than those treated with 5-FU/LV (39 versus 22%) ( $p < 0.001$ ). No data were reported regarding amount of hospitalisation due to treatment-related adverse effects.

In the Carmichael study,<sup>47</sup> UFT/LV treatment resulted in significantly fewer episodes of stomatitis/mucositis, neutropenia, thrombocytopenia and anaemia of any grade than

the 5-FU/LV treatment. With regard to grade 3–4 adverse events, UFT/LV treatment resulted in significantly less stomatitis/mucositis (2 versus 16%) and neutropenia (3 versus 31%). A total of 127 patients were hospitalised during the study, 59 (31%) in the UFT/LV group and 68 (37%) in the 5-FU/LV group. Reasons for hospitalisation were not reported apart from for five patients, all in the 5-FU/LV group, who were hospitalised for febrile neutropenia.

### **Health-related quality of life**

Health-related QoL for UFT/LV was included in both studies.<sup>46,47</sup> In the Douillard study<sup>46</sup> QoL was measured using the Functional Living Index – Cancer (FLIC) and in the Carmichael study<sup>47</sup> using EORTC QLQ-C30. No significant differences in QoL were found between the two treatment groups in either study. These data are presented in more detail in the section ‘Quality of life evidence’ (p. 35).

QoL was also measured in an unpublished preliminary report (study CA 146-075). This trial was an open-label, phase II randomised, non-comparative study to evaluate health-related QoL, patient preference and healthcare resource use. These data are presented in the sponsor submission<sup>48</sup> only and used the EORTC QLQ-C30 to measure health-related QoL at baseline and every week during the first course of therapy. Patients were treated with UFT (300 mg/m<sup>2</sup>/day) and LV (90 mg/day) administered for 28 days every 35 days ( $n = 137$ ) or 5-FU (425 mg/m<sup>2</sup>/day) and LV (20 mg/m<sup>2</sup>/day) intravenously for 5 days repeated every 4 weeks for two cycles then every 35 days ( $n = 65$ ). Preliminary data from this trial show scores for functional and symptom scales to be either improved or unchanged from baseline in the UFT/LV group over time but worse in the 5-FU/LV group. Symptom scores on diarrhoea worsened for both treatment groups. No information is given regarding the actual values or significance.

### **Patient preference**

Borner and colleagues<sup>50</sup> reported a crossover trial of 37 patients with advanced colorectal cancer. Patients received UFT 300 mg/m<sup>2</sup>/day plus LV 90 mg/m<sup>2</sup>/day for 28 days every 5 weeks or intravenous 5-FU 425 mg/m<sup>2</sup>/day plus LV 20 mg/m<sup>2</sup>/day for 5 days every 4 weeks. Patients were crossed-over to the other treatment regimen for the second treatment cycle. Patients were asked to complete a therapy preference questionnaire prior to the first and after the second treatment cycle. Thirty-six patients were included in the trial

(one was excluded owing to elevated serum bilirubin) and, of these, 31 completed the questionnaire. Of those who completed the questionnaire, 84% preferred the UFT/LV regimen. Reasons for preference of the UFT/LV regimen included being able to take medication at home, less stomatitis and diarrhoea and being able to use a tablet instead of an injection.

### **Conclusions on the effectiveness of UFT/LV**

Two trials of UFT/LV<sup>46,47</sup> were identified in the literature searches, both comparing UFT/LV with 5-FU/LV treatment, one using the standard Mayo regimen and one using a modification of the Mayo regimen. No studies were identified that compared UFT/LV treatment with the de Gramont or modified de Gramont 5-FU/LV regimens, both in common use in the UK.

The two UFT/LV trials are not comparable for three main reasons. First, the comparator in the Douillard study<sup>46</sup> was the standard Mayo 5-FU/LV regimen whereas that in the Carmichael study,<sup>47</sup> as stated above, was a modification of the Mayo 5-FU/LV regimen that has not yet been tested for efficacy. Second, the Douillard study<sup>46</sup> used two different doses of leucovorin, depending on the study site, whereas the Carmichael study<sup>47</sup> used only one dosage. Finally, the primary outcome measures differ in that the Douillard study<sup>46</sup> used survival and the Carmichael study<sup>47</sup> used time to disease progression as primary outcome measures.

There were no significant differences with regard to overall response rates, duration of response or survival between UFT/LV and 5-FU/LV in either trial. Time to disease progression was significantly inferior for the UFT/LV group than the 5-FU/LV group in the Douillard study.<sup>46</sup> There was no difference in time to disease progression between the two groups in the Carmichael study,<sup>47</sup> although this is possibly due to the use of a non-standard Mayo regimen. The use of this less dose-intensive regimen may make it less effective, thereby obscuring any deficit in the effectiveness of UFT/LV. It is worth noting that survival in the 5-FU/LV group was much lower in this study (10.3 months) than in the Douillard study<sup>46</sup> (13.4 months) whereas the UFT/LV survival was similar in the two studies (12.4 and 12.2 months).

With regard to toxicity, in the Douillard study,<sup>46</sup> UFT/LV was associated with significantly less diarrhoea, nausea/vomiting, mucositis, neutropenia

and thrombocytopenia than 5-FU/LV for all grades and mucositis, neutropenia, thrombocytopenia and anaemia for grades 3–4. Increased bilirubin, without other liver function abnormalities, was significantly more common in UFT/LV patients than those treated with 5-FU/LV ( $p < 0.001$ ). No data were reported regarding amount of hospitalisation due to treatment-related adverse effects.

In the Carmichael study,<sup>47</sup> UFT/LV treatment resulted in significantly fewer episodes of stomatitis/mucositis, neutropenia, thrombocytopenia and anaemia of any grade. With regard to grade 3–4 adverse events, UFT/LV treatment resulted in significantly less stomatitis/mucositis and neutropenia.

# Chapter 4

## Economic analysis

### Overview

In this chapter, the published economic literature is reviewed, along with the economic analyses included as part of the sponsor submissions from Roche (capecitabine)<sup>45</sup> and Bristol-Myers Squibb (UFT/LV).<sup>48</sup> In addition, we have undertaken our own economic evaluation.

### Identification of studies

Studies were identified through a systematic search of medical databases, as detailed in Chapter 3. Two economic evaluations by Murad and colleagues<sup>51,52</sup> were found, based on the same South American study comparing UFT with 5-FU. Two resource use studies were also identified, one relating to medical resource use in the two capecitabine trials<sup>53</sup> and one to resource use in the Carmichael UFT/LV trial.<sup>54</sup> No published cost-effectiveness evaluations were found for capecitabine.

In addition to the published studies, an economic evaluation was included as part of the sponsor submissions from Roche<sup>45</sup> and Bristol-Myers Squibb.<sup>48</sup>

### Review of existing economic evidence

#### **Murad and colleagues, 1997<sup>51,52</sup>**

An economic evaluation was undertaken of the treatment of patients with colorectal cancer in Brazil and Argentina. This study estimated the total cost of a course of treatment over 18 months with UFT/LV compared with a course of treatment with 5-FU. The treatment regimen with 5-FU was not given. Therapeutic equivalence was assumed. The study used a modified Delphi technique with a panel composed of three physicians from Brazil and three from Argentina. Costs were divided into four categories: pre-chemotherapy care, chemotherapy cycles, chemotherapy follow-up and adverse event management. Cost per life year gained (LYG) was not estimated.

The results were divided by country and by chemotherapy for metastatic disease or adjuvant chemotherapy. The treatment cost in US\$ for metastatic colorectal cancer in Brazil was \$10,179

(£6454) for UFT and \$10,491 (£6652) for 5-FU. The savings incurred through use of UFT treatment were \$312 (£198). In Argentina, the treatment cost was \$12,369 (£7483) for UFT and \$13,557 (£8596) for 5-FU. The savings incurred through UFT treatment were \$1188 (£753). The cost savings came mainly in the area of adverse event management. All other cost areas were fairly similar. In Brazil, the pre-chemotherapy cost favoured UFT, but all other cost areas (excepting adverse events) favoured 5-FU. In Argentina, all cost areas favoured UFT. A Monte Carlo sensitivity analysis gave a range of cost savings between \$250 (£159) and \$410 (£260) for Brazil and \$1500 (£951) and \$875 (£555) for Argentina. The authors of this study concluded that there was an economic advantage for oral UFT over 5-FU in the treatment of colorectal cancer in Brazil and Argentina.

A number of issues make this study difficult to apply to the UK context. This study was not based on an RCT, but rather on a panel of physicians attempting to simulate a real-world situation, as experienced in their practices. No information was given on which resources were actually used in the cost calculations, and whether the treatment regimens were relevant to the UK setting. Also, the small number of physicians on the panel means that treatment options, particularly in the treatment of adverse effects, will be biased towards the preferences of these physicians. The study noted that an improved adverse effect profile could have a positive effect on QoL, but no QoL data were collected. The authors concluded that prospective economic research and quality of life evaluations are needed to assess the economic impact of UFT treatment.

#### **Ollendorf, 1999<sup>54</sup>**

This study examined the use of inpatient and outpatient services in an international phase III trial comparing UFT plus LV with 5-FU plus LV<sup>43</sup> in patients with metastatic colorectal cancer. In this trial, 5-FU/LV was given according to a modified Mayo regimen with doses of 425 mg/m<sup>2</sup> daily for 5 days every 5 weeks. All hospital and nursing home admissions were recorded, including hospitalisations for febrile neutropenia, infection, tumour progression, drug toxicity and

transfusion. Drug administration data were not collected. Outpatient services included GP consultations, hospitals, private nurses, physiotherapists and home-help visits.

The number of hospitalisations recorded was higher among the 5-FU/LV group than the UFT/LV group, as was the total number of days in hospital. No difference was observed between the groups in use of outpatient services. Among patients who were employed at baseline, fewer UFT/LV patients missed work owing illness than 5-FU/LV patients, and the mean number of days of work lost was lower in the UFT/LV group. The author concluded that UFT with LV may be associated with reductions in the use of inpatient services and work loss due to illness among patients with metastatic colorectal cancer.

This study is useful but limited. It gives volumes of resources used, but formal hypothesis testing was not undertaken as the study was not adequately powered to detect potentially important differences between treatment groups in the measures of interest and the comparator regimen was not standard. Also, other resources used over a course of treatment are not mentioned in this study, and no benefits were calculated.

#### **Twelves and colleagues, 2001<sup>53</sup>**

This group analysed the resource use of 602 patients with advanced or metastatic colorectal cancer in an international trial comparing capecitabine treatment with Mayo regimen 5-FU/LV treatment.<sup>41</sup> Data were collected on hospital visits required for drug administration, hospital admissions, and drugs and unscheduled consultations with physicians for the treatment of adverse effects. Treatment-related resource use included clinic visits, both number and duration, and chemotherapy agents. Resource use related to adverse event management included consultations, hospitalisation days and treatments for the management of adverse effects.

The number of hospital visits per patient for drug administration was 2109 for capecitabine patients and 7625 for 5-FU/LV patients. The number of hospital days for adverse event management was 368 for capecitabine patients and 477 for 5-FU/LV patients. The number of consultations for the treatment of adverse events was similar in the two arms. Drug use for the management of adverse events was analysed with emphasis on expensive drugs that are likely to be economically important. Increased quantities of expensive drugs were required for the treatment of adverse events

stemming from 5-FU/LV treatment compared with capecitabine treatment, where the most common side-effect was hand–foot syndrome, which was treated with inexpensive creams. No estimation of benefit was made in this study.

The authors concluded that capecitabine in comparison with 5-FU/LV leads to a reduction in medical resource use and improved response rate and tolerability, and that the data support capecitabine as the preferred fluoropyrimidine-based regimen for the treatment of advanced colorectal cancer.

This study is not a cost-effectiveness analysis and does not calculate costs or cost per LYG. However, it is useful because the resource use is likely to be similar to that of the UK, and UK prices combined with international resource use would give a good estimate of likely UK costs.

#### **Roche sponsor submission<sup>45</sup>**

An unpublished sponsor submission received from Roche used the Van Cutsem<sup>41</sup> and Hoff<sup>40</sup> trial evidence in their calculations. They made no mention of any other studies in terms of cost-effectiveness. The submission included an economic evaluation of first-line treatment with capecitabine for patients with advanced colorectal cancer. This evaluation is reviewed below.

The Roche sponsor submission presents the hypothesis that “capecitabine as a monotherapy treatment in advanced colorectal cancer is at least cost-effective, but most likely cost-saving compared to the Mayo regimen using the England and Wales perspective”.<sup>45</sup> Roche used outcome and resource use data from the Van Cutsem and Hoff trials, which were funded by Roche. Roche were involved as sponsors of the work and therefore may have access to data that were not available to ScHARR.

#### **Cost estimates**

Their costing took an NHS perspective, using a time horizon spanning from start of treatment until progression of the disease (4–5 months). Therefore, drug costs and administration were assumed to be incurred during this short time period, and costs were not discounted. Costs incurred after disease progression were not included. Costs are summarised in Table 17.

Drug doses were assumed to be the same as those used in the clinical trials: capecitabine 1250 mg/m<sup>2</sup> twice daily for 14 days every 3 weeks, as licensed and recommended in the Summary of Product Characteristics; and infusional 5-FU/LV given by

**TABLE 17** Costs (£) used in Roche model

Component of healthcare utilisation	Capecitabine	Mayo regimen	Net cost savings
Hospital use	434	503	68
Infusion administration (hospitalisation only)	0	2707	2,707
Transportation to hospital for treatment	0	333	333
Drug therapy	2072	725	-1347
Treating adverse events	166	681	515
Physician consultations	39	28	-11
Total costs	2713	4979	2266

the Mayo regimen of calcium folinate 20 mg/m<sup>2</sup> followed by 5-FU 425 mg/m<sup>2</sup> for 5 days every 4 weeks. All doses were based on an average patient of 1.7 m<sup>2</sup>. The report stated that the Mayo regimen 5-FU/LV may be considered a suitable comparator, since it is one of the many intravenous regimens used widely in the UK. Costs of calcium folinate and infusional 5-FU, and also capecitabine, were the same as those on the British National Formulary (BNF) website (BNF No. 43).<sup>55</sup> LV costs were not discounted, although they are known to be in practice.

The cost of administration was only calculated for the Mayo regimen. The only administration costs presented were the additional number of hospital visits incurred by patients on the Mayo regimen. Doctor and nurse time and the cost of infusions were not included for either treatment regimen, which means that the calculated administration cost of capecitabine was zero. Five hospital outpatient visits were assumed per cycle for most patients, with a small proportion of trial participants who required overnight visits for infusion assigned the cost of an inpatient day. We disagree with this method, since based on consultation with clinicians we have assumed that patients undergoing capecitabine treatment will have at least one scheduled consultation with a specialist each cycle, to discuss their treatment and any adverse effects they might be experiencing and receive their new prescription. The number of scheduled consultations would likely be higher for capecitabine patients than for Mayo patients, since the cycle is shorter and adverse events would have to be monitored more carefully. Therefore, the non-hospitalisation costs of administration are unlikely to be equivalent, and should have been calculated for both arms.

The cost of adverse event-related hospitalisations was calculated using the average number of hospitalisations per patient and the cost of an inpatient hospital day from Netten and colleagues<sup>56</sup> This cost was similar across both arms

of the study (£434 for capecitabine treatment and £503 for Mayo regimen). Unit costs and resource use were not presented in the sponsor report, but were available in the spreadsheet document that accompanied the submission. Costs were also calculated for unscheduled physician consultations related to adverse events (£39 for capecitabine and £28 for Mayo) and the drug costs of treating adverse events (£166 for capecitabine and £681 for Mayo). There were errors in the spreadsheet calculations of these drug costs, however, and the numbers should have been lower for both arms.

Return transportation ambulance costs (£333) were included for a proportion of Mayo patients as established by a survey conducted by Roche. No transportation costs were included for capecitabine patients since no administration costs were assumed.

The total amount over the cost horizon used in the analysis was £2713 for capecitabine treatment and £4979 for Mayo regimen treatment. The main differences came in the areas of drug cost, which favoured Mayo, administration, which favoured capecitabine, and the cost of drug therapy for the treatment of adverse events, which favoured capecitabine. The cost of capecitabine itself accounted for the majority of the capecitabine treatment cost. Administration made up the largest proportion of Mayo regimen costs. Treatment time was similar across both treatment arms, so duration of treatment did not contribute substantially to the cost difference.

### Outcomes

It seems that the intention was to use survival, progression-free survival and quality-adjusted survival as outcomes; however, since the survival difference was negligible, a cost-minimisation analysis was performed instead. Outcome results were used from the trials mentioned above.<sup>40,41</sup> Although capecitabine patients experienced a higher response rate, there was no statistical difference in time to progression or overall survival, so therapeutic equivalence was assumed.

### Cost minimisation analysis

The incremental cost of the Mayo regimen over capecitabine, according to the Roche analysis, is £2266. Therefore, the use of capecitabine presents a cost saving to the NHS. The authors conclude that capecitabine is dominant over the Mayo regimen owing to an improved side-effect profile and more convenient administration.

### Sensitivity analysis

The main savings with capecitabine lie in the areas of administration and adverse events. Since capecitabine cannot be administered intravenously and 5-FU/LV cannot be administered orally, the administration costs were not tested in the sensitivity analysis. Therefore, the sensitivity analysis dealt only with variations in adverse event rates. Three extreme scenarios were tested, one in which neither arm experienced any side-effects, one in which capecitabine patients did but Mayo patients did not, and one in which Mayo patients did but capecitabine patients did not. In every scenario, capecitabine was cost saving, showing that adverse event rates, although they contribute to the cost difference, do not change the advantage of capecitabine over Mayo.

A threshold analysis was performed to find the maximum average cost of a visit to the hospital for Mayo administration. The authors found that this cost would be £17, and concluded that since this low figure was impossible to achieve, capecitabine was clearly cost saving.

No sensitivity analysis was performed for the cost of either drug, despite the fact that this element makes up a large proportion of total treatment costs, and discounts are frequently given to hospital pharmacies on the cost of calcium folinate.

### Discussion of Roche economic evaluation

Although the published paper on resource use based on the capecitabine trials was well constructed and comprehensive, the cost analysis included in the sponsor submission was too brief and included errors and omissions.

Although the comparator chosen was suitable, many different intravenous 5-FU regimens are used in the UK, and it would be useful for comparison to see the cost savings of capecitabine over other commonly used regimens. The time horizon of time to progression seems suitable, since there is no evidence on which treatment might be used as second-line therapy after capecitabine treatment, or what proportion of patients would receive any second-line treatment.

The decision to perform a cost-minimisation analysis was reasonable, since there was no difference in survival outcomes. The cost calculations themselves, however, were of poor quality. No resource use data or unit costs were given in the report, and the explanations of how the costs had been categorised and collected were unclear. The sensitivity analysis did not test enough variables to show that the cost of capecitabine was robust.

No mention of QoL was made in the economic evaluation, despite the fact that QoL data had been collected from the trials by a well-validated method. The results of the postal survey conducted by Roche on society preferences were presented, however. The authors concluded that the survey demonstrated a societal preference for a description of capecitabine treatment over a description of Mayo treatment. The preference results for other kinds of treatment were not presented.

Despite these deficiencies, however, the cost differences are small, and it is unlikely that in any case capecitabine would become more expensive than the Mayo regimen unless the drug price were to be raised substantially. Therefore, the errors do not impact the authors' conclusion that capecitabine provides a cost-saving option with therapeutic equivalence to Mayo regimen 5-FU.

### Bristol-Myers Squibb sponsor submission<sup>48</sup>

The unpublished sponsor submission from Bristol-Myers Squibb (BMS)<sup>48</sup> reviewed the South American study by Murad and colleagues<sup>51,52</sup> and also cost analyses by Avon, Somerset, Wiltshire Cancer Services (November 2000) and Devon and Cornwall Cancer Services (March 1999) as well as a NICE rapid review of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.<sup>24</sup> It also included a brief summary of an economic evaluation commissioned by BMS comparing UFT/LV with intravenous 5-FU/LV treatment. This economic evaluation used a Markov model over a 5-year time horizon to estimate costs of treatment with 5-FU/LV and UFT/LV. The model included first- and second-line chemotherapy costs, costs of palliative care, treatment of adverse events, hospitalisations not due to adverse events and monitoring. The results showed a minor cost saving in favour of UFT/LV (£289 per patient), with the majority of savings arising from decreased hospitalisation costs for administration.

The submission also included two economic evaluations of UFT/LV as a first-line treatment for advanced colorectal cancer, one based on each of

the studies funded by BMS: Douillard and colleagues<sup>42,46</sup> and Carmichael and colleagues.<sup>43</sup> The trials each used different infusional 5-FU/LV regimens, one with a 4-week cycle and one with a 5-week cycle. The authors chose to present the 5-week cycle trial<sup>43</sup> in the main body of the report, despite an irregular administration schedule and a smaller patient population. The reasoning is that because UFT/LV is given on a 5-week cycle the difference in cycle lengths between the two treatment arms has the potential to affect the relative number of cycles received and therefore the costs. Also, a number of patients in the Douillard study<sup>46</sup> received a reduced LV dose. Although different resource use was recorded in the two trials owing to different trial protocols, the main cost areas of drugs and administration were included in both trials, so the total cost-effectiveness should be similar.

### Cost estimates

The costing took an NHS perspective with a time horizon lasting the same length as treatment time in the trials, since costs were based on actual resource utilisation data from the trials. Since treatment times were less than 1 year and costs incurred outside of treatment were not counted, no costs were discounted. Average costs are summarised in *Table 18* and *19*.

Drug costs were calculated from the actual doses prescribed in the trial. A standard dose consisted of 300 mg/m<sup>2</sup> daily UFT and 90 mg daily LV, both for 28 days followed by a 7-day rest period. Dose

reductions and escalations were accounted for by assuming an average dose of 250 mg/m<sup>2</sup> for dose reductions and 350 mg/m<sup>2</sup> for dose escalations. The mean body surface area of patients in this trial was 1.83 m<sup>2</sup>, and all doses are based on this. The expected cost per patient for UFT/LV treatment was £2315 in the Carmichael trial. The LV cost was discounted by 87% for both UFT and 5-FU/CV treatments, based on market research conducted by BMS. The 5-FU/LV dose was 425 mg/m<sup>2</sup> 5-FU with 20 mg LV daily for 5 days every 5 weeks. The expected cost per patient on 5-FU/LV treatment was £269.

Administration resource use data were not collected in the Carmichael study, but consultation with an oncologist determined that UFT/LV patients would visit an oncologist once a cycle so that tests could be performed and another cycle could be prescribed. 5-FU/LV patients visited a chemotherapy unit each time their medication was delivered. It was assumed that 5-FU/LV patients would require more expensive day case visits whereas UFT/LV patients would only require the cost of a medical oncology outpatient follow-up appointment. The costs of both appointments were taken from NHS reference costs. The authors took a conservative approach and assumed that UFT/LV patients would visit a specialist once a week for the first treatment cycle, and once each cycle thereafter. The expected cost of chemotherapy administration was £4160 for patients treated with 5-FU/LV and £592 for patients treated with UFT/LV.

**TABLE 18** Average costs (£) per patient in the Carmichael trial,<sup>47</sup> from the BMS submission<sup>48</sup>

Resource component	UFT/LV	5-FU/LV	Incremental cost
Chemotherapy medications	2315	269	2046
Chemotherapy administration	592	4160	-3568
Hospitalisations	272	387	-115
Concomitant medications	17	14	4
Other medical resources	50	69	-18
Total direct costs	3246	4897	-1651

**TABLE 19** Average costs (£) per patient in the Douillard study,<sup>46</sup> from the BMS submission<sup>48</sup>

Resource component	UFT/LV	5-FU/LV	Incremental cost
Chemotherapy medications	2471	293	2178
Chemotherapy administration	606	5279	-4673
Hospitalisations	314	346	-32
Healthcare visits	60	59	1
Diagnostic procedures	166	158	8
Concomitant medications	3	4	-1
Total direct costs	3620	6138	-2518

Adverse event costs were given in terms of number and cost of hospital admissions. NHS reference costs were used to estimate the average cost of an admission of patients suffering from various conditions. The admission cost was multiplied by the number of admissions recorded for each condition in the trials. Because many admissions did not fall into any of the categories, the number of admissions in the 'Other' category was more than all the specific categories combined. As the 'Other' category was so broad, it is possible that there is a large margin for error in these cost estimates. All hospitalisations over the treatment period were included in these calculations, not only those resulting directly from treatment.

The costs of concomitant medications and clinical procedures were also included in the submission, but contributed little to either the incremental cost or the total cost. These medications and tests are generally incurred with all treatments, leading to a similar cost for capecitabine and Mayo as well as UFT/LV.

Indirect costs were also estimated in the sponsor submission, in terms of the number of work days lost by patients in the Carmichael trial. The value of lost work time using the UK average weekly wage and the friction-cost method was approximately £799 per UFT/LV patient and £1030 per 5-FU/LV patient.

### Outcomes

The outcome used in this analysis is improvement in toxicity end-points. UFT/LV was not inferior to 5-FU/LV in any toxicity end-point in the trial, which led the authors to perform a cost-effectiveness analysis. Because the authors had decided to do a cost-effectiveness analysis, only the end-points that favoured UFT/LV were appropriate for the evaluation. The incremental cost-effectiveness ratios derived from these clinical end-points represent the extra cost of UFT/LV for an additional patient to be free of the specified adverse event. Only toxicity end-points that significantly favoured UFT/LV were considered in the economic evaluation. These outcomes included both grades 1–4 and grades 3–4 stomatitis/mucositis, leucopenia and neutropenia, and also thrombocytopenia of any grade, febrile neutropenia and infection/fever.

### Cost-effectiveness analysis

Because the total cost of UFT/LV treatment was lower than 5-FU/LV treatment and the only end-points used favoured UFT/LV, UFT/LV was found

to be dominant in every case, and hence an incremental analysis was not performed.

### Sensitivity analysis

A sensitivity analysis showed that the incremental cost of UFT/LV is relatively robust, most sensitive to chemotherapy administration costs and least sensitive to adverse event hospital costs and other medical resource costs. The only scenarios in which UFT/LV cost more than 5-FU/LV were where the cost of chemotherapy administration was £86 for both groups or if LV was acquired at BNF list prices.<sup>55</sup> The incremental cost of UFT/LV over 5-FU/LV varied from -£2365 to +£866.

Because cost is most sensitive to administration costs, a threshold analysis was performed to test the number and cost of specialist consultations and outpatient visits for the administration of UFT/LV. In the base case, UFT/LV patients received an average of 1.775 specialist consultations per cycle and each consultation costs £86. To be equal in cost to 5-FU/LV patients, the number of consultations each cycle would be 6.730. If the cost per consultation is £218, cost equivalence would be achieved at 2.657 consultations per cycle.

### Discussion of Bristol-Myers Squibb economic evaluation

BMS have presented a comprehensive economic evaluation of UFT/LV as a first-line treatment of advanced colorectal cancer. Their cost calculations are detailed and relatively unbiased, as are the calculations of administration costs. Although only adverse events severe enough to require hospitalisation were costed, the superior adverse effect profile of UFT/LV would likely be reflected by lower costs of adverse event-related consultations and drug treatment, and hence costing every element of adverse event management would be unlikely to change the results.

The authors of this study chose not to perform a cost-minimisation analysis as Roche did, but rather a cost-effectiveness analysis. Since the only trials comparing UFT/LV with a recognised regimen (Mayo) were designed to show non-inferiority, the only situation in which UFT/LV has a proven superiority to 5-FU/LV is in selected adverse events. By the nature of this selectivity, some of the drawbacks associated with UFT/LV are overlooked, namely significantly reduced time to progression (although only amounting to 0.3 month), and a statistically non-significant but possibly clinically important reduced overall survival (1.0 month in

the Douillard study<sup>46</sup>), and also adverse events that are statistically equivalent between treatment arms. Since the authors had chosen to perform a cost-effectiveness analysis, it would have been useful to have had an analysis of the incremental cost-effectiveness (using different outcomes) of 5-FU/LV over UFT/LV and of UFT/LV over 5-FU/LV. Since UFT/LV has both a slight advantage in terms of adverse events and a slight disadvantage in terms of progression-free and overall survival, the slight advantage is reflected in the economic analysis, but not the slight disadvantage.

The economic evaluation of UFT/LV made no mention of QoL, although data had been collected and were presented earlier in the report. The QoL data show that the improved adverse effect profile has no effect on QoL.

As in the capecitabine analysis, the evaluation showed that the main cost differences between oral therapies and infusional regimens arise from drug cost and administration.

Since neither evaluation performed any kind of sensitivity analysis in which outcomes were tested, it is not known whether cost would be sensitive to variation in outcome.

### **Summary of existing economic evidence**

In summary, the existing economic evidence shows that oral drugs may have an economic advantage over the Mayo intravenous regimen, primarily owing to their savings in administration, and possibly also to improved adverse event profiles. Although the quality of evidence is good in the resource-use studies,<sup>53,54</sup> these studies do not report costs. Although the South American economic evaluations<sup>51,52</sup> claim to show cost savings associated with UFT usage, the quality of evidence is poor, as the resource-use data do not come from trials or broadly based surveys, the rate of resource use was not given and it is doubtful whether the aggregated cost data are applicable to current UK practice. Hence there are no evaluations that can be directly translated to the UK context.

The analyses show that the increased drug acquisition cost associated with oral therapies is offset by the reduced cost of administration, and as a result the cost differences between the oral regimens and the Mayo regimen are small.

The major limitation of both submissions is that there is no economic analysis presented

comparing oral drugs with any 5-FU regimen other than the Mayo regimen. Many different 5-FU intravenous regimens are currently used in the UK, and therefore the submissions are only partially relevant to current UK practice.

### **Quality of life evidence**

#### **Capecitabine**

Although QoL data were collected in the capecitabine trials, the results have not yet been published. Both trials used the EORTC QLQ-C30 questionnaire, assessed at baseline and at the start of each treatment cycle.

Results reported in the Roche sponsor submission<sup>45</sup> showed that there was no significant difference in global QoL between capecitabine and Mayo treatments, as measured by the EORTC QLQ-C30, and that QoL was maintained for patients in both arms of the studies.

The Roche sponsor submission<sup>46</sup> also included a social preferences study (Appendix 5 in the submission), conducted by post on randomly chosen members of the public. These were not people who had necessarily had any personal experience of colorectal cancer. A detailed questionnaire was used to determine social preference weights associated with the different treatment scenarios. The questionnaire was extremely long and complex and may well have been confusing to the respondents.

#### **UFT/LV**

QoL data for UFT/LV were collected and have been published.<sup>46,47</sup> In the Douillard study,<sup>46</sup> QoL was assessed with the FLIC 22-item questionnaire. In the Carmichael trial,<sup>47</sup> the EORTC QLQ-C30 was used. Like the capecitabine results, the UFT/LV trials showed no significant difference in favour of oral therapies. When adjusted for baseline characteristics, the Douillard study<sup>46</sup> revealed no statistically significant differences between treatment arms. When the Carmichael study was adjusted for baseline characteristics, the subscale for diarrhoea remained statistically different ( $p = 0.022$ ) in favour of the 5-FU/LV arm. This seems at odds with the safety analysis, which showed no statistically significant higher incidence of diarrhoea in the UFT/LV arm, leading the investigators to hypothesise that the timing of the questionnaire may have influenced the results.

Although both oral drugs showed an improved adverse event profile, owing to lower frequency of grade 3 and 4 adverse events, this was not

reflected in improved QoL for the patients. This may be because Mayo patients experience severe adverse events during the middle of their cycle, but they have mostly recovered by the time they are receiving their next course of treatment. If QoL questionnaires are administered at the beginning of each treatment cycle, and (as in the case of the EORTC) refer only to the preceding week, then they are less likely to capture the adverse effects on QoL of Mayo treatment. It is also possible that QoL is improved through intravenous treatment, owing to increased contact with nurses and peer support of other patients. It would be useful to investigate these possibilities further in future trials.

## Methods for economic evaluation

An economic evaluation was undertaken to compare the cost-effectiveness of UFT/LV and capecitabine with that of intravenous 5-FU/LV. Intravenous 5-FU/LV is an appropriate comparator because it is the most common first-line treatment for metastatic colorectal cancer currently in use in the UK.

A number of intravenous 5-FU regimens are in common use in the UK: the Mayo regimen, the de Gramont (inpatient and outpatient regimens), the modified de Gramont (MdG) regimen and continuous infusion regimens. These are detailed in Appendix 2. The decision as to which regimen to use depends on the preferences of the physician and the patient, the resources available at the local treatment centre and the distances the patient may have to travel in order to receive treatment.

### Estimation of net benefits

#### **UFT/LV**

Two phase III RCTs<sup>46,47</sup> of UFT/LV were identified (011 and 012). These are reviewed in full in the section 'Quantity and quality of research available: UFT/LV' (p. 20).

#### **Douillard and colleagues, 2002<sup>46</sup>**

In the Douillard study<sup>46</sup> (study 011) comparing UFT/LV with the Mayo regimen, UFT/LV demonstrated statistical equivalence in terms of response rate (12 versus 15%) and median overall survival (12.4 versus 13.4 months). UFT/LV had a significantly inferior median progression-free survival rate (3.5 versus 3.8 months,  $p = 0.011$ ).

Mean survival was calculated from the survival curve published in the sponsor submission using area under the curve (AUC) analysis. The area

under a survival curve gives the mean overall survival experienced in the trial. Therefore, the area between the UFT/LV survival curve and the 5-FU/LV survival curve gives the mean survival benefit of UFT/LV over 5-FU/LV. Calculated in this way, the mean survival of UFT/LV was 15.3 months and the mean survival of 5-FU/LV was 15.7 months.

#### **Carmichael and colleagues, 2002<sup>47</sup>**

In the Carmichael study<sup>47</sup> (study 012), comparing UFT/LV with a modified Mayo regimen, UFT/LV demonstrated equivalence to infusional 5-FU/LV in terms of response rate (11 versus 9%), time to progression (3.4 versus 3.3 months) and overall survival (12.2 versus 10.3 months). The values for 5-FU/LV are, however, lower than would be expected compared with other 5-FU/LV trials.<sup>17</sup>

Mean survival was calculated from the survival curve published in the sponsor submission using AUC analysis. The mean time to progression was 4.3 months for UFT/LV and 4.6 months for 5-FU/LV and mean survival was 14.0 months for UFT/LV and 12.7 months for 5-FU/LV.

*Discussion of results.* In the Carmichael study,<sup>47</sup> the 5-FU/LV dose was reduced by 25% since it was administered over 5-week intervals instead of 4-week intervals to avoid a monitoring bias. However, median doses were lower than the protocol dosage level in both trials (median 452 mg/m<sup>2</sup>/week versus protocol 531 mg/m<sup>2</sup>/week 5-FU in the Douillard study<sup>46</sup> and median of 418 mg/m<sup>2</sup>/week versus protocol 425 mg/m<sup>2</sup>/week 5-FU in the Carmichael trial), a difference of only 8%.

The survival rate of the 5-FU/LV arm was lower in the Carmichael study<sup>47</sup> than in the Douillard study,<sup>46</sup> whereas the survival rate of the UFT/LV arm remained the same. The regimen used in the Carmichael study is, however, not considered to be a good comparator, given that the protocol 5-FU doses used in the modified Mayo arm were 20% lower than standard Mayo regimens and the survival rates from that trial are considerably lower than expected for an efficient 5-FU regimen. The survival rates in the Douillard study<sup>46</sup> were similar to those observed in other 5-FU trials.<sup>17</sup>

For the purposes of economic analysis, the results of the Douillard study<sup>46</sup> were used, since this study involved a larger number of participants and used the widely recognised 4-week Mayo regimen as its comparator treatment. The UFT/LV results were consistent between the two trials, so the choice of the Douillard study<sup>46</sup> does not bias the analysis.

### **Capecitabine**

Two international RCTs<sup>40,41</sup> with identical protocols compared capecitabine with the Mayo Clinic regimen. The data from these two trials were also pooled in a report by Twelves.<sup>36</sup> These are reviewed in full in the section 'Quantity and quality of research available: capecitabine' (p. 11).

### **Hoff and colleagues, 2001<sup>40</sup>**

In a published trial by Hoff and colleagues,<sup>40</sup> capecitabine demonstrated equivalence with the Mayo regimen in median time to progression (4.3 versus 4.7 months) and median survival (12.5 versus 13.3 months). Capecitabine had a superior response rate (24.8 versus 15.5%).

The survival and progression-free survival curves were also published, and were used to calculate mean time to progression (5.4 months for capecitabine and 5.5 months for Mayo) and mean survival (14.8 months for capecitabine and 15.1 months for Mayo).

### **Van Cutsem and colleagues, 2001<sup>41</sup>**

In a published trial by Van Cutsem and colleagues,<sup>41</sup> comparing capecitabine with Mayo regimen 5-FU/LV, capecitabine demonstrated an improved response rate (26.6 versus 17.9%) as well as equivalent survival (13.2 versus 12.1 months) and progression-free survival (5.2 versus 4.7 months). The median survival and progression-free survival rates were similar to those seen in other studies of 5-FU/LV in the treatment of metastatic colorectal cancer patients.<sup>20,19</sup>

The mean survival for the capecitabine regimen, calculated through AUC analysis of the survival curves, was 15.1 months and that for the Mayo regimen was 14.1 months. The mean time to progression was 5.4 months for the capecitabine and 5.8 months for the Mayo regimen.

### **Twelves, 2002<sup>36</sup>**

In a report<sup>36</sup> using pooled data from Hoff and colleagues<sup>40</sup> and Van Cutsem and colleagues,<sup>41</sup> capecitabine demonstrated a significantly superior response rate (25.7 versus 16.7%,  $p < 0.0002$ ) and equivalent median progression-free survival (4.6 versus 4.7 months) and overall survival (12.9 versus 12.8 months). The mean survival, estimated using AUC analysis, for the capecitabine regimen was 15.7 months and that for the Mayo regimen was 15.1 months.

We chose to use the results published in the Twelves paper<sup>36</sup> in our analysis. The trials were

performed using identical protocols for the purpose of pooling the data at a later date. The pooled study includes a large number of patients at a wide range of centres and provides high-quality data for comparison.

### **Choice of comparator regimen**

The Mayo regimen was used as a comparator in the trials because it is internationally the most widely used regimen. There is, however, no gold standard therapy in the UK for the treatment of advanced colorectal cancer. It is not known with certainty to what extent different regimens are used. However, a recent survey, based on responses from 43 members of the British Oncology Pharmacy Association, reported that 37% of hospitals covered by the survey used low-dose FA and 5-FU bolus (weekly or monthly) more often than any other regimen for first-line chemotherapy options for advanced colorectal cancer. The proportions of hospitals using MdG, de Gramont and PVI 5-FU regimens more often than any other regimen were 26, 12 and 7%, respectively.<sup>57</sup>

We therefore chose to compare the oral drugs against the Mayo regimen and two infusional regimens: the MdG regimen, given on an outpatient basis, and the inpatient de Gramont regimen.

There is, however, no direct trial evidence comparing oral drugs with infusional 5-FU regimens. Therefore, to compare the oral drugs against the MdG and inpatient de Gramont regimens, it is necessary to consider an indirect comparison of the Mayo regimen against infusional regimens.

### **Efficacy of bolus versus infusional 5-FU regimens**

A range of published survival estimates for the de Gramont regimen are outlined in Appendix 5. These range from 42 to 64 weeks. Case-mix selection is an important determinant of survival and may account for the variability in these estimates.

Little published evidence was identified on the MdG regimen, although it is now widely used in the UK. The MdG regimen preserves the main elements of the de Gramont regimen: dose-intensive exposure to FU with LV for 48 hours every 2 weeks, with minimal haematological gastrointestinal toxicity.<sup>21</sup> The MRC have made the decision to move over to the MdG regimen without a large randomised equivalence trial because the MdG regimen is more 5-FU dose-intensive and it

has better non-randomised phase II response rates than the old de Gramont regimen. (Seymour M, Cookridge Hospital, Leeds: personal communication, 2002). In addition, it is more convenient for patients and hospitals.

Evidence on the efficacy of bolus regimens (such as the Mayo) against infusional regimens (such as the de Gramont and the MdG) is limited. A small number of studies have been identified and these are considered below.

#### **Meta-analysis Group in Cancer, 1998<sup>15</sup> (Appendix 3)**

In a meta-analysis of trials comparing continuous infusion 5-FU regimens with bolus 5-FU regimens, continuous infusion regimens were found to be slightly more effective. However, only two of the trials involved regimens in which bolus or continuous infusions were given alongside LV. In these two trials no significant survival benefit was demonstrated for continuous infusional regimens. In addition, the meta-analysis used the results of six trials, none of which involved the de Gramont regimen and only one of which involved the Mayo regimen. All of the continuous infusion arms of these trials used prolonged infusions that continued for a number of days without interruption, and hence differ from the MdG regimen used in the UK. This meta-analysis is therefore not considered to provide high-quality evidence on the relative effectiveness of the Mayo and de Gramont regimens.

#### **De Gramont and colleagues, 1997<sup>17</sup> (Appendix 4)**

A study by de Gramont and colleagues<sup>17</sup> compared the Mayo regimen with the de Gramont regimen. The de Gramont regimen had higher response rates (32.6 versus 14.4%,  $p = 0.0004$ ), increased median time to progression (27.6 versus 22 weeks,  $p = 0.004$ ) and insignificantly increased overall survival (62 versus 56.8 weeks,  $p = 0.067$ ). Overall grade 3–4 toxicity was also lower on the de Gramont regimen (11.1 versus 23.9%,  $p = 0.0004$ ).

Although overall survival rates were higher for the de Gramont regimen, the difference was not statistically significant. In addition, the survival rates in the Mayo arm of the de Gramont trial (56.8 weeks) are higher than those observed in the capecitabine and UFT/LV trials. They are also at the upper end of the published survival rates for de Gramont regimen (Appendix 5). This suggests that other factors are impacting on survival in the de Gramont trial. These may include issues

relating to patient selection and possible early diagnosis of metastatic disease.

#### **Cheeseman and colleagues, 2002<sup>21</sup>**

A recently published phase II trial by Cheeseman and colleagues<sup>21</sup> to establish dose intensities for the MdG regimen reported that the optimum doses were 350 mg LV, 400 mg/m<sup>2</sup> bolus 5-FU followed by 2800 mg/m<sup>2</sup> 5-FU infusion given over 46 hours. This regimen was given on an outpatient basis, with the bolus infusion being given during an outpatient attendance and a district nurse visiting the patient at home to disconnect the patient's line and flush it weekly. Forty-six patients participated in the trial. At the optimum infusion dose level, eight out of 22 (36%) patients experienced a partial response, with disease stability achieved in a further seven (32%). Median failure-free survival was 9.3 months. Fifteen of the 22 patients went on to receive second-line chemotherapy, and median overall survival from starting treatment was 16.8 months. This survival is similar to that reported by de Gramont and colleagues.<sup>17</sup> The toxicity profile is similar to de Gramont regimen. The most common toxicities observed were nausea or vomiting and lethargy, with no adverse events worse than grade 3. No hospitalisation data were reported.

In conclusion, the limited evidence available demonstrates that the de Gramont regimen is superior to the Mayo regimen in terms of progression-free survival and in relation to toxicity, but that there is no statistically significant survival benefit.

For purposes of the economic analysis, we have assumed that the survival benefits for the MdG and de Gramont regimens are identical. In addition, it is assumed that the de Gramont regimens offer the same survival benefit as the Mayo regimen. This assumption has been tested in sensitivity analysis.

#### **Estimation of net costs**

No published UK costs for the use of oral drugs in advanced colorectal cancer were identified.

Cost estimates were divided into three categories: drug acquisition cost, chemotherapy administration costs and adverse event management costs (including hospital admissions, physician consultations and drug treatment).

All costs are inflated to the year 2002 using the Hospital and Community Health Service<sup>58</sup> cost index until 2001 and GDP from 2001 to 2002. Unit costs are reported in Appendix 9.

No discounting has been applied given that the median survival times of patients with advanced metastatic colorectal cancer are around 12 months.

#### **Drug costs**

Drug acquisition costs were based on an individual with a body surface area of 1.75 m<sup>2</sup> undergoing therapy at standard treatment doses as listed in the Summaries of Product Characteristics.<sup>45,48</sup> It was assumed that doses remained at the prescribed level for the duration of treatment. This may result in a slight overestimate because in the trials the average doses administered were lower than the prescribed dose. The impact of this assumption is tested in the sensitivity analysis.

The prescribed capecitabine dose was 4300 mg daily: 4 × 500-mg tablets and 1 × 150-mg tablet administered each morning and evening. The prescribed UFT dose was five UFT capsules each day, or 1680 mg/m<sup>2</sup>/week. The prescribed Mayo dose was 425 mg/m<sup>2</sup>/day 5-FU with 20 mg/m<sup>2</sup>/day LV. The de Gramont dose was assumed to be 1000 mg/m<sup>2</sup>/day 5-FU with 200 mg/m<sup>2</sup>/day LV. The MdG dose was assumed to be 350 mg LV, 400 mg/m<sup>2</sup> 5-FU bolus then 2800 mg/m<sup>2</sup> 5-FU infusion over 46 hours.

Drug costs for 5-FU, LV and capecitabine were taken from the BNF website (BNF No. 43).<sup>55</sup> Drug costs for UFT were taken from the letter announcing price changes included in the sponsor submission from BMS.<sup>48</sup> Value added tax (VAT) was calculated on all drug costs.

A sensitivity analysis was tested in which LV was acquired at a discounted price, based on estimated discounts (87% for tablets) established by market research in the unpublished BMS submission.<sup>48</sup> We were able to verify from discussions with a number of pharmacists that substantial discounts are often offered to hospitals for this drug. As discounts are kept confidential to hospitals, we were not able to verify the estimated discount. The impact of the discount of LV on the cost of the Mayo and de Gramont regimens is substantial, given that LV accounts for over 50% of the total drug cost for these regimens.

Costs were calculated per cycle and then adjusted to generate a cost per 28-day period to allow comparison. The drug cost per 28-day period was £464 for capecitabine, £892 for UFT/LV, £189 for the Mayo, £563 for the de Gramont and £394 for the MdG regimen. These costs include VAT, but not discounts.

#### **Administration costs**

Administration costs were divided into two groups: costs that were incurred each cycle (cyclical costs) and costs that were incurred only once over the period of treatment (one-off costs). One-off costs included education for patients on oral therapies and line insertion and overnight admissions associated with the outpatient de Gramont regimens. Cyclical costs included inpatient and outpatient hospital visits, a creatinine test for capecitabine patients, preparatory drugs, community nurse infusion administration and home visits, infusion pumps, pharmacy preparation and materials.

The costs of outpatient appointments were taken from the Christie Hospital (Hawkins R, Christie Hospital, Manchester: personal communication, 2002). The cost of an outpatient appointment with chemotherapy was assumed to be £150, whilst the cost of an outpatient clinic appointment without chemotherapy was assumed to be £80. The costs of inpatient stays and other administration costs were taken from the Personal and Social Services Research Unit (PSSRU).<sup>58</sup> The cost of outpatient appointments were the key driver to the cost of administration for capecitabine, UFT/LV, Mayo and the MdG regimens. These costs were tested in the sensitivity analysis.

Diagnostic tests have not been included in the analysis. They are assumed to be similar across all treatment arms. Costs of primary care and transportation (in hospital ambulances) were reported in the sponsor submissions but have not been included as they make only a small contribution to total incremental costs.

#### **One-off costs**

The costs of time and materials for patient education were estimated following discussion with a number of clinicians. Patients receiving oral drugs are assumed to receive a 15-minute nurse appointment at the beginning of their treatment to discuss their role and responsibilities. They were also given materials to take home with them. The estimated cost of £7, based on 15 minutes of nurse time, was assumed to be the same for both capecitabine and UFT/LV treatments. The MdG regimen was assumed to have a one-off cost of £265 for line insertion.<sup>59</sup> The Mayo regimen and the inpatient de Gramont regimen were assumed to have no one-off costs.

#### **Cyclical costs**

Patients undergoing oral therapies were assumed to attend one outpatient appointment each cycle

(Orr B, Weston Park Hospital, Sheffield: personal communication, 2002). Patients on the Mayo regimen incurred the costs of five outpatient attendances to a cancer ward each cycle, in addition to the cost of the infusions themselves.<sup>60</sup> Patients on the MdG regimen incurred one outpatient attendance to the cancer ward each cycle and two community nurse home visits each cycle to disconnect and maintain their infusion lines.<sup>21</sup> They also incurred the costs of infusion pumps and materials associated with pump and line maintenance.

The 28-day cyclical administration costs were £113 for capecitabine, £64 for UFT/LV, £839 for Mayo patients, £650 for MdG and £1500 for inpatient de Gramont.

#### **Management of adverse events**

Both oral drugs have been reported to have improved toxicity profiles compared with the Mayo regimen.

The costs of management of adverse events was divided into three groups: hospitalisations, physician consultations and drug treatment costs.

#### **Capecitabine**

For capecitabine, resources used relating to hospitalisations and physician consultations were taken from the study by Twelves and colleagues<sup>53</sup> and combined with UK unit costs taken from the PSSRU.<sup>56</sup> Only hospitalisations directly related to adverse events associated with treatment were considered. Costs of drug treatment for adverse events were taken from the Roche sponsor submission<sup>45</sup> and checked against common treatments and costs according to clinicians and the BNF.

#### **UFT/LV**

The number of hospitalisations was consistent between the two UFT/LV trials; however, the hospitalisation rates appear to include all non-administration related hospitalisations. This includes adverse events associated with disease symptoms and other illnesses in addition to treatment-related adverse events. This is likely to overestimate the cost of managing treatment-related adverse events. An alternative estimate of adverse events was considered.

Since the adverse event profile is equivalent or superior to the Mayo regimen in nearly all categories, it could be assumed that the resource use rates for treatment-related adverse events would be similar but slightly lower than those

incurred in Mayo treatment. Therefore, a reasonable maximum cost would be the treatment-related adverse event costs of Mayo treatment calculated from the Twelves analysis,<sup>53</sup> that is, £851. Although this may still be an overestimate, it is more reasonable than counting all non-administration-related costs.

#### **Mayo regimen**

Adverse event costs for the Mayo regimen were calculated using the same methodology as for the costs of adverse events for capecitabine. The cost estimate obtained for Mayo treatment was very close to the figure previously reported in a recent NICE analysis of colorectal cancer drugs.<sup>24</sup>

#### **De Gramont and MdG regimens**

The de Gramont and MdG regimens are assumed to have the same toxicity profile. They are assumed to be less toxic than the Mayo regimen.<sup>17</sup> The number of hospital days and drug treatment costs were taken from a previous NICE analysis of colorectal therapies<sup>24</sup> and multiplied by the PSSRU cost of a medical oncology inpatient day. However, since different trials and hence different patient groups are being considered, these costs must be viewed with caution.

The cost of line complications needs to be taken into account for patients on outpatient regimens, such as the MdG regimen. Complications range from minor to major, and may even require re-siting of the line. Estimates of the frequency of occurrence and cost of treating complications have been provided by Professor James (James R, Mid Kent Oncology Centre, Maidstone: personal communication, 2002). Based on 100 patients receiving treatment, it is assumed that 20 patients experience a minor complication at a cost of £50, 10 patients experience a major complication at a cost of £250 and five patients require re-siting of the line at a cost of £250, giving a total cost of £4750 for 100 patients.

The 28-day cost of treating adverse events is £131 for capecitabine, £170 for the Mayo regimen (and UFT), £29 for the MdG regimen and £22 for the inpatient de Gramont regimen. Given the uncertainty relating to the estimation of adverse event costs, a sensitivity analysis was examined in which adverse events were excluded and only drug acquisition and administration costs were considered.

#### **Total treatment costs**

Total treatment costs were derived by multiplying the cost per 28-day period by the treatment

duration and adding on the one-off administration costs.

No consistent policy exists amongst UK clinicians regarding duration of treatment for patients receiving chemotherapy for advanced colorectal cancer.<sup>61</sup> Treatment for patients who are responding or who have stable disease can be continued until disease progression or stopped after a fixed period of time, usually between 3 and 6 months.

A recent study by Maughan and colleagues<sup>61</sup> that compared continuous or intermittent chemotherapy for advanced colorectal cancer suggested that there was no clear evidence of a benefit in continuing therapy indefinitely. Patients who were responding or had stable disease after receiving 12 weeks of de Gramont, Lockich or raltitrexed treatment were randomised to either 'continue' therapy until progression or 'stop', re-starting on the same therapy on progression. Of the 178 patients allocated to stop therapy, 39% re-started treatment for a median time of 83 days. There was no clear evidence of a difference in progression-free survival or overall survival. In addition, there appears to be a gain in QoL for patients on intermittent therapy, supporting a stopping policy for chemotherapy after 12 weeks.

For the purposes of economic evaluation, it was assumed that all patients would be treated for 12 weeks. The survival results reported in the RCTs of the oral drugs are based on patients treated until disease progression. It was assumed that there was no detrimental impact on survival resulting from stopping treatment at 12 weeks. The assumption that patients are treated for only 12 weeks may underestimate total treatment costs given that, based on the Maughan study,<sup>61</sup> a proportion of patients who stop treatment at 12 weeks may continue treatment on first-line therapy at a later stage. A sensitivity analysis was considered in which

patients were treated until disease progression. In reality, treatment duration may well lie between these two scenarios for many patients.

Treatment costs are likely to be overestimated given that treatment may be stopped earlier for some patients owing to toxic effects or progression.

The estimated total treatment costs are given in *Table 20*.

### Discussion of results

The costs of both capecitabine and UFT/LV were estimated to be lower than the treatment costs for the three intravenous regimens based on a treatment duration of 12 weeks. The cost estimates for UFT/LV, the Mayo regimen and the MdG regimen were similar. The cost estimate for inpatient de Gramont is substantially higher than for the MdG regimen delivered on an outpatient basis, in terms of both drug costs and administration costs.

It should be noted, however, that the cost of UFT/LV and the infusional regimens do not take into account the substantial discount offered on BNF prices on LV.

For capecitabine and UFT/LV, the relatively high drug costs of the oral drugs were offset by lower administration costs.

A comparison of the costs estimates derived by ScHARR and those provided in the sponsor submissions is given in *Table 21*. The sponsor submission costs have been converted into 28 day costs for ease of comparison.

Comparison of treatment costs is not straightforward. For instance, ScHARR's estimates for drug costs include VAT whereas the sponsor submissions do not. In addition, the BMS

**TABLE 20** Total treatment costs (£)

	Capecitabine	UFT/LV	Mayo	MdG (outpatient)	de Gramont (inpatient)
Drug cost	464	892	189	394	563
Administration	113	64	839	650	1500
Adverse events	131	170	170	29	22
Total 28-day costs	708	1126	1198	1073	2085
One-line costs	7	7	–	285	
Treatment period (weeks)	12	12	12	12	12
Total treatment costs	2132	3385	3593	3485	6255

**TABLE 21** Comparison of 28-day treatment costs (£)

	Capecitabine		UFT/LV		Mayo		
	ScHARR	Roche	ScHARR	BMS	ScHARR	BMS	Roche
Drug cost	464	395	892	422	189	77	145
Administration	113	0	64	121	839	1100	541
Adverse event management	131	122	170	75	170	84	243
Other	N/A	0	N/A	34	N/A	34	67
Total 28 day costs	708	517	1126	652	1198	1295	996

estimates for drug costs include a discount of 87% on the BNF price of LV. When these were taken into account there is little difference in the costs of drugs between the ScHARR estimates and the sponsor submissions.

The Roche submission presented the incremental cost of administration over the Mayo regimen and therefore did not include a cost for administration of capecitabine. The BMS submission took a conservative approach to estimating the cost of administering UFT/LV by assuming that patients visited a specialist weekly during the first cycle of chemotherapy, as opposed to once per cycle.

The 'other' category in the Roche cost estimates includes transportation for hospital administration. The 'other' category in the estimation of BMS cost includes concomitant medications and clinical procedures. These items had little impact on the cost of medical resources.

### Second-line treatment

The Carmichael study<sup>47</sup> records the number of participants who go on to receive second-line treatment after treatment with the UFT/LV and Mayo regimens. In this study, 41% of UFT/LV patients and 39% of modified Mayo patients went on to receive second-line treatment; 49% of the UFT/LV patients and 47% of the Mayo patients received 5-FU treatment, 28% of each arm received irinotecan only and 13% of UFT/LV patients and 16% of Mayo patients received either oxaliplatin or irinotecan with oxaliplatin. The effect of second-line treatment on survival was similar across both arms.

In the recent NICE rapid review of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer,<sup>24</sup> it was estimated that 30–35% of patients who die of colorectal cancer have received chemotherapy and, of these patients, approximately 65% go on to have second-line chemotherapy. The proportion of

patients who are likely to receive second-line treatment in normal clinical practice is unknown.

If it is assumed that a similar proportion of patients receiving oral therapies and intravenous therapies will go on to receive second-line treatment and that the duration of treatment is similar for both, then the cost of second-line therapy will not change between the different therapies and will not influence the incremental cost between therapies.

The cost of second-line treatment is not included in the base-case scenario. It is included in a sensitivity analysis to demonstrate the possible costs incurred.

## Cost analysis

### Methods

A cost-minimisation analysis was performed for comparisons of capecitabine and UFT/LV with the Mayo regimen, since the survival benefits have been shown to be statistically equivalent.

A cost-minimisation analysis was also performed for comparisons of capecitabine and UFT/LV with the infusional regimens. This was based on no proven evidence of survival difference between the Mayo and the infusional regimens and hence no assumed survival difference between the oral drugs and the infusional regimens (see the section 'Efficacy of bolus versus infusional 5-FU regimens', p. 37).

### Results

The results of the cost-minimisation analyses are presented in Table 22.

### Discussion of results

In comparison with the intravenous regimens, both capecitabine and UFT/LV were shown to have lower costs. Although the drug costs are higher, oral drugs offer the advantage of a lower volume

**TABLE 22** Cost savings from oral drugs (£)

	<b>Capecitabine</b>	<b>Mayo</b>	<b>MdG (outpatient)</b>	<b>de Gramont (inpatient)</b>
Total treatment costs	2132	3593	3485	6255
Cost saving from capecitabine		-1461	-1353	-4123
	<b>UFT/LV</b>	<b>Mayo</b>	<b>MdG (outpatient)</b>	<b>de Gramont (inpatient)</b>
Total treatment costs	3385	3593	3485	6255
Cost saving from UFT/LV		-209	-101	-2870

of hospital visits and avoid the need for line insertions and their potential complications or inpatient administration of chemotherapy.

Fewer hospital visits may, however, be seen as a disadvantage, as this scenario provides less opportunity for symptom monitoring and consultation with medical staff. Clearly, this has potential implications for patient safety, and some patients may need varying degrees of monitoring in order to ensure their safety. Roche currently offer a Hospital at Home service to patients on capecitabine. This involves a trained nurse contacting new patients by telephone twice within the first 2 weeks to check patients are coping adequately and also provides a support line for patients with concerns or questions. If this service is withdrawn by the manufacturer, it may be necessary for hospitals or the community to provide support to patients on oral chemotherapy. Provision of this service has not been included in the cost analysis.

The costs used in the economic evaluation were not based on published studies and are subject to uncertainty. Key uncertainties related to the price of LV, which is known to be discounted substantially below BNF prices, the treatment duration for different therapies, which impacts on their total treatment cost, the costs of managing adverse events and the cost of outpatient appointments. These issues are tested in the sensitivity analysis.

The greatest uncertainty is based around the comparison of oral drugs with the de Gramont regimens. This is based on an indirect comparison. The evidence comparing bolus and infusional regimens is limited and subject to debate. The study by de Gramont and colleagues<sup>19</sup> comparing the Mayo regimen with the de Gramont regimen reported that overall survival rates were higher for the de Gramont regimen, but that the difference was not statistically significant (62 versus 56.8 weeks,  $p = 0.067$ ). This

difference of 5.2 weeks may, however, be considered clinically significant. A cost-effectiveness analysis was therefore performed to demonstrate the impact assuming a survival difference between the de Gramont regimens over oral drugs.

In addition, the use of a cost-minimisation approach for comparing the de Gramont regimens with the oral drugs ignores the advantages offered by the de Gramont regimen over the Mayo regimen in terms of response rates, progression-free survival, toxicity and QoL. In the de Gramont study,<sup>19</sup> the de Gramont regimen had increased median time to progression (27.6 versus 22 weeks,  $p = 0.004$ ) and lower grade 3–4 toxicity than the Mayo regimen (11.1 versus 23.9%,  $p = 0.0004$ ). An additional cost-effectiveness analysis was therefore performed to explore the impact of these factors on the economic evaluation.

### Sensitivity analysis

A number of assumptions were made in the base case methodology that could have an impact on the final results. To study the potential impact of these assumptions, they were tested in a sensitivity analysis.

#### **Scenario A: base case**

#### **Scenario B: discounts on drug costs**

In the base case, the drugs were all costed according to the list prices on the BNF website.<sup>55</sup> In practice, many hospitals obtain discounts on drugs, some of which can be substantial. There was no indication that discounts were offered on capecitabine, Uftoral or 5-FU; however, LV, which accompanies UFT and both intravenous regimens, is often discounted heavily. A sensitivity analysis was tested in which LV was costed, based on estimated discounts of 87% for tablets, as established by market research in the unpublished BMS submission.<sup>48</sup> For consistency, the same discount was applied to LV vials. The exact cost of LV is likely to vary between institutions.

**Scenario C: dose intensity**

In the base case, doses were costed according to the indications in the Summaries of Product Characteristics.<sup>45,48</sup> In practice, however, doses are often adjusted owing to adverse effects. Median doses prescribed in the trials were lower than the indicated doses set out in the trial protocol. A scenario was tested in which the average doses were costed instead of the protocol doses.

For UFT/LV, the median dose intensity in the Douillard study<sup>46</sup> was 1555 mg/m<sup>2</sup>/week (93%) and in the Carmichael study<sup>47</sup> 1542 mg/m<sup>2</sup>/week (98%). The average trial dose of 93% from the Douillard study<sup>46</sup> was used in the sensitivity analysis. For capecitabine, an average of 81% was used in the sensitivity analysis, based on the average capecitabine dose intensity in the trials: 80% in the Hoff trial<sup>40</sup> and 82% in the Van Cutsem trial.<sup>41</sup> For the Mayo regimen the delivered dose was 85% in the Douillard study,<sup>42,46</sup> 86% in the Hoff trial<sup>40</sup> and 95% in the Van Cutsem trial.<sup>41</sup> An average of 90% was used in the sensitivity analysis. For studies using the de Gramont and MdG regimens, only the prescribed dosage was reported therefore no dose adjustment was used in the sensitivity analysis.

**Scenario D: cost of outpatient appointments**

In the base case it was assumed that a cost difference existed between outpatient appointments with chemotherapy and outpatient appointments without chemotherapy. The outpatient costs were assumed to be £150 and £80, respectively, and were supplied by Christie Hospital (Hawkins R, Christie Hospital, Manchester: personal communication, 2002). It is known that these outpatient costs will vary between institutions. A scenario was tested in which outpatient appointments for infusional chemotherapy and outpatient appointments for oral drugs were assumed to incur the same costs, based on the cost of medical oncology outpatient attendance of £109 from Netten and colleagues.<sup>56</sup> In addition, the cost of a medical oncology outpatient follow-up appointment, £86, and the cost of a day case appointment, £218, from NHS reference costs were also tested in the sensitivity analysis.

**Scenario E: exclusion of costs of managing adverse events**

Owing to lack of resource-use information, particularly regarding UFT/LV and MdG treatments, many assumptions were made in the calculation of the costs of treating adverse events. Because of the resultant uncertainty, a scenario was tested in which adverse event costs were not

included, and costs could be compared only on the basis of drug costs and administration costs, the two main cost drivers.

**Scenario F: treatment until disease progression**

The total cost of treatment was sensitive to the length of treatment time. This may vary between regimens. A scenario in which patients were treated until disease progression was considered to reflect possible variations in treatment period. Time to progression for capecitabine, UFT/LV and Mayo regimens were 4.6, 3.5 and 4.7 months, respectively. It was assumed that the time to progression for the MdG and de Gramont regimens was the same as that for the Mayo regimen. However, there is evidence available that the de Gramont regimen offers advantages over the Mayo regimen in terms of time to progression. This is explored further in the section 'Market share of oral drugs' (p. 47).

**Scenario G: cost of second-line therapy included**

There is little information regarding how treatment would differ after disease progression for patients on different treatment arms, and therefore no costs after progression (tests, primary care, palliative treatment, second-line treatment) were estimated in the base case.

A sensitivity analysis was undertaken in which second-line treatment costs were included. It was assumed that 40% of patients received second-line chemotherapy and that all of these patients received irinotecan. Patients undergoing second-line therapy were assumed to be treated for 3 months after disease progression. The monthly cost of second-line chemotherapy with irinotecan was taken from the NICE rapid review of irinotecan, oxaliplatin and raltitrexed.<sup>24</sup> The cost of second-line treatment per patient, based on these figures, is £2125.

Treatment costs in scenarios B–G and incremental costs are summarised in Table 23 and 24, respectively.

**Discussion of results of scenarios B–G**

The sensitivity analysis showed that the cost estimates for capecitabine were robust to changes in the cost parameters. Capecitabine offered cost savings relative to all three intravenous therapies under all scenarios. UFT/LV costs were lower than those of all intravenous regimens except in scenario D1 where outpatient appointments with and without chemotherapy are assumed to have the same cost. However, the majority of institutions do appear to differentiate in cost terms between

**TABLE 23** Treatment costs (£) in scenarios B–G

	Capecitabine	UFT/LV	Mayo	MdG (outpatient)	de Gramont (inpatient)
A: Basecase	2132	3385	3593	3485	6255
B: Discounted LV price	2132	2504	3296	2615	4852
C: Average dose intensities from trials	1867	3197	3536	3485	6255
D1: OP appointments have equal cost	2258	3460	3015	3254	6255
D2: OP appointments based on NHS reference costs	2164	3404	4687	3923	6255
E: Adverse events costs excluded	1738	2875	3084	3400	6188
F: Treatment until progression	3546	4288	6115	5745	10645
G: Cost of second-line therapy included	4257	5510	5718	5610	8380
OP, outpatients.					

**TABLE 24** Incremental costs (£) in sensitivity scenarios

	Capecitabine			UFT/LV		
	Mayo	MdG (outpatient)	de Gramont	Mayo	MdG (outpatient)	de Gramont
A: Basecase	-1461	-1353	-4123	-209	-101	-2870
B: Discounted LV price	-1164	-483	-2721	-792	-111	-2349
C: Average dose intensities from trials	-1669	-1618	-4388	-339	-288	-3058
D1: OP appointments have equal cost	-757	-996	-3997	445	206	-2795
D2: OP appointments based on NHS reference costs	-2523	-1759	-4091	-1283	-519	-2851
E: Adverse events costs excluded	-1346	-1662	-4450	-209	-524	-3312
F: Treatment until progression	-2569	-2199	-7099	-1827	-1457	-6357
OP, outpatients.						

outpatient appointments for oral drugs and those at which intravenous chemotherapy is administered (often classified as day-case visits rather than outpatient appointments) and therefore this scenario is unlikely to reflect the costing policy of most NHS Trusts.

The cost savings offered by capecitabine were minimised in scenario B, in which a substantial discount is assumed for LV. This discount reduced the cost of all the intravenous regimens. In this scenario, the cost difference between capecitabine and the MdG regimen is less than £500. This scenario may well reflect current costs to many NHS institutions, although the exact size of the discount received by individual institutions is not known. This discount also reduces the cost of UFT/LV and therefore the impact of this scenario on the cost savings offered by UFT/LV were lower.

Treatment costs are sensitive to treatment duration. In the base case, all treatments were assumed to be given for 12 weeks. Given that the time to progression is assumed to be higher for the de Gramont regimens than for oral therapies, using the assumption that patients were treated until progression substantially increased the cost

saving offered by oral therapies. Owing to lack of evidence, no difference to the survival benefits offered by the regimens was assumed whether treatments were given for 12 weeks or until progression.

### Further sensitivity analysis – cost per life year and cost per life year gained

#### *Survival difference between the de Gramont regimens and the oral drugs*

A sensitivity analysis was carried out to demonstrate the impact of assuming that the de Gramont regimens offered a survival advantage over the oral drugs. The base case assumed that the survival outcomes for the de Gramont regimens were equivalent to the outcomes from the oral drugs.<sup>40,41</sup> The survival difference between the de Gramont regimen and the Mayo comparator from the de Gramont trial<sup>17</sup> was 5.2 weeks, although the difference was not statistically significant. The impact of this survival difference was assessed in terms of the cost per LYG for illustrative purposes.

#### **Capecitabine**

The results of the cost-effectiveness analysis showed that capecitabine offered a cost saving of £1461

over the MdG regimen and £4123 over the inpatient de Gramont regimen, but resulted in a reduction in survival benefit of 5.2 weeks. Expressed in terms of a cost per LYG, MdG treatment over capecitabine treatment was £13,571 and inpatient de Gramont treatment over capecitabine treatment was £41,344. The additional survival benefit of MdG over capecitabine is therefore achieved at a reasonable cost and the cost saving from oral drugs is not sufficient to make it a more cost-effective option.

#### **UFT/LV**

The results of the cost-effectiveness analysis showed that UFT/LV offered a cost saving of £209 over the MdG regimen and £2870 over the inpatient de Gramont regimen, but resulted in a reduction in survival benefit of 5.2 weeks. Expressed in terms of cost per LYG, the cost per MdG treatment over UFT/LV treatment was £758 and that of inpatient de Gramont treatment over UFT/LV treatment was £21,631. The additional survival benefit of MdG and inpatient de Gramont over UFT/LV is achieved at a reasonable cost and therefore the cost saving from UFT/LV is not sufficient to make it a more cost-effective option.

These numbers are illustrative only. Further evidence is needed on the survival difference, if any, between de Gramont regimens and the oral drugs. However, it does illustrate that the cost savings offered by the oral drugs, particularly in relation to MdG, are not large and therefore if the oral drugs do reduce the survival of patients by an order of 5.2 weeks, they may not be considered a cost-effective option relative to the MdG regimen. It is difficult to draw any firm conclusions from this cost-effectiveness analysis, given that it is based on an indirect comparison of patients from two different studies.

#### **Difference in progression-free survival between de Gramont regimens and oral drug regimens**

Progression-free survival is considered important because disease progression may impair both physical and emotional health. In addition, progression-free survival is an important outcome measure, given that the relationship between progression-free survival and overall survival may be confounded by the use of second-line treatment following progression.

#### **Capecitabine**

The progression-free survival difference between the de Gramont regimen and the Mayo comparator from the de Gramont trial<sup>17</sup> was 5.6

weeks. The progression-free survival gain of MdG over capecitabine was therefore assumed to be 5.6 weeks. The cost per progression-free LYG was £12,567. The progression-free survival gain of inpatient de Gramont over capecitabine was also assumed to be 5.6 weeks. The cost per progression-free LYG was £32,286.

#### **UFT/LV**

The progression-free survival gain of MdG over UFT/LV was assumed to be 6.9 weeks. The cost per progression-free LYG was £758. The progression-free survival gain of inpatient de Gramont over UFT/LV was also assumed to be 6.9 weeks. The cost per progression-free LYG was £21,631.

These numbers are illustrative only. The results of the cost-effectiveness analyses should be viewed with caution, since the outcomes are based on an indirect comparison of regimens from different trials. However, they do show that the cost savings offered by the oral drugs, particularly in relation to MdG, are not large and therefore on the assumption that oral drugs do reduce the progression-free survival of patients by an order of 5.6 weeks, oral drugs cannot be considered a cost effective option relative to the MdG regimen in terms of the cost per progression-free LYG.

#### **Difference in quality-adjusted progression-free survival between de Gramont regimens and oral drug regimens**

The purpose of chemotherapy for advanced metastatic disease is as much palliation of symptoms as relatively small survival benefits. It is essential to ensure, therefore, that the burden of treatment does not negate the palliative and survival benefits.

None of the clinical trials measured utility values. However, Petrou and Campbell<sup>62</sup> have previously assessed utility values for patients with advanced colorectal cancer. Descriptions of 23 health states representative of those for colorectal cancer, including responding, stabilised and progressive disease, with and without toxic side-effects of treatment, were drawn up by a panel of experts. Thirty nurses, all experienced in the care of colorectal cancer patients, were used as proxies for patients, to estimate the utilities of the various health states using the standard gamble technique. The results, given as median utility score, are presented only for health states free of toxic effects, with some discussion of the effect of toxicities on reducing the utility values of them.

In order to estimate the effect of adjusting progression-free survival for QoL, the following assumptions were made. All days in hospital, whether for chemotherapy (including outpatient administration) or toxic effects, count as zero. The value of zero is arbitrary and is tested in a sensitivity analysis using the value 0.5. The remaining days are multiplied by the quality-adjusted life-year value shown by Petrou and Campbell<sup>62</sup> for stable disease of 0.95. The method outlined above has been used in a previous NICE report<sup>41</sup> and has similarities to the QTWIST method described by Gelber and colleagues.<sup>63</sup>

The progression-free survival gain of MdG over capecitabine was previously assumed to be 1.3 months (5.6 weeks). Taking account of the potential impact of QoL, the progression-free survival gain fell to 1.2 months. The MdG regimen involved higher hospitalisation for administration but lower hospitalisation for adverse events. In addition, the benefit of the remaining time prior to progression was reduced by the assumed utility value of 0.95. The overall effect was, however, small.

The progression-free survival gain of MdG over UFT/LV was previously assumed to be 1.6 months (6.9 weeks). Taking account of the potential impact of QoL, the progression-free survival gain rose to 1.7 months. The UFT/LV involved longer duration of hospital stay for adverse events, which offset the reduction in benefit of the remaining time prior to progression by the assumed utility value of 0.95. The overall effect was, however, small.

## **Impact on the NHS**

### **Patient volumes**

In 2003, it is estimated, based on current colorectal cancer incidence rates, that the number of new patients presenting with colorectal cancer will be 29,643.<sup>5</sup> Of these patients, it is estimated that 29% (8596) will present with metastatic colorectal cancer<sup>1</sup> and 50% (10,524) of those remaining will go on to develop metastatic disease.<sup>56</sup> This results in a pool of 19,120 patients annually with metastatic colorectal cancer.

Approximately 30% of those who die of metastatic colorectal cancer have received chemotherapy treatment.<sup>56</sup> It has been suggested that not all patients who could benefit from chemotherapy currently receive treatment, with a further 15% having the capacity to benefit from such

treatment.<sup>56</sup> Based on these figures, 5736 patients with colorectal cancer would therefore be treated with first-line chemotherapy at current rates, with the potential to treat up to 8604 patients. Since some patients who currently refuse intravenous therapy would accept oral therapy, it is likely that widespread use of oral therapies will increase the proportion of patients who are treated.

### **Market share of oral drugs**

The proportion of patients currently receiving oral drugs is not known.

Factors influencing the proportion of patients, who are fit for treatment, likely to receive oral agents as first-line therapy in the future include:

- proportion of patients not eligible for or who refuse the FOCUS trial
- proportion of patients not eligible for oxaliplatin downstaging of liver metastases
- proportion of patients experiencing line complications with 5-FU.

Use of oral therapies will also be dependent on patient preference and is therefore likely to vary between providers.

It is assumed that 45% (8604) of patients with metastatic colorectal cancer receive chemotherapy. Of these, it is assumed that 10% enter the FOCUS trial and that 10% receive oxaliplatin. The remaining patients could then receive either oral drugs or intravenous 5-FU.

The maximum number of patients who are receiving oral drugs would be 6883 (36% of all patients with metastatic cancer), assuming that no patients receive intravenous 5-FU.

### **Impact on the drugs budget**

An increase in the proportion of patients on oral drugs will result in an increase in expenditure on drugs.

It is assumed that 6883 patients receive intravenous 5-FU. The additional drug cost to the NHS of these patients switching to capecitabine treatment would be £0.6 million. The additional drug cost of these patients switching to UFT/LV treatment would be £3.5 million. This cost will be an overestimate, given that some patients are already receiving oral drugs.

### **Impact on total costs**

The cost of drug prescriptions is the only resource that will directly impact on the NHS budget.

However, other resource use will change, including costs relating to chemotherapy infusions and hospitalisations. In particular, oral drugs required one outpatient visit per cycle rather than day-case or inpatient visits for intravenous regimens.

Assuming that 6883 patients currently receive intravenous 5-FU, divided evenly between Mayo

and MdG and inpatient regimens, the total cost saving to the NHS of these patients switching to capecitabine treatment would be £12.6 million. The cost savings of these patients switching to UFT/LV treatment would be £4.0 million. This cost saving will be an overestimate, given that some patients are currently receiving treatment with oral drugs.

# Chapter 5

## Implication for other parties

### **Work days lost**

The study by Ollendorf<sup>54</sup> includes number of work days missed by patients employed at baseline (25%), and concludes that patients undergoing UFT/LV therapy miss fewer days of work than patients undergoing Mayo regimen treatment. In the BMS sponsor submission,<sup>48</sup> the value of these lost days is calculated using the friction-cost method. The cost of work days lost was £799 per patient employed for the UFT/LV arm and £1030 for the modified Mayo arm, resulting in a cost saving of £231 per employed patient.

### **Support of families and friends**

Costs are also incurred by the patient's family and friends. They may also miss work through caring for patients or taking them to hospital. Regimens with many hospital visits are likely to require more support from friends and families, as are regimens with serious adverse events. Also, some patients

may not be competent enough on their own to take oral medications reliably, but may be prescribed them if they have someone to help them comply with their therapy.

### **Transportation**

In the Roche sponsor submission,<sup>45</sup> the cost per patient of transportation to and from hospital, only including transportation by hospital ambulances, for infusion administration was estimated (£333, for Mayo regimen patients only). It could be assumed to be much higher if it were also to include private costs. While the Roche estimate can only be illustrative as it did not count any administration costs incurred by capecitabine patients, it demonstrates the possible costs of transportation, which will of course be greater for patients who have to visit the hospital more frequently, that is, patients on the Mayo regimen in particular, but also MdG patients, who visit once every 2 weeks instead of once every 3 weeks.



# Chapter 6

## Factors relevant to the NHS

### **Outreach clinics**

Oral chemotherapeutic agents offer the advantage of delivery outside a specialist cancer centre. Outreach clinics, for example, may be a particularly useful place for delivery of oral chemotherapeutic agents for patients who are either geographically isolated or prefer not to travel to a cancer centre. This raises many issues with regard to patient education and the monitoring of adverse events which normally take place within the specialist cancer centre. Therefore, the needs of patients with regard to education and support must be considered if patients are to receive oral chemotherapeutic agents in an outreach clinic. The provision of staff, such as chemotherapy nurses, to provide for these needs must be taken into account when planning such a service.

### **Cost incentives within the NHS**

A shift towards the greater use of oral drugs within the NHS may exert cost pressures on NHS Trusts, as a result of existing contracting arrangements. An oral prescription is classed as an outpatient visit, whereas outpatient intravenous chemotherapy is classed as a day-case expense. A shift towards using oral drugs is therefore likely to provide less income to the Trust and may also result in the Trust failing to meet activity targets under existing contracts. Further cost pressures may be exerted on Cancer Centres in terms of reduced activity, if oral drugs are made available to patients via local outreach units rather than patients travelling into Cancer Centres to receive intravenous therapy. Consideration will therefore need to be given to methods of activity measurement in future NHS Trust contracts.

### **Pharmacy and nursing time**

Oral therapies can be prescribed and monitored during an outpatient appointment with an oncologist and dispensed without procedure at the hospital pharmacy. In contrast, infusional regimens are costly not only in terms of nurses and doctors administering the infusions, but also

in terms of pharmacy time and resources. Infusional drugs need to be prepared in a special isolated area, and other costs such as bags, pumps and tubing are also incurred. Although pharmacist time and disposables have been included in this analysis, the costs imposed by the necessity of dedicated isolator cabinets situated in pharmaceutical clean rooms has not been counted, nor has the cost of training specialist pharmacists to deal with cytotoxic drugs. Oral therapies offer the opportunity to reduce the pressure on these services, which are currently overstretched in many hospitals. More specialist staff are needed in all areas of administration for infusional regimens, as radiologists and radiographers may also be needed for line insertion, and specialist pharmacists and nurses are needed for the preparation and administration of drugs.

### **Training for doctors and nurses**

The introduction of oral therapies may necessitate additional training for doctors and nurses in patient identification and education. Since it is very important for the safety of the patients that they are well-enough informed to assume responsibility for their treatment and physically and mentally competent to take it reliably, it is therefore vital that physicians offer oral treatment only to patients who are able to take it, and that they have a suitable relationship with patients to encourage them to report any problems. The same is also true of the nurses charged with educating patients on the risks of non- and over-compliance.

### **Concordance**

Concordance is a key factor when using oral chemotherapeutic agents. Concerns have been raised by the FDA concerning the use of an oral formulation of a cytotoxic anticancer drug over a parenteral formulation because of the uncertainty of the amount actually taken by the patient and the narrow safety margin. This uncertainty is less important with drugs for other conditions where the safety margin is much greater.<sup>49</sup> The majority of dangers with these drugs lies in over-compliance rather than under-compliance, as

patients may be motivated to take medication even when they are experiencing adverse effects.

There may therefore be a need for patient support in the community to ensure patient safety, for example, an oncology nurse who is available for telephone contact or who initiates contact with the patient at regular intervals. GPs may also become more closely involved with the treatment of patients and monitoring of adverse events. People with colorectal cancer are often elderly and therefore may have problems with confusion and home support.

## **Place of oral chemotherapy in combination therapy**

It has been suggested that in future, chemotherapy for metastatic colorectal cancer may consist of a combination of therapies including potentially irinotecan or oxaliplatin.<sup>64</sup> If this is the case, it is important to consider that these drugs may still need to be administered in a parenteral manner and the place of oral chemotherapies in combination with these treatments must be carefully considered as much of the saving on administration cost would no longer apply.

# Chapter 7

## Discussion

### Main results

#### **Capecitabine**

Two trials were identified<sup>40,41</sup> that compared capecitabine with 5-FU/LV administered via the Mayo regimen. An additional study was identified<sup>36</sup> that pooled the data from these two trials. No studies were identified that compared capecitabine treatment with the de Gramont or MdG 5-FU/LV regimens.

One study<sup>41</sup> reported only investigator-assessed overall response rates to be significantly greater in the capecitabine group than the 5-FU/LV group. The other trial<sup>40</sup> and the pooled data both found that investigator-assessed and IRC-assessed overall response rates were significantly greater in the capecitabine group than the 5-FU/LV group.

Duration of response, time to disease progression or death, time to treatment failure and overall survival were found not to be significantly different between the capecitabine groups and the 5-FU/LV groups in the two trials and in the pooled data.

With regard to toxicity, patients in the capecitabine groups reported less diarrhoea, stomatitis, nausea and alopecia of all grades than those in the 5-FU/LV groups. Those in the capecitabine group also had significantly less grade 3–4 neutropenia and less frequent hospitalisation for adverse events. Hand–foot syndrome and grade 3 hyperbilirubinaemia were significantly greater in the capecitabine group.

#### **UFT/LV**

Two trials comparing treatment with UFT/LV with 5-FU/LV<sup>46,47</sup> were identified in the literature searches. These two trials are not comparable for two main reasons. First, the comparator in the Douillard study<sup>46</sup> is the standard Mayo 5-FU/LV regimen whereas the comparator in the Carmichael study<sup>47</sup> is a modification of the Mayo 5-FU/LV regimen that has not been tested for efficacy. Second, the Douillard study<sup>46</sup> uses two different doses of leucovorin, depending on the study site, whereas the Carmichael study<sup>47</sup> uses only one dosage.

There were no significant differences with regard to overall response rates, duration of response or

survival between UFT/LV and 5-FU/LV in either trial. Time to disease progression was inferior for the UFT/LV group compared with the 5-FU/LV group in the Douillard study.<sup>46</sup> There was no difference in time to disease progression between the two groups in the Carmichael study,<sup>47</sup> although this is possibly due to the use of a non-standard Mayo regimen. The use of this less dose-intensive regimen may make it less effective, thereby obscuring any deficit in the effectiveness of UFT/LV.

In the Douillard study<sup>46</sup> (study 011), UFT/LV was associated with significantly less diarrhoea, nausea/vomiting, mucositis, neutropenia and thrombocytopenia than 5-FU/LV for all grades and mucositis, neutropenia, thrombocytopenia and anaemia for grades 3–4. Increased bilirubin, without other liver function abnormalities was significantly more common in UFT/LV patients than those treated with 5-FU/LV ( $p < 0.001$ ). In the Carmichael study<sup>47</sup> (study 012), UFT/LV treatment resulted in significantly fewer episodes of stomatitis/mucositis, neutropenia, thrombocytopenia and anaemia of any grade. With regard to grade 3–4 adverse events, UFT/LV treatment resulted in significantly less stomatitis/mucositis and neutropenia.

#### **Patient preference**

Studies<sup>50,65</sup> have shown that patients prefer oral over intravenous therapies if efficacy is not compromised. However, other factors apart from patient preference must be taken into account. Although oral chemotherapeutic agents offer greater convenience and avoidance of problems related to venous access among others, oral administration may be associated with over- or under-compliance and control of side-effects may be difficult.<sup>66</sup>

Liu and colleagues<sup>65</sup> administered a structured questionnaire to 103 patients with advanced cancer who would be undergoing palliative treatment. The purpose of the questionnaire was to determine preferences regarding route of administration of treatment. Of those responding, 89% preferred oral therapy but 70% were unwilling to accept a lower response rate and 74% were unwilling to accept a shorter duration of response.

One study<sup>50</sup> measuring patient preference for UFT/LV treatment was identified. The results of this small study found that patients preferred the UFT/LV regimen to the 5-FU/LV regimen. No studies of patient preference involving capecitabine were identified.

### **Quality of life**

Both capecitabine trials and both UFT/LV trials included health-related QoL data, although the capecitabine QoL data have not been published and were available in the sponsor submissions only.<sup>45,48</sup> Neither UFT/LV or capecitabine therapy was associated with an improvement in health-related QoL.

### **Economic results**

Two economic studies<sup>55,54</sup> and two resource-use studies<sup>57,58</sup> were identified. The economic studies were not relevant to the UK context.

The two unpublished sponsor submissions compared the oral drugs with the Mayo regimen, a bolus 5-FU/LV regimen. In both sponsor submissions, the economic analysis presented showed that the oral drugs may have an economic advantage over the Mayo regimen, primarily due to savings in administration costs.

However, a number of different intravenous 5-FU/LV regimens are currently in use in the UK. No cost analysis was presented in the sponsor submissions comparing oral drugs with 5-FU/LV regimen other than the Mayo regimen. An economic evaluation was therefore undertaken to compare the cost-effectiveness of UFT/LV and capecitabine with three intravenous 5-FU/LV regimens widely used in the UK: the Mayo regimen, the MdG regimen (outpatient) and the inpatient de Gramont regimen.

A cost-minimisation analysis was performed for comparisons of capecitabine and UFT/LV with the Mayo regimen, since the survival benefits have been shown to be statistically equivalent. The costs of capecitabine and UFT/LV were estimated to be £2132 and £3385, respectively, based on a 12-week treatment period. The cost of the Mayo regimen was estimated to be £3593. The estimated cost savings of the oral therapies relative to the Mayo regimen were £1461 and £209 for capecitabine and UFT/LV, respectively. Drug acquisition costs were higher for the oral therapies than for the Mayo regimen, but were offset by lower administration costs. Adverse event treatment costs were similar across the three regimens.

A cost-minimisation analysis of the oral therapies against the MdG and the inpatient de Gramont was performed on the basis of no proven survival benefit of the de Gramont regimen over the Mayo regimen. The oral therapies were once again shown to be cost saving. The cost of the MdG regimen and the de Gramont regimen were estimated to be £3485 and £6255 respectively.

However, the only randomised trial identified which compared the de Gramont regimen with the Mayo bolus regimen found that the de Gramont regimen had an increased overall survival (62 versus 56.8 weeks,  $p = 0.067$ ).<sup>19</sup> This survival difference of 5.2 weeks was not statistically significant but is considered clinically significant. In addition, the infusional regimens, such as the de Gramont regimens, have been shown to be more effective in terms of progression-free survival and toxicity.<sup>19</sup> The impact of these differences in outcome was explored in the sensitivity analysis in terms of cost per LYG and cost per progression-free LYG of the oral drugs relative to the de Gramont regimens.

Based on a survival difference of 5.2 weeks between the oral therapies and the MdG and the de Gramont regimens, the cost per LYG of MdG treatment over capecitabine treatment was £13,571 and that of inpatient de Gramont treatment over capecitabine treatment was £41,344. On this basis, the cost saving from oral drugs is not sufficient to make it a more cost-effective option. The cost per LYG of MdG treatment over UFT/LV treatment was £758 and that of inpatient de Gramont treatment over UFT/LV treatment was £21,631. These numbers are illustrative only. However, they do show that the cost savings offered by the oral drugs, particularly in relation to MdG, are not large and therefore if the oral drugs do reduce the survival of patients by an order of 5.2 weeks, they cannot be considered a cost-effective option relative to the MdG regimen. It is difficult to draw any firm conclusions from this cost-effectiveness analysis, given that it is based on an indirect comparison of patients from two different studies.

Likewise, provisional estimates of the cost per progression-free LYG of MdG and inpatient de Gramont over capecitabine and UFT/LV showed that the cost savings offered by the oral drugs, particularly in relation to MdG, are not large. On the assumption that oral drugs do reduce the progression-free survival of patients by an order of 5.6 weeks, oral drugs cannot necessarily be considered a cost-effective option relative to the

MdG regimen in terms of the cost per progression-free LYG. Further work is needed in this area.

## Assumptions, limitations and uncertainties

The RCT evidence for oral drugs compares capecitabine and UFT/LV against the Mayo regimen. However, a number of different intravenous 5-FU/LV regimens are currently in use in the UK. No direct comparisons of the oral drugs and infusional regimens were identified. For purposes of economic evaluation, an indirect comparison was therefore required.

The costs used in the economic evaluation were not based on published studies and are subject to uncertainty. Key uncertainties related to the price of LV, which is known to be discounted substantially below BNF prices, the treatment duration for different therapies, which impacts on their total treatment cost, the costs of managing adverse events and the cost of outpatient appointments. These issues are tested in sensitivity analysis.

In addition there is no trial evidence on utility data.

## Cost and benefit assumptions

There is considerable uncertainty in the economic analysis, particularly in relation to the indirect comparison of the oral drugs with the infusional regimens.

### Costs

The drug costs were based on an assumed individual with a body surface area of 1.75 m<sup>2</sup> undergoing treatment with no dose reductions, and assuming that all drugs were supplied at BNF list prices. Drug discounts were not included in the base case. Substantial discounts are, however, currently available on LV, although the precise scale of the discount is confidential and will vary between hospitals.

The cost of a hospital outpatient appointment was assumed to differ for patients on oral therapy and patients receiving intravenous therapy. Cost data from a local provider were used but are likely to vary between institutions.

No published data were available relating to the cost of managing adverse events. Resource use

data were taken from the unpublished sponsor submissions. However, a number of assumptions had to be made and therefore these cost data are open to uncertainty.

### Benefits

A cost-minimisation analysis was performed for comparisons of capecitabine and UFT/LV with the Mayo regimen, since the survival benefits have been shown to be statistically equivalent.

However, no direct comparisons of the oral drugs and the de Gramont regimens (MdG and inpatient de Gramont) were identified and therefore an indirect comparison was undertaken for the purposes of economic evaluation. Evidence on the survival benefits of the Mayo regimen versus the de Gramont regimen was reviewed. On the basis that there is no proven survival difference between the Mayo and the de Gramont regimens, it was inferred that there was no survival difference between the oral drugs and the de Gramont regimens. Therefore, a cost-minimisation analysis was also performed for comparisons of capecitabine and UFT/LV with the de Gramont regimens.

Evidence on the efficacy of the MdG regimen is limited. There are no randomised trials of MdG versus the traditional de Gramont regimen. The MRC have made the decision to move over to MdG without a large randomised equivalence trial because the MdG regimens are more 5FU dose-intensive and they have better non-randomised phase II response rates than the old de Gramont regimen (Seymour M, Cookridge Hospital, Leeds: personal communication, 2002). In addition, they are more convenient for patients and hospitals. The economic analysis assumes that de Gramont and MdG regimens are equally effective and that they have similar adverse event profiles, but this is not proven.

Although there is no proven survival benefit of infusional regimens, such as the de Gramont regimen, over bolus regimens, such as the Mayo regimen, in advanced colorectal cancer, infusional regimens have been shown to be more effective in terms of progression-free survival, tumour response and toxicity.<sup>19</sup> The impact of a potential difference in progression-free survival between the oral drugs and the infusional regimens was explored in terms of the impact on the cost per progression-free year gained.

No significant differences in QoL were found between the oral drugs and the Mayo regimen.

Values from a previous study on colorectal cancer using nurses as proxy subjects have been used to explore the potential impact of utility on estimated benefits in terms of quality-adjusted progression-free life-years. These are shown for illustrative purposes only.

## **Need for further research**

The following points have been identified as areas requiring further research:

- QoL data should be included in trials of colorectal cancer treatments. Well-validated instruments should be used and this research should be conducted by independent researchers. It may be necessary to use more than one instrument in order to identify differences in QoL. It may also be necessary to identify the components of QoL that vary with different treatments.
- More research is needed to determine the place of effective oral treatments in the treatment of colorectal cancer. This should focus on when such treatments should be given alone and when they should be given in combination with

other chemotherapeutic agents. Research is needed on the combination of oral agents with other chemotherapy agents (notably irinotecan and oxaliplatin) and novel agents.

- Some types of patients may benefit more from oral treatment than others. Research is needed to determine what safety mechanisms are needed in order to ensure compliance and the monitoring of adverse effects.
- The optimum duration of treatment needs to be determined, for example, with respect to disease progression, response, unacceptable toxicity or death. Intermittent treatment with a pause after 12 weeks for those with stable or responding disease also needs to be considered.
- The issue of patient preference must be given careful consideration in future trials and all trials should incorporate the measurement of patient preference.
- In order to make a precise estimate of the cost-effectiveness of capecitabine and UFT/LV versus MdG treatment, a phase III comparative trial would be necessary to determine whether there was any survival advantage. This would also give clinicians clear information on survival to present to patients, who can then make an informed choice with regard to treatment.

## Chapter 8

### Conclusions

**T**here is good evidence to suggest that capecitabine is effective in improving overall response rates compared with Mayo regimen 5-FU/LV therapy in the treatment of metastatic colorectal cancer. Duration of response, time to disease progression or death, time to treatment failure and overall survival were found to be equivalent. Capecitabine use was associated with fewer adverse events apart from hand-foot syndrome and hyperbilirubinaemia.

There is some evidence to suggest that UFT/LV is equivalent to the Mayo regimen 5-FU/LV and some evidence to suggest that UFT/LV treatment is associated with inferior time to disease progression. UFT/LV was associated with fewer adverse events than the 5-FU/LV regimen.

There was no evidence that either capecitabine or UFT/LV affects health-related QoL. No studies were identified regarding patient preference for capecitabine. One small cross-over trial found that patients preferred UFT/LV treatment over treatment with 5-FU/LV.

Given that the survival benefits of therapy have been shown to be similar for the oral and the Mayo regimens, a cost-minimisation analysis was undertaken. The results of the economic analysis showed that both capecitabine and UFT/LV offer cost advantages over the Mayo regimen. The cost savings offered by capecitabine and UFT/LV in relation to the Mayo regimen were estimated to be £1461 and £209, respectively. Savings in the cost of administration more than offset the higher drug costs of the oral therapy regimens.

There is no direct evidence to compare the survival benefits of MdG or inpatient de Gramont regimens with the oral regimens. No evidence was identified that showed a significant survival advantage of de Gramont regimens over the Mayo regimen and therefore a cost-minimisation analysis was undertaken. The results of the economic analysis showed that both capecitabine and UFT/LV offer cost advantages over the MdG regimen and the inpatient de Gramont regimen. However, infusional regimens have been shown to be more effective in terms of progression-free survival, tumour response and toxicity.<sup>17</sup> Preliminary analysis undertaken to explore the impact of these factors on cost-effectiveness suggests that oral drugs cannot necessarily be considered a cost-effective option relative to the MdG regimen in terms of the cost per progression-free LYG. Further evidence in terms of both benefits and costs is needed in this area.

Costs and cost-effectiveness are sensitive to discounts on the drug acquisition cost of LV, the cost of outpatient appointments and the treatment time.

In order to make a precise estimate of the cost-effectiveness of capecitabine and UFT/LV versus MdG treatment, a phase III comparative trial would be necessary to determine whether there was any survival advantage. This would also give clinicians clear information on survival to present to patients, who can then make an informed choice with regard to treatment.



## Acknowledgements

Professor Robert Hawkins (CRC Professor and Director of Medical Oncology, Christie CRC Research Centre, Manchester), Dr Maria Marples (Senior Lecturer/Honorary Consultant in Medical Oncology, Weston Park Hospital, Sheffield), Dr Brian Orr (Consultant in Clinical Oncology, Weston Park Hospital, Sheffield) and Dr Matthew Seymour (Senior Lecturer and Consultant in Medical Oncology, Cookridge Hospital, Leeds) provided clinical advice.

This report was commissioned by the NHS R&D HTA programme. The views expressed in this report are those of the authors and not necessarily those of the NHS R&D HTA programme. Any errors are the responsibility of the authors.

### Contributions of authors

Eva Kaltenthaler carried out the review of the background information and the clinical effectiveness review. Sue Ward and Johanna Cowan carried out the cost-effectiveness review.

Naomi Brewer undertook the electronic literature searches.

### Publication information

Trent Institute for Health Services Research is a collaborative venture between the Universities of Leicester, Nottingham and Sheffield, with support from the NHS Executive Trent. Members of staff in the Sheffield Unit, based in the School of Health and Related Research (ScHARR), have been engaged in reviewing the effectiveness and cost-effectiveness of healthcare interventions in support of the National Institute for Clinical Excellence.

In order to share expertise on this work, we have set up a wider collaboration, InterTASC, with units in other regions. These are the Wessex Institute for Health Research and Development, Southampton University, The University of Birmingham Department of Public Health and Epidemiology, and The Centre for Reviews and Dissemination, University of York.



## References

1. Quinn M, Babb M, Broch A, Kirby L, Jones J. Cancer trends in England and Wales 1950–1999. Studies in Medical and Population Subjects No. 66. London: The Stationery Office; 2001. pp. 34–9.
2. Boyle P, Langman JS. ABC of colorectal cancer: epidemiology. *BMJ* 2000; **321**:805–8.
3. NHS Centre for Reviews and Dissemination. The management of colorectal cancer. *Effective Health Care Bull* 1997; **3**:1–12.
4. NHS Executive. Improving outcomes in colorectal cancer: the manual. Cat. No. 97CV0119. London: Department of Health; 1997.
5. Office for National Statistics Mortality Statistics. Cause: review of the Registrar General on deaths by cause, sex and age, in England and Wales, 1998. Series DH2, No. 25. London: The Stationery Office; 2000.
6. Young A, Rea D. ABC of colorectal cancer. Treatment of advanced disease. *BMJ* 2000; **321**:1278–81.
7. Seymour MT, Stenning SP, Cassidy J. Attitudes and practice in the management of metastatic colorectal cancer in Britain. *Clin Oncol* 1997; **9**:248–51.
8. Jonker DJ, Maroun JA, Kocha W. Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. *Br J Cancer* 2000; **82**:1789–94.
9. Colorectal Cancer Collaborative Group. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. *BMJ* 2000; **321**:531–5.
10. Best L, Simmonds P, Baughan C, Buchanan R, Davis C, Fentiman I, et al. Palliative chemotherapy for advanced or metastatic colorectal cancer (Cochrane Review). The Cochrane Library. Oxford: Update Software; 2002.
11. Chemotherapy for metastatic colorectal cancer. *Drug Ther Bull* 2002; **40**:49–52.
12. Waters J, Cunningham D. The changing face of chemotherapy in colorectal cancer. *Br J Cancer* 2001; **84**:1–7.
13. Seitz JF. 5-Fluorouracil/leucovorin versus capecitabine in patients with stage III colon cancer. *Semin Oncol* 2001; **28**:41–4.
14. Cunningham D, Coleman R. New options for outpatient chemotherapy – the role of oral fluoropyrimidines. [Review; 67 refs]. *Cancer Treat Rev* 2001; **27**:211–20.
15. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. *J Clin Oncol* 1998; **16**:301–8.
16. Meta-analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. *J Clin Oncol* 1998; **16**:3537–41.
17. de Gramont A, Bosset JF, Milan, C, Rougier P, Bouche O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup Study. *J Clin Oncol* 1997; **15**:808–15.
18. Maughan TS, James RD, Kerr DJ. Comparison of survival, palliation and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. *Lancet* 2002; **359**:1555–63.
19. de Gramont A, Figer A, Seymour M. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. *J Clin Oncol* 2000; **18**:2938–47.
20. Douillard JY, Cunningham D, Roth AD. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. *Lancet* 2000; **355**:1041–7.
21. Cheeseman SL, Joel SP, Chester JD, Wilson G, Dent JT, Richards FJ, et al. A ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. *Br J Cancer* 2002; **87**:393–9.
22. Rowe M, James R. A prospective comparison of in-patient versus outpatient DeGramont therapy: using quality of life, acceptability and response measures: a pilot study. *Eur J Cancer* 1999; **35**:573.
23. Scase A, Ross P, Cunningham D. The Royal Marsden Hospital experience with raltitrexed (‘Tomudex’) and its comparison with protracted venous infusion 5-fluorouracil and bolus 5-fluorouracil. *GI Cancer* 1998; **2**:267–75.
24. Lloyd-Jones M, Hummel S, Bansback N, Orr B, Seymour M. A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. *Health Technol Assess* 2001; **5**(25).

25. Mountney L, Sanderson H, Harris J. Colorectal cancer. In Stevens A, Raftery J, editors. *Healthcare needs assessment*. Vol. 1. Oxford: Radcliffe Medical Press; 1994.
26. Cunningham D, James RD. Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer. [Review; 59 refs]. *Eur J Cancer* 2001;**37**:826–34.
27. Electronic medicines compendium (eMC). URL: <http://emc.vhn.net/>. 2002.
28. Blanke CD, Teng M, Choy H. The role of UFT in combined-modality therapy. *Oncology (Huntingt)* 1999;**13**:47–54.
29. Sulkes A, Benner SE, Canetta RM. Uracil-*ftorafur*: an oral fluoropyrimidine active in colorectal cancer. *J Clin Oncol* 1998;**16**:3461–75.
30. Hoff PM, Lassere Y, Pazdur R. Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil. [Review; 43 refs]. *Drugs* 1999;**58**:77–83.
31. Perevodchikova NI, Manzyuk LV, Gorbunova VA, Abramova NA, Lukyanchenko AB. *Ftorafur (Ft) + leucovorin (Lv) and ftorafur (Ft) in advanced colorectal cancer (randomized study)*. Anti-Cancer Treatment Sixth International Congress, Paris, 6–9 February, 1996;121, abstract 319.
32. Wellington K and Goa KL. Oral tegafur/uracil. *Drugs Aging* 2001;**18**:935–48.
33. Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials* 1996;**17**:1–12.
34. Oxman AD, Cook DJ, Guyatt GH. How to use an overview. *JAMA* 1994;**272**:1367–71.
35. Levine M, Walter S, Lee H, Haines T, Holbrook A, Moyer V. How to use an article about harm. *JAMA* 1994;**271**:1615–19.
36. Twelves C. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. *Eur J Cancer* 2002;**38**:Suppl 2:15–20.
37. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. *Lancet* 2000;**356**:373–8.
38. Louvet C, de Gramont A, Tournigand C, Artru P, Maindrault, Goebel F, Krulik M. Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. *Cancer* 2001;**91**:2033–8.
39. Twelves CJ, Cassidy J. Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer? *Br J Cancer* 2002;**86**:1670–6.
40. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. *J Clin Oncol* 2001; **19**:2282–92.
41. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. *J Clin Oncol* 2001; **19**:4097–106.
42. Pazdur R, Douillard JY, Skillings JR, Eisenberg PD, Davidson N, Harper P, et al. Multicenter Phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer. *Proc Am Soc Clin Oncol* 1999; **18**:263a, abstract 1009.
43. Carmichael J, Popiela T, Radstone S, Falk S, Fey M, Oza A, et al. Randomized comparative study of ORZEL (oral uracil/tegafur (UFT) plus leucovorin (LV)) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer. *Proc Am Soc Clin Oncol* 1999; **18**:264a, abstract 1015.
44. Hoff PM, Cassidy J, Schmoll HJ. The evolution of fluoropyrimidine therapy: from intravenous to oral. *Oncologist* 2001; **6**:3–11.
45. Roche. Roche Xeloda (capecitabine): achieving clinical excellence in the treatment of metastatic colorectal cancer. Sponsor submission to the National Institute for Clinical Excellence. 2002.
46. Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin vs 5-fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. *J Clin Oncol* 2002; **20**:3605–16.
47. Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, et al. Randomized comparative study of tegafur/uracil and oral leucovorin vs. parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. *J Clin Oncol* 2002; **20**:3617–27.
48. Bristol-Myers Squibb Company. Uftoral treatment of metastatic colorectal cancer. Sponsor submission to the National Institute for Clinical Excellence. 2002.
49. Benner S. 63rd US Federal Drug Administration Oncology Advisory Board Meeting Slides. URL: <http://www.fda.gov/ohrms/dockets/ac/99/slides/3540/3540s1a-g/index.htm>. 1999 (accessed 26.06.02).
50. Borner MM, Schoffski P, deWit R, Caponigro F, Comella G, Sulkes A, et al. Patient preference and pharmacokinetics of oral modulated UFT versus

- intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. *Eur J Cancer* 2002;**38**:349–58.
51. Murad AM, de Andrade CA, Delfino C, Arikian S, Doyle JJ, Dezii CM, et al. Pharmacoeconomic evaluation of tegafur–uracil (UFT) vs fluorouracil for the management of colorectal cancer in Brazil and Argentina. *Clin Drug Invest* 1997;**13**:90–8.
  52. Murad A, de Andrade CA, Delfino C, Arikian S, Doyle J, Sinha N. A pharmacoeconomic comparison of UFT and 5-FU chemotherapy for colorectal cancer in South America. *Oncology (Huntingt)* 1997;**11**:128–35.
  53. Twelves C, Boyer M, Findlay M, Cassidy J, Weitzel C, Barker C, et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. *Eur J Cancer* 2001;**37**:597–604.
  54. Ollendorf D. Impact of uracil/tegafur plus oral calcium folinate on resource utilization. *Oncology (Huntingt)* 1999;**13**:42–3.
  55. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary No. 43. URL: [www.bnf.vhn.net](http://www.bnf.vhn.net). 2002.
  56. Netten A, Rees T, Harrison G. Unit costs of health and social care 2001. Canterbury: Personal Social Services Research Unit, University of Kent; 2001.
  57. Summerhayes M. Summary report: pharmacy and nursing questionnaire on chemotherapy workload and colorectal cancer. 2002.
  58. Financial Matters Health Service Cost Index. *Financial Matters* 2002.  
<http://www.doh.gov.uk/finman.htm> (accessed 08.09.03).
  59. Iveson TJ, Hickish T, Schmitt C, Van Cutsem E. Irinotecan in second line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. *Eur J Cancer* 1999;**35**:1796–804.
  60. Avon, Somerset and Wiltshire Cancer Services Cancer Drug Policy Forum. Prescribing issues in colorectal cancer: final summary report. Bristol: Avon, Somerset and Wiltshire Cancer Services; 2000.
  61. Maughan T, Kerr JD, Ledermann J, McArdle C, Seymour M, Topham C, et al. Continuous vs intermittent chemotherapy for advanced colorectal cancer: preliminary results of the MRC Cr06b randomised trial. *American Society of Clinical Oncology* 2001;**20**:125a.
  62. Petrou S, Campbell N. Stabilisation in rectal cancer. *Int J Palliative Nurs* 1997;**3**:275–80.
  63. Gelber RD, Goldhirsh A, Cole BF. A quality adjusted time without symptoms or toxicity (Q-Twist) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. *J Nat Cancer Inst* 1996;**88**:1039–45.
  64. Mayer RJ. Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it's all the same. *J Clin Oncol* 2001;**19**:4093–6.
  65. Liu G, Franssen E, Fitch MI. Patient preferences for oral versus intravenous palliative chemotherapy. *J Clin Oncol* 1997;**15**:110–15.
  66. Borner M, Scheithauer W, Twelves C, Maroun J, Wilke H. Answering patients' needs: oral alternatives to intravenous therapy. *Oncologist* 2001;**6**:12–16.
  67. Smithies A, Stein K. Irinotecan as second line chemotherapy in colorectal cancer. Development and Evaluation Committee report 97. Wessex Institute for Health Research and Development, University of Southampton; 1999.
  68. World Health Organization. Handbook for reporting results of cancer treatment. Publication No. 48. Geneva: World Health Organization; 1979.
  69. [http://ctep.cancer.gov/forms/CTCv20\\_4.30.992.pdf](http://ctep.cancer.gov/forms/CTCv20_4.30.992.pdf) (accessed 11.09.03).



## Appendix I

# WHO criteria for evaluation of response<sup>67,68</sup>

**B**idimensionally or unidimensionally measurable disease.

### **Complete response**

Disappearance of all known disease, determined by two observations not less than 4 weeks apart.

### **Partial response**

In the case of bidimensionally measurable disease, a decrease by at least 50% of the sum of the products of the largest perpendicular diameters of all measurable lesions as determined by two observations not less than 4 weeks apart. For unidimensionally measurable disease, a decrease by at least 50% in the sum of the largest diameters of all lesions as determined by two observations not less than 4 weeks apart.

It is not necessary for all lesions to have regressed to qualify for partial response, but no lesion should have progressed and no lesion should appear. Serial evidence of appreciable change must be obtained and available for subsequent review. The assessment must be objective.

### **Minor response**

In the case of bidimensionally measurable disease, a decrease by at least 25% but less than 50% of the sum of the products of the largest perpendicular

diameters of all measurable lesions as determined by two observations not less than 4 weeks apart. For unidimensionally measurable disease, a decrease by at least 25% but less than 50% in the sum of the largest diameters of all lesions as determined by two observations not less than 4 weeks apart. It is not necessary for all lesions to have regressed to qualify for minor response, but no lesion should have progressed and no lesion should appear. Serial evidence of appreciable change must be obtained and available for subsequent review. The assessment must be objective.

### **No change**

For bidimensionally measurable disease, a <25% decrease and <25% increase in the sum of the products of the largest perpendicular diameters of all measurable lesions. For unidimensionally measurable disease, a <25% decrease and <25% increase in the sum of the diameter of all lesions. No new lesions should appear.

### **Progressive disease**

A >25% increase in the size of at least one bidimensionally or unidimensionally measurable lesion (in comparison with the measurements at nadir), or appearance of a new lesion. The occurrence of pleural effusion or ascites is also considered as progressive if this is substantiated by positive cytology.



## Appendix 2

### 5-FU-based treatment regimens

<b>Regimen</b>	<b>Schedule</b>
Bolus 5-FU: Mayo	5-FU 425 mg/m <sup>2</sup> /day + FA 20 mg/m <sup>2</sup> /day for 5 days every 4 weeks
Infusional 5FU: AIO	2-hour infusion of FA (500 mg/m <sup>2</sup> ) followed by a 24-hour infusion of 5-FU (2600 mg/m <sup>2</sup> ), weekly for 6 weeks; cycle time 8 weeks
de Gramont	2-hour infusion of FA (200 mg/m <sup>2</sup> ) + bolus 5-FU (400 mg/m <sup>2</sup> ) followed by a 22-hour infusion of 5-FU (600 mg/m <sup>2</sup> ) on days 1 and 2 of each fortnight <sup>11</sup>
MDG	FA (350 mg) + bolus 5-FU (400 mg/m <sup>2</sup> ) followed by a 46-hour infusion of 5-FU (2800 mg/m <sup>2</sup> ) fortnightly <sup>44</sup>
Lokich	5-FU 250–300 mg/m <sup>2</sup> as prolonged continuous i.v. infusion until progression/toxicity
AIO, Arbeitsgemeinschaft Internische Onkologie.	



## Appendix 3

### Continuous infusion versus bolus 5-FU regimens – meta-analysis

<b>Study</b>	<b>Research question</b>	<b>No. of trials</b>	<b>Searches</b>	<b>Study selection</b>
Meta-analysis Group in Cancer, 1998 <sup>15</sup>	To compare the administration of 5-FU by continuous intravenous infusion with bolus administration in patients with advanced colorectal cancer	Six randomised clinical trials	MEDLINE 1984–94, Proceedings of major congresses, personal contacts with investigators	Seven trials were identified, one was excluded because original patient data could not be retrieved and the randomisation procedure was based on hospital record numbers

## Study details

Study	Included trials	Treatment schedules and number of patients			
		Study	5-FU ci	5-FU bolus	No. of patients
Meta-analysis Group in Cancer, 1998 <sup>15</sup>	ECOG, 1996	ECOG	5-FU 300 mg/m <sup>2</sup> /d without interruption then 5-FU 600 mg/m <sup>2</sup> d, q7d	5-FU mg/m <sup>2</sup> dl-d5	324
	National Cancer Institute of Canada (NCIC), 1992	NCIC	5-FU 350 mg/m <sup>2</sup> dl-d15, q28d	5-FU 400–450 mg/m <sup>2</sup> /dl-d5, q28d	185
	Southwest Oncology Group (SWOG1), 1995	SWOG 1	5-FU 300 mg/m <sup>2</sup> dl-d28, q35d	5-FU 500 mg/m <sup>2</sup> /dl-d5, q35d	181
	Mid-Atlantic Oncology Program (MAOP), 1989	MAOP	5-FU 300 mg/m <sup>2</sup> /d without interruption	5-FU 500 mg/m <sup>2</sup> /dl-d5, q35d	173
	France, 1992	France	5-FU 750 mg/m <sup>2</sup> dl-d7, q21d	5-FU 500 mg/m <sup>2</sup> /dl-d5, q28d	155
	Southwest Oncology Group (SWOG2), 1995	SWOG 2	5-FU 200 mg/m <sup>2</sup> dl-d28, q35d+ Folinic acid 20 mg/m <sup>2</sup> i.v., q7d	5-FU 425 mg/m <sup>2</sup> + folinic acid 20 mg/m <sup>2</sup> i.v. dl-d5, q28d×2, then q35d	175
	Jerusalem, 1989	Jerusalem	5-FU 600 mg/m <sup>2</sup> + folinic acid 15 mg/6 h orally dl-d5, q21d	5-FU 600 mg/m <sup>2</sup> + folinic acid 15 mg/6 h orally dl-d5, q21d	26

ECOG, Eastern Cooperative Oncology Group.

## Study details continued

Study	Trial characteristics	Predicted cumulative doses of 5-Fu in 5-FU bolus arm and in 5-FU ci arm (doses expressed in mg/m <sup>2</sup> )					
		Trial	Treatment arm	After week 1	4	8	12
Meta-analysis Group in Cancer, 1998 <sup>15</sup>	ECOG was a three-arm trial with one arm receiving 5-FU ci plus cisplatin. This arm was not included in the meta-analysis. The SWOG trial had seven arms, three of which were not included in the meta-analysis  In the ECOG and MAOP trials, ci 5-FU was administered without a rest period. In the SWOG trial, 5-FU infusion was maintained over 80% of the time. In the NCIC and the French trial, duration of 5-FU infusion was between 33 and 50% of the time	ECOG	5-FU ci	2100	8400	16,800	25,200
			5-FU bolus	2500	3700	6100	8500
		NCIC	5-FU ci	2450	4900	9800	14,700
			5-FU bolus	2250	2250	4500	6750
		SWOG 1	5-FU ci	2100	8400	14,700	21,000
			5-FU bolus	2500	2500	5000	7500
		MAOP	5-FU ci	2100	8400	16,800	25,200
			5-FU bolus	2500	2500	5000	7500
		France	5-FU ci	5250	10,500	15,750	21,000
			5-FU bolus	2500	2500	5000	7500
		SWOG 2	5-FU ci	1400	5600	9800	14,000
			5-FU bolus	2125	2125	4250	6375
		Jerusalem	5-FU ci	3000	6000	9000	12,000
			5-FU bolus	3000	6000	9000	12,000

## Patient characteristics

Study	Patient characteristics							
	Trial	Accrual period	Treatment arm	No. of patients	Primary colon (%)	PS < 2 (%)	Metastases (%)	
							Liver only	Lung only
Meta-analysis Group in Cancer, 1998 <sup>15</sup>	ECOG	1987–90	5-FU ci	162	81	94	23	8
			5-FU bolus	162	80	89	23	7
	NCIC	1986–89	5-FU ci	95	68	85	49	5
			5-FU bolus	90	78	89	49	4
	SWOG1	1989–92	5-FU ci	88	85	88	NA	NA
			5-FU bolus	93	72	89	NA	NA
	MAOP	1984–86	5-FU ci	88	76	90	34	5
			5-FU bolus	85	74	91	34	8
France	France	1987–90	5-FU ci	77	66	92	44	12
			5-FU bolus	78	64	90	51	12
	SWOG2	1989–92	5-FU ci	86	70	92	NA	NA
			5-FU bolus	89	72	88	NA	NA
	Jerusalem	1984–86	5-FU ci	11	38	82	45	18
			5-FU bolus	15	80	93	33	13
	Total	1984–92	5-FU ci	607	75	91	35	7
			5-FU bolus	612	75	90	36	7

A total of 1219 patients were considered in the meta-analysis. The median patient age was 63 years and 61% of patients were male. At the time of analysis, 91% of patients had died.

## Study quality

Study	Agreement between reviewers	Similarity of included studies	Tests for homogeneity
Meta-analysis Group in Cancer, 1998 <sup>15</sup>	Data were extensively checked and discussed with all collaborators at a plenary meeting of the Meta-analysis Group	Studies use different regimens of 5-FU both continuous and bolus and two (SWOG2 and Jerusalem) add LV	Tests for heterogeneity were calculated for tumour response odds ratios and survival hazards ratios (both NS)

## Results

Study	Outcomes measured	Tumour response	Survival	Prognostic factors
Meta-analysis Group in Cancer, 1998 <sup>15</sup>	Tumour response and survival	<p>A total of 1103 patients were included in the tumour response analysis as 116 patients in the SWOG trial had non-measurable disease</p> <p>5-FU ci 22% (CR 3%, PR 19%)</p> <p>5-FU bolus 14% (CR 2%, PR 12%).</p> <p>Overall response odds ratio (OR) was 0.55 (95% CI: 0.41 to 0.75), indicating a highly significant advantage for 5-FU ci (<math>p = 0.0002</math>), equivalent to a risk reduction of 45% with a standard error of 12%.</p> <p>However, advantage of 5-FU ci over 5-FU bolus was only statistically significant in three <i>individual</i> trials (ECOG, MAOP, French).</p> <p>A logistic regression model showed that treatment and performance status were the only independent prognostic factors with no interaction between the two</p> <p><i>Median duration of tumour response</i> 5-FU ci 7.1 months (95% CI: 5.7 to 8.5 months)</p> <p>5-FU bolus 6.7 months (95% CI: 5.7 to 8.5 months)</p>	<p>No individual trial showed a benefit of 5-FU ci but their combination showed a small but statistically significant advantage for 5-FU ci over 5-FU bolus [hazards ratio (HR): 0.88, 95% CI: 0.78 to 0.99; <math>p = 0.04</math>]</p> <p><i>Median survival duration</i> 5-FU CI: 12.1 months (95% CI: 11 to 13.1) 5-FU bolus: 11.3 months (95% CI: 10.5 to 12)</p> <p><i>LV modulation</i> 5-FU/LV (SWOG2 and Jerusalem) overall survival was not significantly better for 5-FU ci compared with 5-FU bolus (HR 1.03; 95% CI: 0.77 to 1.38; <math>p = 0.84</math>) but based on too few patients to be informative.</p> <p>Cox regression model stratified for trial showed that treatment, performance status and primary tumour site were independent prognostic factors for survival</p>	<p>Randomised treatment, age (continuous), sex, performance status (ECOG), primary tumour location (rectum or colon) and site of metastases (liver only or not) were considered in the prognostic factor analyses.</p> <p>Randomised treatment and performance status were independent prognostic factors for haematological toxicity. Patients assigned to 5-FU bolus (<math>p &lt; 0.0001</math>) and patients with a poor performance status (<math>p = 0.03</math>) had a significantly higher risk of haematological toxicity.</p> <p>Age, sex and performance status were independent prognostic factors for non-haemotological toxicity. Older patients (<math>p = 0.01</math>), female patients (<math>p = 0.03</math>) and patients with good performance status (<math>p = 0.007</math>) had a significantly higher risk of toxicity.</p>

continued

Study	Outcomes measured	Tumour response	Survival	Prognostic factors
		<p>5-FU/LV (SWOG2 and Jerusalem) found the difference between 5-FU/LV and bolus 5-FU/LV did not reach statistical significance tumour response, OR = 0.82 (95% CI: 0.33 to 2.07), but only 145 patients were included in this group</p> <p><i>Duration of treatment</i></p> <p>Tumour response OR was 0.55 (95% CI: 0.37 to 0.81) when duration of 5-FU infusion was &gt;80% of the time (ECOG, MAOP, SWOG1), compared with 0.48 (95% CI: 0.26 to 0.89) when 5-FU infusion was between 33 and 50% of the time <math>\chi^2</math> for interaction 0.14; <math>p = 0.70</math></p>		<p>Randomised treatment, age and sex were independent prognostic factors for hand-foot syndrome.</p> <p>Survival duration was added to the logistic regression model and found to be unrelated to haematological toxicity (<math>p = 0.99</math>), marginally related to non-haematological toxicity (<math>p = 0.08</math>) and strongly related to hand-foot syndrome (<math>p &lt; 0.0001</math>).</p>

## Toxicity

Study	Haematological toxicity	Non-haematological toxicity	Hand-foot syndrome
Meta-analysis Group in Cancer, 1998 <sup>16</sup>	<p>Overall proportion of grade 3–4 haematological toxicity was 4% for patients assigned to 5-FU ci (23 of 607) and 31% for patients assigned to 5-FU bolus (191 of 612).</p> <p>Adjusted haematological toxicity rate ratio (RR) was 0.14 (95% CI: 0.09 to 0.21), indicating that patients receiving 5-FU ci were on average seven times less likely to experience a grade 3–4 haematological toxicity than patients receiving 5-FU bolus (<math>p &lt; 0.0001</math>)</p>	<p>Overall grade 3–4 non-haematological toxicity occurred in 13% of patients in 5-FU ci (79 of 607) and in 14% of those in 5-FU bolus (84 of 612).</p> <p>Adjusted non-haematological toxicity RR was 0.96 (95% CI: 0.72 to 1.28; <math>p = 0.78</math>).</p> <p>Risks of severe diarrhoea, nausea/vomiting and mucositis were not different in the 5-FU ci and 5-FU bolus groups: 4 vs 6%, 3 vs 4% and 9 vs 7% respectively</p>	<p>Overall proportion of hand-foot syndrome was 34% for 5-FU ci patients (206 of 607) and 13% for 5-FU bolus patients (977 of 612). The adjusted RR was 1.87 (95% CI: 1.50 to 2.34), which indicates that the risk of hand-foot syndrome is almost doubled when 5-FU is given by ci (<math>p &lt; 0.0001</math>).</p>

d, days; q, every; i.v., intravenous; h, hours, ci, continuous infusion; OR, odds ratio; PS, performance status; NA, not available; SWOG 1 and SWOG 2 refer to two different arms of one SWOG trial.



## **Appendix 4**

### **Continuous infusion versus bolus 5-FU regimens – RCTs**

Study	Study site	Comparators, dosage and procedure	Type of study	Numbers randomised	Funding
de Gramont et al., 1997 <sup>17</sup>	70 centres in France	<p>Arm A (Mayo): <i>Monthly</i> 5-FU bolus, low-dose LV for 5 consecutive days. LV given by i.v. bolus at 20 mg/m<sup>2</sup>/day and immediately followed by 5-FU bolus at 425 mg/m<sup>2</sup>/day, repeated for 5 consecutive days. Cycles every 4 weeks.</p> <p>Arm B (de Gramont): <i>Bimonthly</i> high-dose LV with 5-FU bolus and continuous infusion for 2 consecutive days. LV was given at 200 mg/m<sup>2</sup>/day as a 2-hour infusion followed by i.v. bolus 5-FU at 400 mg/m<sup>2</sup>/day and 22- hour infusion 5-FU 600 mg/m<sup>2</sup>/day all repeated for 2 consecutive days. Cycles at 2-week intervals.</p> <p>The full regimen was administered until disease progression [neutrophils were &gt;1500/mm<sup>3</sup>, platelet count was &gt;100,000/mm<sup>3</sup>, and toxicity remained tolerable (WHO grade 0–2)]. Study regimens were stopped when disease progression occurred and second-line chemotherapy, including 5-FU continuous infusion, could be administered in both trial arms</p>	RCT	448 total patients	Wyeth-Lederle laboratories (Paris, France)

## Study design

Study	Length of study	Inclusion criteria	Exclusion criteria	Power calculation	Baseline comparability
de Gramont et al., 1997 <sup>17</sup>	Patients assigned to treatment from February 1991 to April 1994; follow-up time for the whole cohort was 43.5 months	Adenocarcinoma of the colon or rectum, progressive or histologically proven non-resectable metastases at presentation, no central nervous system metastasis, no exclusive bone metastases, no secondary malignancy (except adequately treated <i>in situ</i> carcinoma of the cervix or non-melanomic skin cancer), life expectancy over 2 months, age between 19 and 75 years, WHO performance status 0–2, no previous therapy for metastatic disease, no previous adjuvant therapy if completed less than 6 months before inclusion or if it included LV, metastases outside the radiation field in patients who had previously had radiation therapy, initial evaluation 2 weeks or less before inclusion, neutrophils >1500/mm <sup>3</sup> , platelets greater than 100,000/mm <sup>3</sup> , serum creatinine <300 µmol/L and partial thrombin time >50%	As stated in inclusion criteria	Yes, to detect difference in survival	Yes

## Patient details

Study	Sex (M/F)	Age	Performance score	Primary site	Sites of metastasis		
de Gramont et al., 1997 <sup>17</sup>	Arm A: 145/71 Arm B: 135/82	Mean SD: Arm A: 61.7 ± 9.6 Arm B: 60.9 ± 9.5	WHO performance status  WHO status 0      Arm A (%)      Arm B (%) WHO status 1–2    118 (54.6)    120 (55.3)	Colon Rectum Multiple or non-specified	Arm A (%) 142 (65.7) 68 (31.5) 6 (2.8)	Arm B (%) 139 (64.1) 73 (33.6) 5 (2.3)	
				Liver Lung Other 1 site ≥2 sites No. of sites not specified	Liver Lung Other 1 site ≥2 sites No. of sites not specified	Arm A (%) 172 (80.7) 34 (16) 40 (18.8) 182 (85) 32 (15) 2	Arm B (%) 176 (81.5) 34 (15.7) 40 (18.5) 182 (84.3) 34 (15.7) 1

## Quality assessment

Study	Randomised/method	Blinding/appropriate method	Description of withdrawals and dropouts	Jadad score
de Gramont et al., 1997 <sup>17</sup>	Yes, method not described.  Patients were stratified according to performance status, measurable disease, synchronous vs metachronous metastases and institution	No blinding described	Withdrawals and dropouts adequately described	2/5

## Outcomes

Study	ITT analysis	Primary end-points	Secondary end-points	Duration of treatment
de Gramont et al., 1997 <sup>17</sup>	No, 348 of 448 original randomised patients were included in the analysis of response rates and 433 of 448 in other analyses	Survival	Tumour response	Patients in Arm A received a median of 5 cycles (range: 1–21) and in Arm B a median of 12 cycles (range: 1–42)

## Results

Study	Response rate		Duration of response	Median time to disease progression or death	Survival
de Gramont et al., 1997 <sup>17</sup>	Overall objective tumour responses; number of patients (%) Arm A            Arm B	CR                  4 (2.3)            10 (5.7) PR                  21 (12.1)            47 (26.9) Stable               68 (39.3)            62 (35.4) Progression        80 (46.2)            56 (32) CR + PR            25 (14.45)*        57 (32.57)*	Median duration of response was 48.5 weeks in Arm A and 47 weeks in Arm B ( $p = 0.78$ )	Not reported	Progression-free survival Arm B (bimonthly regimen) had significantly longer median progression-free survival than those in Arm A (monthly regimen), 27.6 vs 22 weeks ( $p = 0.0010$ ; OR = 0.72)  Median survival Arm B (bimonthly regimen) had slightly longer median survival than Arm A (monthly regimen) (62.0 vs 56.8 weeks $p = 0.067$ ).  Patients with measurable disease had a median survival of 63 vs 46 weeks in patients with non-measurable disease ( $p = 0.0186$ ). Interaction test between treatment arms and measurable/non-measurable diseased showed borderline significance ( $p = 0.07$ ). OR ratio was significant only for patients with measurable disease treated with the bimonthly regimen compared with the monthly regimen (OR = 0.75, $p = 0.015$ ).  Median survival in patients with measurable disease was 72 weeks in Arm B and 58.4 weeks in Arm A

## Toxicity

Study	Types of side-effects				Treatment-related deaths
de Gramont et al., 1997 <sup>17</sup>	Toxicity per patient:				
		Arm A (monthly) (n = 205)	Arm B (n = 208) (bimonthly)		
		Grade 1–2 (%)	Grade 1–2 (%)	Grade 3–4 (%)	Comparison <sup>a</sup>
	Neutrophils	14 (6.8)	20 (9.6)	4 (1.9)	0.0052
	Platelets	1 (0.5)	1 (0.48)	2 (1.0)	1.00
	Infection	14 (6.8)	11 (5.3)	2 (1.0)	0.095
	Nausea	72 (35.1)	80 (38.5)	8 (3.9)	0.95
	Diarrhoea	54 (26.3)	59 (28.4)	6 (2.9)	0.039
	Mucositis	38 (18.5)	42 (20.2)	4 (1.9)	0.0001
	Angina pectoris	2 (1.0)	8 (3.8)	0	(0.14)
	Cutaneous	25 (12.2)	31 (14.9)	2 (1.0)	(0.59)
	Alopecia	26 (12.7)	25 (12.0)	1 (0.5)	0.37
	Epistaxis	7 (3.4)	19 (9.1)	0	(0.019)
	Conjunctivitis	10 (4.9)	29 (13.9)	0	(0.003)
	Neurological	3 (1.5)	7 (3.4)	1 (0.5)	1.00
	Maximal	90 (43.9)	119 (57.2)	23 (11.1)	0.0004

<sup>a</sup> Comparisons are for grade 3–4 toxicity Arm A vs Arm B; those in parentheses in the comparison column refer to grade 1–2 toxicities.



## Appendix 5

### Summary of de Gramont study results

<b>Study</b>	<b>Response rates (%)</b>	<b>Progression-free survival</b>	<b>Median overall survival</b>
de Gramont et al., 1997 <sup>17</sup>	32.6	27.6 weeks	62 weeks
de Gramont et al., 2000 <sup>19</sup>	28.6; 22.3 <sup>a</sup> ; 21.9 (ITT)	26.9 weeks; 26.1 weeks <sup>a</sup>	63.9 weeks
Douillard et al., 2000 <sup>20b</sup>	22 (ITT); 31 [de Gramont alone: 21.0 (ITT)]	4.4 months (17.6 weeks) [de Gramont alone: 3.7 months (14.8 weeks)]	14.1 months (56.4 weeks) [de Gramont alone: 13.0 months]
Maughan et al., 2002 <sup>18</sup>	23	25 weeks	294 days (42 weeks)

<sup>a</sup> Independent assessor.  
<sup>b</sup> In this trial, both de Gramont and AIO regimens included.



## Appendix 6

### Performance status scales

#### **WHO scale for performance status**

- 0 Fully active, able to carry on all predisease performance without restriction
- 1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g. light housework, office work
- 2 Ambulatory and capable of self-care but unable to carry out any work activities. Up and about more than 50% of waking hours
- 3 Capable of only limited self-care, confined to bed or chair more than 50% of waking hours
- 4 Completely disabled. Cannot carry out any self-care. Totally confined to bed or chair
- 5 Dead

#### **Eastern Cooperative Oncology Group (ECOG) performance status**

Status	Patient findings
0	No symptoms
1	Patient symptomatic but ambulatory
2	Patient bedridden less than half the day
3	Patient bedridden half the day or longer
4	Patient chronically bedridden and requires assistance with activities of daily living

#### **Karnofsky performance scale**

%	Description
100	Normal; no complaints; no evidence of disease
90	Able to carry out normal activity; minor signs or symptoms of disease
80	Normal activity with effort; some signs or symptoms of disease
70	Cares for self; unable to carry on normal activity or do active work
60	Requires occasional assistance, but is able to care for most of his/her needs
50	Requires considerable assistance and frequent medical care
40	Disabled; requires special care and assistance
30	Severely disabled; hospitalisation is indicated although death is not imminent
20	Very sick; hospitalisation necessary, active supportive treatment necessary
10	Moribund; fatal processes progressing rapidly
0	Dead



# Appendix 7

## Search strategies

### **Electronic bibliographic databases searched**

1. BIOSIS previews (the new online version of Biological Abstracts)
2. CancerLit
3. CCTR (Cochrane Controlled Trials Register)
4. CDSR (Cochrane Database of Systematic Reviews)
5. CINAHL
6. EBM Reviews – ACP Journal Club
7. EMBASE
8. HEED (Health Economic Evaluations Database)
9. MEDLINE
10. NHS DARE (Database of Assessments of Reviews of Effectiveness)
11. NHS EED (Economic Evaluations Database)
12. NHS HTA (Health Technology Assessment)
13. PreMedline
14. Science Citation Index
15. Social Sciences Citation Index

### **Other sources searched**

1. Adverse Event Reporting System
2. AHRQ (Agency for Healthcare Research and Quality), USA
3. Bandolier
4. Beating Bowel Cancer
5. British Geriatrics Society – Gastro Special Interests Group
6. British Oncological Association
7. British Psychosocial Oncology Society
8. Cancer BACUP
9. Cancer Research UK
10. CCOHTA (Canadian Coordinating Office for Health Technology Assessment)
11. CenterWatch
12. CHE (Centre for Health Economics), York
13. Clinical Evidence
14. CliniWeb
15. CMA (Canadian Medical Association) InfoBase
16. COIN (DoH)
17. Colon Cancer Concern
18. Current Controlled Trials
19. CriB (Current Research in Britain)
20. Drug Safety Research Unit

21. DES Reports (West Midlands Health Technology Assessment Collaboration)
22. DoH
23. eBNF (electronic British National Formulary)
24. eGuidelines
25. EMEA (European Agency for the Evaluation of Medicinal Products)
26. eMedicines Compendium
27. European Society for Medical Oncology
28. GOOGLE
29. Health Evidence Bulletin, Wales
30. HSRU (Health Services Research Unit), Aberdeen
31. INAHTA (International Network of Agencies for Health Technology Assessment) Clearinghouse
32. Index to Theses (Sheffield University)
33. ISI Proceedings (Web of Science)
34. Long Term Medical Conditions Alliance
35. Macmillan Cancer Relief
36. Marie Curie Cancer Care
37. MEDLINEplus Drug Information
38. MeRec
39. MRC Trials Register
40. National Assembly for Wales
41. National Cancer Alliance
42. National Cancer Research Institute
43. National Guidelines Clearinghouse
44. National Research Register (2002 Issue 2)
45. NCCHTA (National Coordinating Centre for Health Technology Assessment)
46. NHS CRD (Centre for Reviews and Dissemination), University of York
47. OMNI
48. POINT (DoH)
49. RAND
50. ReFeR (Research Findings Register)
51. Royal College of General Practitioners
52. Royal College of Nursing
53. Royal College of Physicians
54. Royal College of Radiologists
55. Royal College of Surgeons
56. Royal Pharmaceutical Society
57. ScHARR Library catalogue
58. SIGN (Scottish Intercollegiate Guidelines Network)
59. SEEK (Sheffield Evidence for Effectiveness and Knowledge)
60. Toxline
61. Trent Working Group on Acute Purchasing Reports

- 62. TRIP (Turning Research into Practice) Database
- 63. Wessex DEC (Development and Evaluation Committee) Reports
- 64. WHO

## **Search strategies used**

### **Biological Abstracts**

**1985–2002**

#### **SilverPlatter WebSPIRS**

**Search undertaken April 2002**

- #1. Capecitabine\*
- #2. Xeloda
- #3. 154361-50-9
- #4. EU?1?00?163?001
- #5. EU?1?00?163?002
- #6. Ro09?1978
- #7. Fluoropyrimidine\*
- #8. Tegafur\*
- #9. 17902-23-7
- #10. Uftoral
- #11. PL?11184?0087
- #12. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11
- #13. Carcinoma\* or neoplasia\* or neoplasm\* or adenocarcinoma\* or cancer\* or tumor\* or tumour\* or malignan\* or disease\*) near3 (colorectal\* or colon\* or rect\* or intestin\* or bowel\*)
- #14. #12 and #13

### **CDSR and CCTR**

**2002, Issue 1**

**The Cochrane Library, Update Software  
(CD ROM version)**

**Search undertaken April 2002**

- #1. COLORECTAL-NEOPLASMS\*:ME
- #2. NEOPLASMS\*:ME
- #3. CARCINOMA\*:ME
- #4. ADENOCARCINOMA\*:ME
- #5. #2 OR #3 OR #4
- #6. COLONIC-DISEASES\*:ME
- #7. RECTAL-DISEASES\*:ME
- #8. COLON\*:ME
- #9. RECTUM\*:ME
- #10. #6 OR #7 OR #8 OR #9
- #11. #5 AND #10
- #12. ((CARCINOMA\* OR NEOPLASIA\* OR NEOPLASM\* OR ADENOCARCINOMA\* OR CANCER\* OR TUMOR\* OR TUMOUR\* OR MALIGNAN\*) NEAR (COLORECTAL OR COLON\* OR RECT\* OR INTESTIN\* OR BOWEL\*))
- #13. #1 OR #11
- #14. #12 OR #13
- #15. CAPECITABINE\*
- #16. XELODA\*

- #17. 154361-50-9
- #18. EU100163001
- #19. EU100163002
- #20. RO091978
- #21. FLUOROPYRIMIDINE\*
- #22. TEGAFUR\*
- #23. 17902-23-7
- #24. UFTORAL
- #25. PL111840087
- #26. #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25
- #27. #14 AND #26

### **CINAHL**

**1982–2002**

#### **Ovid Biomed**

**Search undertaken April 2002**

- #1. Exp Colorectal Neoplasms/
- #2. Neoplasms/
- #3. Carcinoma/
- #4. Adenocarcinoma/
- #5. or/2-4
- #6. Colonic Diseases/
- #7. Rectal Diseases/
- #8. Exp Colon/
- #9. Exp Rectum/
- #10. or/6-9
- #11. 5 and 10
- #12. ((Carcinoma\$ or neoplasia or neoplasm\$ or adenocarcinoma\$ or cancer\$ or tumor\$ or tumour\$ or malignan\$) adj3 (colorectal or colon\$ or rect\$ or intestin\$ or bowel\$)).tw
- #13. 1 or 11 or 12
- #14. Capecitabine.af
- #15. Xeloda.af
- #16. 154361-50-9.af
- #17. EU#1#00#163#001.af
- #18. EU#1#00#163#002.af
- #19. Ro09?1978.af
- #20. Fluoropyrimidine\$.af
- #21. Tegafur.af
- #22. 17902-23-7.af
- #23. Uftoral.af
- #24. PL?11184?0087.af
- #25. Or/14-24
- #26. 13 and 25

### **Citation Indexes (Science and Social Sciences)**

**1981–2002**

#### **Web of Science**

**Search undertaken May 2002**

Database limits:  
 DocType=All document types; All languages;  
 Databases=SCI-EXPANDED, SSCI; Timespan>All years

((Capecitabine or Xeloda) and (colorectal or colon\* or rect\* or intestin\* or bowel\*))  
 ((154361-50-9 or EU?1?00?163?001 or EU?1?00?163?002) and (colorectal or colon\* or rect\* or intestin\* or bowel\*))  
 ((Ro09?1978 and (colorectal or colon\* or rect\* or intestin\* or bowel\*))  
 ((Fluoropyrimidine\* or tegafur or uftoral) and (colorectal or colon\* or rect\* or intestin\* or bowel\*))  
 ((17902-23-7) and (colorectal or colon\* or rect\* or intestin\* or bowel\*))  
 ((PL?11184?0087) and (colorectal or colon\* or rect\* or intestin\* or bowel\*))

### **CRD databases (NHS DARE, EED, HTA)**

#### **CRD Web site – complete databases**

#### **Search undertaken April 2002**

Capecitabine/all fields  
 Xeloda/all fields  
 Tegafur/all fields  
 Uftoral/all fields  
 Fluoropyrimidine/all fields

### **EMBASE**

**1980–2002**

#### **SilverPlatter WebSPIRS**

#### **Search undertaken April 2002**

- #1. Explode ‘colorectal-cancer’ / all subheadings
- #2. Explode ‘colorectal-carcinoma’ / all subheadings
- #3. Explode ‘colorectal-tumor’ / all subheadings
- #4. #1 or #2 or #3
- #5. Explode ‘neoplasm-’ / all subheadings
- #6. Explode ‘carcinoma-’ / all subheadings
- #7. Explode ‘adenocarcinoma-’ / all subheadings
- #8. #5 or #6 or #7
- #9. Explode ‘colon-disease’ / all subheadings
- #10. Explode ‘rectum-disease’ / all subheadings
- #11. Explode ‘colon-’ / all subheadings
- #12. Explode ‘rectum-’ / all subheadings
- #13. #9 or #10 or #11 or #12
- #14. #8 and #13
- #15. ((Carcinoma\* or neoplasia\* or neoplasm\* or adenocarcinoma\* or cancer\* or tumo\* or malignan\*) near3 (colorectal or colon\* or rect\* or intestin\* or bowel\*))
- #16. #4 or #14 or #15
- #17. Capecitabine\*
- #18. Xeloda\*
- #19. 154361-50-9
- #20. EU?1?00?163?001
- #21. EU?1?00?163?002

- #22. Ro09?1978
- #23. Fluoropyrimidine\*
- #24. Tegafur\*
- #25. 17902-23-7
- #26. Uftoral
- #27. PL?11184?0087
- #28. #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27
- #29. #16 and #28

### **HEED (Office of Health Economics Health Economic Evaluation Database)**

**CD ROM version**

#### **Search undertaken May 2002**

##### *Search terms:*

Capecitabine  
 Xeloda  
 Tegafur  
 Uftoral  
 Fluoropyrimidine

##### *Fields searched:*

Quick search – All data

### **MEDLINE**

**1966–2002**

**Ovid Biomed**

#### **Search undertaken April 2002**

- Exp Colorectal Neoplasms/
- #1. Neoplasms/
- #2. Carcinoma/
- #3. Adenocarcinoma/
- #4. or/2-4
- #5. Colonic Diseases/
- #6. Rectal Diseases/
- #7. Exp Colon/
- #8. Exp Rectum/
- #9. or/6-9
- #10. 5 and 10
- #11. ((Carcinoma\$ or neoplasia or neoplasm\$ or adenocarcinoma\$ or cancer\$ or tumor\$ or tumour\$ or malignan\$) adj3 (colorectal or colon\$ or rect\$ or intestin\$ or bowel\$)).tw
- #12. 1 or 11 or 12
- #13. Capecitabine.af
- #14. Xeloda.af
- #15. 154361-50-9.af
- #16. EU#1#00#163#001.af
- #17. EU#1#00#163#002.af
- #18. Ro09?1978.af
- #19. Fluoropyrimidine\$.af
- #20. Tegafur.af
- #21. 17902-23-7.af
- #22. Uftoral.af
- #23. PL?11184?0087.af
- #24. Or/14-24
- #25. 13 and 25

**MEDLINE – for the epidemiology of colorectal cancer only**

**1966–2002**

**Ovid Biomed**

**Search undertaken May 2002**

Exp Colorectal Neoplasms/

#1. Neoplasms/

#2. Carcinoma/

#3. Adenocarcinoma/

#4. or/2-4

#5. Colonic Diseases/

#6. Rectal Diseases/

#7. Exp Colon/

#8. Exp Rectum/

#9. or/6-9

#10. 5 and 10

#11. ((Carcinoma\$ or neoplasia\$ or neoplasm\$ or adenocarcinoma\$ or cancer\$ or tumor\$ or tumour\$ or malignan\$) adj3 (colorectal or colon\$ or rect\$ or intestin\$ or bowel\$)).tw

#12. 1 or 11 or 12

#13. Colorectal neoplasms/ep

#14. 13 and 14

#15. Limit 15 to yr=1990-2002

#16. (Epidemiolog\$ or incidence\$ or prevalence\$).ti

#17. 16 and 17

**MEDLINE – for further references specifically on the two 5-FU regimens (de Gramont and Mayo Clinic)**

**1966–2002**

**Ovid Biomed**

**Search undertaken June 2002**

#1. Gramont.tw

#2. Mayo.tw

#3. 1 or 2

#4. Exp Fluorouracil/

#5. 3 and 4

**Methodological search filters used in Ovid MEDLINE**

**Systematic reviews/meta-analyses**

#1. Meta-analysis/

#2. Exp review literature/

#3. (Meta-analy\$ or meta analy\$ or metaanaly\$).tw

#4. Meta analysis.pt

#5. Review academic.pt

#6. Review literature.pt

#7. Letter.pt

#8. Review of reported cases.pt

#9. Historical article.pt

#10. Review multicase.pt

#11. or/1-6

#12. or/7-10

#13. 11 not 12

**Randomised controlled trials**

#1. Randomized controlled trial.pt

#2. Controlled clinical trial.pt

#3. Randomized controlled trials/

#4. Random allocation/

#5. Double blind method/

#6. Single blind method/

#7. or/1-6

#8. Clinical trial.pt

#9. Exp clinical trials/

#10. ((Clin\$) adj25 (trial\$)).ti,ab

#11. ((Sing\$ or doubl\$ or trebl\$ or tripl\$) adj25 (blind\$ or mask\$)).ti,ab

#12. Placebos/

#13. Placebos.ti,ab

#14. Random.ti,ab

#15. Research design/

#16. or/8-15

#17. Comparative study/

#18. Exp evaluation studies/

#19. Follow up studies/

#20. (Control\$ or prospective\$ or volunteer\$).ti,ab

#21. Prospective studies/

#22. or/17-21

#23. 7 or 16 or 22

**Economic evaluations**

#1. Economics/

#2. Exp “costs and cost analysis”/

#3. Economic value of life/

#4. Exp economics, hospital/

#5. Exp economics, medical/

#6. Economics, nursing/

#7. Economics, pharmaceutical/

#8. Exp models, economic/

#9. Exp “fees and charges”/

#10. Exp budgets/

#11. Ec.fs.

#12. (Cost or costs or costed or costly or costing\$).tw

#13. (Economic\$ or pharmacoeconomic\$ or price\$ or pricing).tw

#14. or/1-13

**Guidelines**

#1. Guideline.pt

#2. Practice guideline.pt

#3. Exp guidelines/

#4. Health planning guidelines/

#5. or/1-4

**Quality of life**

- #1. Exp quality of life/
- #2. Quality of life.tw
- #3. Life quality.tw
- #4. Hql.tw
- #5. (Sf 36 or sf36 or sf thirtysix or sf thirty six or short form 36 or short form thirty six or short form thirtysix or shortform 36).tw
- #6. Qol.tw
- #7. (Euroqol or eq5d or eq 5d).tw
- #8. Qaly\$.tw

- #9. Quality adjusted life year\$.tw
- #10. Hye\$.tw
- #11. Health\$ year\$ equivalent\$.tw
- #12. Health utilit\$.tw
- #13. Hui.tw
- #14. Quality of wellbeing\$.tw
- #15. Quality of well being.tw
- #16. Qwb.tw
- #17. (Qald\$ or qale\$ or Qtime\$).tw
- #18. Or/1-18



## Appendix 8

### National Cancer Institute common toxicity criteria<sup>67,69</sup>

		<b>Toxicity</b>				
		<b>0</b>	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>
White blood cell count (WBC)	>4.0	3.0–3.9	2.0–2.9	1.0–1.9	<1.0	
Infection	None	Mild	Moderate	Severe	Life threatening	
Nausea	None	Able to eat reasonable intake	Intake significantly decreased but can eat	No significant intake		
Vomiting	None	1 episode in 24 hours	2–5 episodes in 24 hours	6–10 episodes in 24 hours	>10 episodes in 24 hours or requiring parenteral support	
Diarrhoea	None	Increase of 2–3 stools/day	Increase of 4–6 stools/day, or nocturnal stools or moderate cramping	Increase of 7–9 stools/day, or incontinence or severe cramping	Increase of >10 stools/day, or grossly bloody diarrhoea or need for parenteral support	
Stomatitis	None	Painless ulcers, erythema or mild soreness	Painful erythema, oedema or ulcers, but can eat	Painful erythema, oedema or ulcers, and cannot eat	Requires parenteral or enteral support	



## Appendix 9

### Unit costs used in economic evaluation<sup>a</sup>

	<b>Cost (£)</b>	<b>Year</b>	<b>Source</b>
Inpatient day	359	2001	PSSRU
Outpatient day	109	2001	PSSRU
Outpatient clinic appointment with chemotherapy	150	2002	Christie Hospital
Outpatient clinic appointment without chemotherapy	80	2002	Christie Hospital
Medical oncology outpatient follow-up	86.07	2001	NHS reference costs
Day-case	218	2001	NHS reference costs
District nurse home visit	20	2001	PSSRU
GP home visit	59	2001	PSSRU
GP telefon consultation	22	2001	PSSRU
Day-care visit	125	2001	PSSRU
GP surgery consultation	19	2001	PSSRU
GP clinic consultation	26	2001	PSSRU
A and E visit	61	2001	PSSRU
Other hospital visits	74	2001	PSSRU
Line insertion	498	2002	Christie Hospital
Line insertion	537	2001	Revised Christie Hospital cost
Line insertion	250	1996/7	Iveson, 1999 <sup>59</sup>
Line insertion-peripherally inserted central catheter	20	2002	Line insertion by nurse
Pumps	65	2002	Christie Hospital
Pumps	62	1996/7	Iveson, 1999 <sup>59</sup>
Consultant hour	86	2001	PSSRU
District nurse hour	43	2001	PSSRU
Grade D pharmacist hour	13.25	2000	Avon, Somerset and Wiltshire Cancer Services Cancer Drug Therapy Forum <sup>60</sup>
MTO 3 pharmacy technician	9.6	2000	Avon, Somerset and Wiltshire Cancer Services Cancer Drug Therapy Forum <sup>60</sup>
Staff nurse hour	27	2001	PSSRU
5-FU 1000-mg vial	12.80	2002	BNF
5-FU 5000-mg vial	64.00	2002	BNF
5-FU 500-mg vial	6.40	2002	BNF
5-FU 250-mg vial	3.20	2002	BNF
LV 50-mg vial	19.41	2002	BNF
LV 350-mg vial	90.98	2002	BNF

<sup>a</sup> All costs are adjusted to 2002 prices for use in the economic evaluation.



# Health Technology Assessment Programme

## Prioritisation Strategy Group

### **Members**

**Chair,**  
**Professor Kent Woods,**  
 Director, NHS HTA Programme & Professor of Therapeutics, University of Leicester

Professor Bruce Campbell, Consultant Vascular & General Surgeon, Royal Devon & Exeter Hospital  
 Professor Shah Ebrahim, Professor in Epidemiology of Ageing, University of Bristol

Dr John Reynolds, Clinical Director, Acute General Medicine SDU, Radcliffe Hospital, Oxford  
 Dr Ron Zimmern, Director, Public Health Genetics Unit, Strangeways Research Laboratories, Cambridge

## HTA Commissioning Board

### **Members**

**Programme Director,**  
 Professor Kent Woods, Director, NHS HTA Programme, Department of Medicine and Therapeutics, Leicester Royal Infirmary, Robert Kilpatrick Clinical Sciences Building, Leicester

**Chair,**  
**Professor Shah Ebrahim,**  
 Professor in Epidemiology of Ageing, Department of Social Medicine, University of Bristol, Canyngate Hall, Whiteladies Road, Bristol

**Deputy Chair,**  
**Professor Jenny Hewison,**  
 Professor of Health Care Psychology, Academic Unit of Psychiatry and Behavioural Sciences, University of Leeds School of Medicine, Leeds

Professor Douglas Altman, Professor of Statistics in Medicine, Centre for Statistics in Medicine, Oxford University, Institute of Health Sciences, Cancer Research UK Medical Statistics Group, Headington, Oxford

Professor John Bond, Professor of Health Services Research, Centre for Health Services Research, University of Newcastle, School of Health Sciences, Newcastle upon Tyne

Professor John Brazier, Director of Health Economics, Sheffield Health Economics Group, School of Health & Related Research, University of Sheffield, ScHARR Regent Court, Sheffield

Dr Andrew Briggs, Public Health Career Scientist, Health Economics Research Centre, University of Oxford, Institute of Health Sciences, Oxford

Dr Christine Clark, Medical Writer & Consultant Pharmacist, Cloudsides, Rossendale, Lancs and Principal Research Fellow, Clinical Therapeutics in the School of Pharmacy, Bradford University, Bradford

Professor Nicky Cullum, Director of Centre for Evidence Based Nursing, Department of Health Sciences, University of York, Research Section, Seebohm Rowntree Building, Heslington, York

Dr Andrew Farmer, Senior Lecturer in General Practice, Department of Primary Health Care, University of Oxford, Institute of Health Sciences, Headington, Oxford

Professor Fiona J Gilbert, Professor of Radiology, Department of Radiology, University of Aberdeen, Lilian Sutton Building, Foresterhill, Aberdeen

Professor Adrian Grant, Director, Health Services Research Unit, University of Aberdeen, Drew Kay Wing, Polwarth Building, Foresterhill, Aberdeen

Professor Alastair Gray, Director, Health Economics Research Centre, University of Oxford, Institute of Health Sciences, Headington, Oxford

Professor Mark Haggard, Director, MRC ESS Team, CBU Elsworth House, Addenbrooke's Hospital, Cambridge

Professor F D Richard Hobbs, Professor of Primary Care & General Practice, Department of Primary Care & General Practice, University of Birmingham, Primary Care and Clinical Sciences Building, Edgbaston, Birmingham

Professor Peter Jones, Head of Department, University Department of Psychiatry, University of Cambridge, Addenbrooke's Hospital, Cambridge

Professor Sallie Lamb, Research Professor in Physiotherapy/Co-Director, Interdisciplinary Research Centre in Health, Coventry University, Coventry

Dr Donna Lamping, Senior Lecturer, Health Services Research Unit, Public Health and Policy, London School of Hygiene and Tropical Medicine, London

Professor David Neal, Professor of Surgical Oncology, Oncology Centre, Addenbrooke's Hospital, Cambridge

Professor Tim Peters, Professor of Primary Care Health Services Research, Division of Primary Health Care, University of Bristol, Cotham House, Cotham Hill, Bristol

Professor Ian Roberts, Professor of Epidemiology & Public Health, Intervention Research Unit, London School of Hygiene and Tropical Medicine, London

Professor Peter Sandercock, Professor of Medical Neurology, Department of Clinical Neurosciences, University of Edinburgh, Western General Hospital NHS Trust, Bramwell Dott Building, Edinburgh

Professor Martin Severs, Professor in Elderly Health Care, Portsmouth Institute of Medicine, Health & Social Care, St George's Building, Portsmouth

Dr Jonathan Shapiro, Senior Fellow, Health Services Management Centre, Park House, Birmingham

## Diagnostic Technologies & Screening Panel

### **Members**

<b>Chair,</b> <b>Dr Ron Zimmern</b> , Director of the Public Health Genetics Unit, Strangeways Research Laboratories, Cambridge	Dr David Elliman, Consultant in Community Child Health, London	Mr Tam Fry, Honorary Chairman, Child Growth Foundation, London	Mr Tony Tester, Chief Officer, South Bedfordshire Community Health Council, Luton
Dr Paul Cockcroft, Consultant Medical Microbiologist/ Laboratory Director, Public Health Laboratory, St Mary's Hospital, Portsmouth	Dr Andrew Farmer, Senior Lecturer in General Practice, Institute of Health Sciences, University of Oxford	Dr Susanne M Ludgate, Medical Director, Medical Devices Agency, London	Dr Andrew Walker, Senior Lecturer in Health Economics, University of Glasgow
Professor Adrian K Dixon, Professor of Radiology, Addenbrooke's Hospital, Cambridge	Dr Karen N Foster, Clinical Lecturer, Dept of General Practice & Primary Care, University of Aberdeen	Dr William Rosenberg, Senior Lecturer and Consultant in Medicine, University of Southampton	Professor Martin J Whittle, Head of Division of Reproductive & Child Health, University of Birmingham
	Professor Jane Franklyn, Professor of Medicine, University of Birmingham	Dr Susan Schonfield, CPHM Specialised Services Commissioning, Croydon Primary Care Trust	Dr Dennis Wright, Consultant Biochemist & Clinical Director, Pathology & The Kennedy Galton Centre, Northwick Park & St Mark's Hospitals, Harrow
	Professor Antony J Franks, Deputy Medical Director, The Leeds Teaching Hospitals NHS Trust	Dr Margaret Somerville, Director of Public Health, Teignbridge Primary Care Trust, Devon	

## Pharmaceuticals Panel

### **Members**

<b>Chair,</b> <b>Dr John Reynolds</b> , Clinical Director, Acute General Medicine SDU, Oxford Radcliffe Hospital	Dr Christopher Cates, GP and Cochrane Editor, Bushey Health Centre, Bushey, Herts.	Mrs Sharon Hart, Managing Editor, <i>Drug &amp; Therapeutics Bulletin</i> , London	Dr Ken Stein, Senior Lecturer in Public Health, University of Exeter
Professor Tony Avery, Professor of Primary Health Care, University of Nottingham	Mr Charles Dobson, Special Projects Adviser, Department of Health	Dr Christine Hine, Consultant in Public Health Medicine, Bristol South & West Primary Care Trust	Professor Terence Stephenson, Professor of Child Health, University of Nottingham
Professor Iain T Cameron, Professor of Obstetrics & Gynaecology, University of Southampton	Dr Robin Ferner, Consultant Physician and Director, West Midlands Centre for Adverse Drug Reactions, City Hospital NHS Trust, Birmingham	Professor Robert Peveler, Professor of Liaison Psychiatry, Royal South Hants Hospital, Southampton	Dr Richard Tiner, Medical Director, Association of the British Pharmaceutical Industry, London
Mr Peter Cardy, Chief Executive, Macmillan Cancer Relief, London	Dr Karen A Fitzgerald, Pharmaceutical Adviser, Bro Taf Health Authority, Cardiff	Dr Frances Rotblat, CPMP Delegate, Medicines Control Agency, London	Professor Dame Jenifer Wilson-Barnett, Head of Florence Nightingale School of Nursing & Midwifery, King's College, London
	Professor Alastair Gray, Professor of Health Economics, Institute of Health Sciences, University of Oxford	Mrs Katrina Simister, New Products Manager, National Prescribing Centre, Liverpool	

## Therapeutic Procedures Panel

### Members

**Chair,**  
**Professor Bruce Campbell,**  
Consultant Vascular and  
General Surgeon, Royal Devon  
& Exeter Hospital

Dr Mahmood Adil, Head of  
Clinical Support & Health  
Protection, Directorate of  
Health and Social Care (North),  
Department of Health,  
Manchester

Professor John Bond, Head of  
Centre for Health Services  
Research, University of  
Newcastle upon Tyne

Mr Michael Clancy, Consultant  
in A & E Medicine,  
Southampton General Hospital

Dr Carl E Counsell, Senior  
Lecturer in Neurology,  
University of Aberdeen

Dr Keith Dodd, Consultant  
Paediatrician, Derbyshire  
Children's Hospital, Derby

Professor Gene Feder, Professor  
of Primary Care R&D, Barts &  
the London, Queen Mary's  
School of Medicine and  
Dentistry, University of London

Ms Bec Hanley, Freelance  
Consumer Advocate,  
Hurstpierpoint, West Sussex

Professor Alan Horwich,  
Director of Clinical R&D, The  
Institute of Cancer Research,  
London

Dr Phillip Leech, Principal  
Medical Officer for Primary  
Care, Department of Health,  
London

Mr George Levvy, Chief  
Executive, Motor Neurone  
Disease Association,  
Northampton

Professor James Lindesay,  
Professor of Psychiatry for the  
Elderly, University of Leicester

Dr Mike McGovern, Senior  
Medical Officer, Heart Team,  
Department of Health, London

Dr John C Poundsford,  
Consultant Physician, North  
Bristol NHS Trust

Professor Mark Sculpher,  
Professor of Health Economics,  
Institute for Research in the  
Social Services, University of  
York

Dr L David Smith, Consultant  
Cardiologist, Royal Devon &  
Exeter Hospital

Professor Norman Waugh,  
Professor of Public Health,  
University of Aberdeen

## Expert Advisory Network

### Members

Mr Gordon Aylward, Chief Executive, Association of British Health-Care Industries, London	Professor Pam Enderby, Professor of Community Rehabilitation, Institute of General Practice and Primary Care, University of Sheffield	Professor Allen Hutchinson, Director of Public Health & Deputy Dean of ScHARR, Department of Public Health, University of Sheffield	Professor Jon Nicholl, Director of Medical Care Research Unit, School of Health and Related Research, University of Sheffield
Ms Judith Brodie, Head of Cancer Support Service, Cancer BACUP, London	Mr Leonard R Fenwick, Chief Executive, Newcastle upon Tyne Hospitals NHS Trust	Professor Rajan Madhok, Medical Director & Director of Public Health, Directorate of Clinical Strategy & Public Health, North & East Yorkshire & Northern Lincolnshire Health Authority, York	Mrs Julietta Patnick, National Co-ordinator, NHS Cancer Screening Programmes, Sheffield
Mr Shaun Brogan, Chief Executive, Ridgeway Primary Care Group, Aylesbury, Bucks	Professor David Field, Professor of Neonatal Medicine, Child Health, The Leicester Royal Infirmary NHS Trust	Professor David Mant, Professor of General Practice, Department of Primary Care, University of Oxford	Professor Chris Price, Visiting Chair – Oxford, Clinical Research, Bayer Diagnostics Europe, Cirencester
Ms Tracy Bury, Project Manager, World Confederation for Physical Therapy, London	Mrs Gillian Fletcher, Antenatal Teacher & Tutor and President, National Childbirth Trust, Henfield, West Sussex	Professor Alexander Markham, Director, Molecular Medicine Unit, St James's University Hospital, Leeds	Ms Marianne Rigge, Director, College of Health, London
Mr John A Cairns, Professor of Health Economics, Health Economics Research Unit, University of Aberdeen	Ms Grace Gibbs, Deputy Chief Executive, Director for Nursing, Midwifery & Clinical Support Servs., West Middlesex University Hospital, Isleworth, Middlesex	Dr Chris McCall, General Practitioner, The Hadleigh Practice, Castle Mullen, Dorset	Professor Sarah Stewart-Brown, Director HSRU/Honorary Consultant in PH Medicine, Department of Public Health, University of Oxford
Professor Howard Stephen Cuckle, Professor of Reproductive Epidemiology, Department of Paediatrics, Obstetrics & Gynaecology, University of Leeds	Dr Neville Goodman, Consultant Anaesthetist, Southmead Hospital, Bristol	Professor Alistair McGuire, Professor of Health Economics, London School of Economics	Professor Ala Szczepura, Professor of Health Service Research, Centre for Health Services Studies, University of Warwick
Professor Nicky Cullum, Director of Centre for Evidence Based Nursing, University of York	Professor Robert E Hawkins, CRC Professor and Director of Medical Oncology, Christie CRC Research Centre, Christie Hospital NHS Trust, Manchester	Dr Peter Moore, Freelance Science Writer, Ashtead, Surrey	Dr Ross Taylor, Senior Lecturer, Department of General Practice and Primary Care, University of Aberdeen
Dr Katherine Darton, Information Unit, MIND – The Mental Health Charity, London	Professor F D Richard Hobbs, Professor of Primary Care & General Practice, Department of Primary Care & General Practice, University of Birmingham	Dr Andrew Mortimore, Consultant in Public Health Medicine, Southampton City Primary Care Trust	Mrs Joan Webster, Consumer member, HTA – Expert Advisory Network
Professor Carol Dezateux, Professor of Paediatric Epidemiology, London	Dr Sue Moss, Associate Director, Cancer Screening Evaluation Unit, Institute of Cancer Research, Sutton, Surrey		
Professor Martin Eccles, Professor of Clinical Effectiveness, Centre for Health Services Research, University of Newcastle upon Tyne			



## **Feedback**

The HTA Programme and the authors would like to know your views about this report.

The Correspondence Page on the HTA website (<http://www.ncchta.org>) is a convenient way to publish your comments. If you prefer, you can send your comments to the address below, telling us whether you would like us to transfer them to the website.

***We look forward to hearing from you.***